Conditions: Asthma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 210
Healthy volunteers: no

Brief summary:
Primary Objective:

To evaluate the efficacy of dupilumab, compared with placebo, for reducing the use of maintenance oral corticosteroids (OCS) in participants with severe steroid-dependent asthma.

Secondary Objectives:

* To evaluate the safety and tolerability of dupilumab.
* To evaluate the effect of dupilumab in improving participants-reported outcomes.
* To evaluate dupilumab systemic exposure and the incidence of treatment-emergent antidrug antibodies.

Detailed description:
The total study duration per participant was up to 46 weeks, consisting of a screening period of 3 to up to 8 weeks (up to 10 weeks for participants who experienced a clinically significant asthma exacerbation during the screening period), a randomized treatment period of up to 24 weeks, and a post-treatment period of 12 weeks.

Participants who completed treatment were considered for eligibility into the long term extension study LTS12551 (NCT02134028).

Arms:
arm 1: 2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. arm 2: 2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.

Interventions: intervention 1: Dupilumab intervention 2: Placebo intervention 3: Oral corticosteroid therapy (prednisone/prednisolone) intervention 4: Inhaled corticosteroid (ICS) therapy intervention 5: Albuterol/Salbutamol intervention 6: Levalbuterol/Levosalbutamol
Intervention descriptions: intervention 1: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm. intervention 2: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm. intervention 3: Oral administration. intervention 4: Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy). intervention 5: Oral inhalation as needed. intervention 6: Oral inhalation as needed.

Protocol document:
Prot_000.pdf: 
NCT number: NCT02528214


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 2 
NAMES AND ADDRESSES OF 
COORDINATING 
INVESTIGATOR 
 
Name: 
Address: 
Tel: 
Fax: 
E-mail: 
 
MONITORING TEAM’S 
REPRESENTATIVE 
 
Name: 
Address: 
Tel: 
Fax: 
E-mail: 
 
SPONSOR 
 
Company: 
Address: 
 
OTHER EMERGENCY 
TELEPHONE NUMBERS 
 
 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 3 
CLINICAL TRIAL SUMMARY 
 
COMPOUND: SAR231893 
STUDY No: EFC13691  
STUDY NAME: VENTURE 
TITLE 
A randomized, double-blind, placebo-controlled study to evaluate the efficacy 
and safety of dupilumab in patients with severe steroid dependent asthma 
INVESTIGATOR/TRIAL LOCATION 
Worldwide 
PHASE OF DEVELOPMENT 
3 
STUDY OBJECTIVE(S) 
 
Primary objective 
x
To evaluate the efficacy of dupilumab compared with placebo, for 
reducing the use of maintenance oral corticosteroids (OCS) in 
patients with severe steroid-dependent asthma. 
Secondary objectives  
x
To evaluate the safety and tolerability of dupilumab 
x
To evaluate the effect of dupilumab in improving patient-reported 
outcomes (PROs) 
x
To evaluate dupilumab systemic exposure and the incidence of 
treatment-emergent anti-drug antibodies (ADA) 
Exploratory objectives  
x
To evaluate baseline and on-treatment levels of biomarkers in 
association with treatment response and for their potential to predict 
treatment responses  
x
To evaluate patient genetic profiles and their potential to predict 
treatment responses 
x
To evaluate the effect of dupilumab on airway markers of 
inflammation (at selected study sites within Canada) 
STUDY DESIGN 
General Design 
Multinational, multicenter, randomized, double-blind, placebo-controlled study 
assessing the effect of dupilumab administered subcutaneously (SC) for a 
maximum of 24 weeks in patients with severe steroid-dependent asthma. 
Periods 
The clinical trial will be divided into the following periods: 
x
Screening and OCS Optimization period (from 3 to up to 8 weeks 
[up to 10 weeks for patients experiencing an asthma exacerbation 
that requires a change in OCS dose to allow for 2 weeks of 
stabilization prior to randomization]): to determine a patient’s 
eligibility status and to ensure that patients enter the treatment 
period on the lowest dose of OCS that will manage their symptoms 
x
Treatment period (24 weeks): includes a 4-week induction phase, a 
16-week OCS reduction phase, and a 4-week maintenance phase  
x
Post-treatment period (12 weeks): to monitor a patient’s status after 
completing/withdrawing from study drug treatment for patients not 
rolling over into a long-term  study. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 4 
Screening and OCS Optimization Period 
Patients who meet eligibility criteria at the Screening visit will enter the OCS 
Optimization Phase.  Prednisone or prednisolone will be the only OCS used.  
During the Screening visit, patients currently using  other  OCS medications 
will be switched to either of these corticosteroids at a dose clinically 
equivalent  to their current stable OCS dose.  The definition of stable OCS 
maintenance dose in EFC13691 is no change of OCS dose within 4 weeks of 
Screening Visit 1.  
OCS optimization phase interruption criteria 
The lowest effective OCS dose will be defined during this phase as the lowest 
dose a patient can tolerate without experiencing any of the following criteria: 
x
Increase in Asthma Control Questionnaire (ACQ)-5 of at least  0.5 
from the last ACQ-5 score recorded in the e-diary 
x
Severe asthma exacerbation 
x
Clinically significant event, based on investigator judgment that 
requires treatment by OCS dose adjustment 
In general, the investigator can refer to the ACQ-5 score at Screening Visit 1 
to guide the OCS dose adjustments made during the optimization phase of 
the study; however, the decision to titrate can be based on the investigator’s 
clinical judgement.  Once determined, the optimized dose must remain stable 
for 2 consecutive weeks along with baseline medications without meeting any 
of the OCS optimization phase interruption criteria prior to randomization.  
Investigators should adjust the OCS dose according to a prespecified titration 
schedule based on the OCS optimization phase interruption criteria, and in 
accordance with their clinical judgement.  During the OCS optimization phase, 
the patient’s asthma control will be assessed weekly by reviewing these 
criteria via scheduled phone calls after Visit 2.  If the patient’s asthma status 
remains controlled and none of the above criteria are met, the investigator 
should down-titrate the patient’s OCS dose.  The downward titration will 
continue until a point when at least 1 of the OCS optimization phase 
interruption criteria is met.  If the down-titration is stopped,  the investigator 
should up-titrate the OCS dose by 1 step per Table 1,  unless the patient’s 
medical condition requires treatment with a higher dose of OCS.   
Those patients who are able to down titrate their OCS dose to 2.5 mg during 
the OCS Optimization phase without experiencing any of the above bulleted 
criteria will be considered screen failures and will not be randomized. 
If a patient experiences a severe asthma exacerbation during the OCS 
Optimization Phase, the exacerbation should be treated with the use of oral or 
parenteral steroids at least double the dose of current maintenance dose of 
OCS.  Following exacerbation treatment, the patient should be placed on the 
OCS dose 1 step higher than the dose they were on when the exacerbation 
occurred.  Note that the optimization period can be extended to 10 weeks to 
allow for 2 weeks of stabilization prior to randomization. 
Randomized Treatment Period 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 5 
Induction Phase (4 weeks) 
At Visit 3 (Week 0), patients who meet the eligibility criteria will be randomized 
in a 1:1 ratio to receive a 600 mg loading dose followed by 300 mg once 
every 2 weeks (q2w) of dupilumab or matching placebo, respectively.  During 
this phase, patients will remain on their optimized dose of OCS along with 
their baseline asthma medications. 
OCS Reduction Phase (16 weeks) 
The OCS dose should be down-titrated during this phase following a 
predetermined schedule that is based upon the optimized OCS dose 
identified during the OCS Optimization Period.  Dose reductions may occur 
every 4 weeks which should allow the minimization of any carryover effects 
from the previous dose and reduce the risk for adrenal insufficiency.  The last 
possible dose reduction can occur at Week 20. No down-titration beyond this 
time point is permitted.  The reduction in OCS dose should occur per the 
schedule unless the patient meets defined criteria indicating that it is not 
acceptable for the patient to reduce the dose.  A clinical assessment should 
be completed prior to each dose reduction.  Primary reasons for not following 
the scheduled dose reduction include: 
x
Mean morning peak expiratory flows (PEF) <70% of baseline 
stability limit 
x
Forced expiratory volume in 1 second (FEV1) 20% reduction from 
baseline stability limit 
x
Rescue medication (metered dose inhaler) use requiring 4 or more 
puffs/day above the mean baseline value for any 2 consecutive 
days in the prior week, or 12 puffs or more on any 1 day in the prior 
week 
x
Change in ACQ-5 score  +0.5 from the prior month OCS dose 
assessment 
x
Clinically significant asthma exacerbation 
x
Clinically significant event, based on investigator judgment, that 
requires treatment by OCS dose adjustment 
The Investigator will decide, depending on the reason for not reducing the 
OCS dose per schedule, whether to maintain or increase his /her current OCS 
dose by 1 step. 
Maintenance Phase (4 weeks) 
Patients will be maintained for the last 4 weeks of the treatment period on the 
same OCS dose established at Week 20.  However, when any of the above 
criteria for not reducing OCS dose is met, the Investigator should decide 
whether to maintain or increase the current OCS dose accordingly. 
If a severe asthma exacerbation occurs during the Reduction or Maintenance 
Phases, the exacerbation should be treated with the use of oral or parenteral 
steroids at a dose at least equivalent to double the dose of current 
maintenance dose of OCS.  Following resolution, the patient should be placed 
on the OCS dose 1 step higher than that which he/she was on when the 
exacerbation occurred for at least 4 weeks and continue with dose reductions 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 6 
(only during the Reduction phase) as per the predefined schedule at the 
following visit.  If a patient experiences 2 exacerbations, no further OCS dose 
reductions will be allowed. 
Post-treatment Period 
After completing the treatment period, patients who do not rollover into a long-
term study will be evaluated for 12 weeks in the post-treatment period.  
During this follow-up period, patients will continue treatment with their stable 
dose of controller medication (includes all medications used to control asthma 
symptoms, with the exception of the investigational medicinal product [IMP]) 
that can be modified based on their level of asthma control, as determined by 
the Investigator. 
During the post-treatment period, patients will continue to collect e-diary 
information that can be used to determine asthma control. 
Eligible patients completing the treatment period may have the opportunity to 
roll over into a long-term study with dupilumab.  Patients subsequently 
enrolled in this long-term study will not participate in the Post-treatment period 
of this trial. 
Patients who permanently discontinue the study medication will be asked and 
encouraged to return to the clinic for all remaining study visits.  In addition, 
patients who discontinue early from treatment or patients who choose not to 
roll over into a long-term study may be asked to return to the clinic to have 
additional ADA samples collected for analysis based on the overall 
assessment of antibody titers and clinical presentation. 
STUDY POPULATION  
Main selection criteria 
Inclusion criteria  
I 01.
Adult and adolescent (12 years of age or older) patients with a 
physician diagnosis of asthma for 12 months, based on the Global 
Initiative for Asthma (GINA) 2014 guidelines and the following 
criteria: 
A)
Patients with severe asthma and well-documented, regular 
prescribed treatment of maintenance systemic corticosteroids in the 
6 months prior to Visit 1 and using a stable OCS dose (ie, no 
change of OCS dose) for 4 weeks prior to Visit 1.  Patients must be 
taking 5 – 35 mg/day of prednisone/ prednisolone, or the equivalent, 
at Visit 1 and at the Randomization visit.  In addition, the patient 
must agree to switch to study-required prednisone/prednisolone as 
their OCS and use it per protocol for the duration of the study. 
B)
Existing treatment with high dose inhaled corticosteroid (ICS; 
>500 Pg total daily dose of fluticasone propionate or equivalent) in 
combination with a second controller (ie, long-acting beta agonist 
[LABA], leukotriene receptor antagonist [LTRA]) for at least 
3 months with a stable dose of ICS for 1 month prior to Visit 1.  In 
addition, patients requiring a third controller for their asthma are 
considered eligible for this study. 
C)
A forced expiratory volume in 1 second (FEV1) <80% of predicted 
normal for adults and 90% of predicted normal for adolescents at 
Visit 1. 
D)
Evidence of asthma as documented by either: 
-
Reversibility of at least 12% and 200 mL in FEV1 after the 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 7 
administration of 200 to 400 Pg (2 to 4 puffs of 
albuterol/salbutamol or levalbuterol/levosalbutamol, or of a 
nebulized solution of albuterol/salbutamol or 
levalbuterol/levosalbutamol, if considered as a standard office 
practice) before randomization or documented in the 
12 months prior to Visit 1 OR 
-
Airway hyperresponsiveness (methacholine: provocative 
concentration that causes a positive reaction [PC20] of 
<8 mg/mL) documented in the 12 months prior to Visit 1.  
Exclusion criteria 
E 01.
Patients <12 years of age or the minimum legal age for adolescents 
in the country of the investigative site, whichever is higher (For 
those countries where local regulations permit enrollment of adults 
only, patient recruitment will be restricted to those who are 
18 years of age).  
E 02.
Patients who weigh <30 kg. 
E 03.
Chronic obstructive pulmonary disease (COPD) or other lung 
diseases (eg, idiopathic pulmonary fibrosis, Churg-Strauss 
Syndrome, etc) which may impair lung function. 
E 04.
Clinical evidence or imaging (eg, chest X-ray, computed 
tomography, magnetic resonance imaging) within 12 months of Visit 
1 with clinically significant findings of lung disease(s) other than 
asthma, as per local standard of care. 
E 05.
A patient who experiences a deterioration of asthma that results in 
emergency treatment or hospitalization within 4 weeks of Screening 
Visit 1.  
E 06.
A patient who requires 12 puffs or more of rescue medication 
(eg, metered dose inhaler) on any 1 day in the week prior to Visit 1. 
E 07.
A patient who has experienced an upper or lower respiratory tract 
infection within the 4 weeks prior to Screening. 
E 08.
Current smoker or cessation of smoking within 6 months prior to 
Visit 1. 
E 09.
Previous smoker with a smoking history >10 pack-years. 
E 10.
Comorbid disease that might interfere with the evaluation of the IMP 
(an example being, but not limited to, neuromuscular disease, etc).
Total expected number of patients 
Approximately 180 patients will be randomized to either dupilumab or 
placebo.  Enrollment will be limited to approximately 46 (25% of total sample 
size) patients whose eosinophil level is <150 cells/PL.  In addition, patients 
whose optimized OCS dose is 5 mg/day at Visit 3 will be limited to 54 patients 
(approximately 30% of the study population).
STUDY TREATMENT(s) 
Investigational medicinal products 
 
Formulations 
Dupilumab (SAR231893/REGN668) or matching placebo. 
 
Dupilumab: 150 mg/mL in a prefilled syringe to deliver 300 mg in 2 mL. 
Placebo: Prefilled syringe to deliver 2 mL. 
Route(s) of administration 
Subcutaneously (SC)
(electronic 




Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 9 
 
Post-treatment Period 
Upon completing the Randomized Treatment Period, patients not rolling over 
into a long-term study will continue treatment with the controller medication 
regimen and dose used during the randomized period, which could be 
adjusted based on the medical judgment of the Investigator based on the 
patient’s asthma control status. 
Reliever Medication 
Patients may administer albuterol/salbutamol or levalbuterol/levosalbutamol 
metered dose inhaler (MDI) as reliever medication as needed during the 
study.  Nebulizer solutions may be used as an alternative delivery method.
ENDPOINTS 
 
Primary endpoint 
Percentage reduction of OCS dose at Week 24 compared with the baseline 
dose, while maintaining asthma control.  A patient will be considered as 
having maintained asthma control between Week 20 and Week 24 if he/she 
does not have a clinically significant event, based on investigator judgment, 
that requires treatment by OCS dose adjustment during this period.  For those 
patients who experience an exacerbation, the final OCS dose will be 
considered to be 1 step higher than the dose they were receiving at the time 
of the exacerbation.  
Secondary endpoints  
Key secondary endpoint 
x
Proportion of patients achieving a reduction of 50% or greater in 
their OCS dose compared with baseline at Week 24, while 
maintaining asthma control.  The relative reduction for each patient 
will be calculated as (optimized OCS dose – final OCS dose at 
Week 24)/optimized OCS dose × 100. 
Efficacy 
x
Absolute reduction of OCS dose at Week 24 compared with the 
baseline dose while maintaining asthma control 
x
Proportion of patients achieving a reduction of OCS dose to 
<5 mg/day at Week 24 while maintaining asthma control 
x
Proportion of patients no longer requiring OCS at Week 24 while 
maintaining asthma control 
x
Proportion of patients achieving their maximum possible reduction 
of OCS dose per protocol at Week 24 while maintaining asthma 
control 
Safety and tolerability 
x
Adverse events (AEs) 
x
Vital signs 
x
Electrocardiogram (ECG) 
x
Clinical laboratory tests 
Pharmacokinetic and ADA 
x
Serum functional dupilumab concentrations 
x
Anti-drug antibodies (ADA) 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 10 
Other endpoints 
Efficacy 
x
Annualized rate of severe asthma exacerbation events defined as a 
deterioration of asthma during the 24-week treatment period 
requiring: 
-
Use of systemic corticosteroids for 3 days (at least double the 
dose currently used); AND/OR 
-
Hospitalization related to asthma symptoms, OR emergency 
room (ER) visit because of asthma requiring intervention with a 
systemic corticosteroid treatment. 
x
Time to first severe asthma exacerbation event 
x
Absolute change from baseline in pre-bronchodilator FEV1 at 
Weeks 2, 4, 8, 12, 16, 20, and 24 
x
Percent change from baseline in pre-bronchodilator FEV1 at Weeks 
2, 4, 8, 12, 16, 20, and 24 
x
Change from baseline in other lung function measurements 
(percent predicted FEV1, morning/evening PEF, forced vital 
capacity [FVC], forced expiratory flow over the 25% to 75% range of 
the vital capacity [FEF25-75%]), at Weeks 2, 4, 8, 16, 20, 12 and 24 
x
Change from baseline in post-bronchodilator FEV1 at Weeks 12 and 
24 
x
Change from baseline in ACQ-5 score at Weeks 2, 4, 8, 12, 16, 20, 
and 24 
x
Change from baseline in Asthma Quality of Life Questionnaire 
(AQLQ) score at Weeks 12, and 24 
x
Annualized rate of asthma exacerbations requiring hospitalization or 
ER visit 
x
Time to first severe asthma exacerbation requiring hospitalization or 
ER visit 
x
Change from baseline at weeks 12 and 24 in: 
-
22-Item Sino Nasal Outcome Test (SNOT-22) in patients with 
bilateral nasal polyposis/chronic rhinosinusitis 
-
Hospital Anxiety and Depression Scale (HADS) 
-
EQ-5D-5L 
x
Change from baseline at Weeks 2, 4, 8 12, 16, 20, and 24 in: 
-
Morning/evening asthma symptom score and nocturnal 
awakenings (eDiary) 
-
Use of rescue medication 
-
Health Care Resource Utilization 
Exploratory endpoints 
x
Blood samples for exploratory genetic analysis of DNA and RNA to 
assess the relationship of DNA variants and/or gene expression 
with asthma and response to dupilumab treatment 
x
Biomarkers 
-
Fractional exhaled nitric oxide (FeNO) levels 
-
Blood eosinophil count 
-
Total and antigen-specific immunoglobulin (Ig)E 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 11 
-
Thymus and activation-regulated chemokine (TARC) 
-
Periostin 
-
Eotaxin-3 
x
Sputum and blood, interleukin (IL) C2 and CD34 cells, and 
cytokines (at selected study sites in Canada)  
x
Change from baseline in airway hyperresponsiveness at Week 24 
(at selected study sites within Canada) 
ASSESSMENT SCHEDULE 
x
Screening period (from 3 to up to 8 weeks [up to 10 weeks for 
patients who experience an asthma exacerbation that requires a 
change in OCS dose to allow for 2 weeks of stabilization prior to 
randomization]) 
x
Randomized Treatment period (up to 24 weeks) 
x
Post-treatment period (12 weeks)
STATISTICAL CONSIDERATIONS 
 
Sample size determination 
The sample size estimation is based on the comparison between dupilumab 
versus placebo in regards to the primary endpoint and the key secondary 
endpoint: percentage reduction of OCS dose at Week 24 compared with the 
baseline dose and proportion of patients achieving a reduction of 50% or 
greater in their OCS dose compared with baseline at Week 24, while 
maintaining asthma control.  For the primary endpoint, assuming a common 
standard deviation of 50%, with 90 randomized patients per group, the study 
will have 94% power to detect a treatment difference of 27% at the 2-tailed 
significance level of Į=0.05.  For the key secondary endpoint, with the same 
sample size of 90 randomized patients per group, the study will have 81% 
power to detect a difference in the proportion of patients achieving 50% or 
greater in their OCS dose of 33% in the placebo group, compared to 54% in 
the dupilumab group at the 2-tailed significance level of Į=0.05. 
Patients will be randomized using a 1:1 randomization ratio for dupilumab 
300mg q2w and placebo.  Randomization will be stratified by optimized OCS 
dose at Week 0 (10 mg/day, >10 mg/day) and country.  
Recruitment of patients whose eosinophil level is below 150 cells/μL will stop 
when approximately 46 (25% of the total sample size) of such patients are 
randomized.  Recruitment will continue with patients whose eosinophil level is 
greater or equal to 150 cells/μL until reaching the total sample size of 180.  In 
addition, the number of patients receiving 5 mg OCS at Visit 3 will be limited 
to approximately 54 patients (approximately 30% of the study population). 
Analysis population 
The analysis population for the efficacy endpoints will be the intent-to-treat 
(ITT) population defined as all randomized patients.  The efficacy analyses 
will be conducted according to the treatment to which they are randomized. 
The analysis population for the safety endpoints will be the safety population 
defined as all patients exposed to study medication, regardless of the amount 
of treatment administered.  The safety analyses will be conducted according 
to the treatment patients actually received. 
Primary analysis 
The outcome of the percentage reduction of OCS dose at Week 24 compared 
with the baseline dose, while maintaining asthma control, will be calculated 
as: (optimized OCS dose – final OCS dose at Week 24)/optimized OCS dose 
× 100%.  The percentage reduction will be analyzed using an analysis of 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 12 
covariance (ANCOVA) model.  The model will include the percentage 
reduction of OCS dose at Week 24 as the response variable, and treatment 
group, baseline eosinophil level subgroups (<150 cells/μL and 150 cells/μL), 
optimized OCS dose at baseline, region as covariates.  Patients who 
permanently discontinue the study medication will be asked and encouraged 
to return to the clinic for all remaining study visits and the Investigator will 
continue to prescribe OCS at the dose specified for OCS titration.  The off-
treatment OCS dose at Week 24 will be used in the primary analysis. 
Analysis of secondary endpoints 
The absolute reduction of OCS dose at Week 24 will be analyzed using an 
ANCOVA model in the same fashion as for the primary endpoint (percent 
reduction of OCS dose at Week 24). 
The proportion of patients achieving OCS reduction will be analyzed using a 
logistic regression model including treatment, baseline eosinophil level 
subgroups, optimized OCS dose at baseline, and region as covariates. 
The annualized rate of severe asthma exacerbation events will be analyzed 
using a negative binomial regression model.  The model will include the total 
number of events occurring during the 24-week Randomized Treatment 
period as the response variable, with the treatment group, baseline eosinophil 
level subgroups, region, baseline optimized OCS dose strata, and number of 
severe exacerbation events prior to the study as covariates.  Log transformed 
treatment duration will be the offset variable.  For patients who permanently 
discontinue the treatment, the events which occurred up to Week 24 will be 
included and the last contact date will be used to calculate the offset variable.  
For patients lost to follow up prior to Week 24, events that occurred up to the 
last contact date will be analyzed, and the last contact date will be used to 
calculate the offset variable. 
Time to severe asthma exacerbation will be analyzed using a Cox regression 
model with time to event as the dependent variable, and treatment group, 
baseline eosinophil level subgroups, region, baseline optimized OCS dose 
strata, number of asthma events prior to the study, and region as covariates.  
The Kaplan-Meier method will be used to derive the proportion of patients 
with an asthma exacerbation event at Weeks 12 and 24 for each treatment 
group. 
The change from baseline in FEV1 will be analyzed using a mixed-effect 
model with repeated measures (MMRM) approach.  The model will include 
change from baseline FEV1 values up to Week 24 as response variables, and 
factors (fixed effects) for treatment, age, sex, height, baseline eosinophil level 
subgroups, region, baseline optimized OCS dose strata, visit, treatment 
by-visit interaction, baseline FEV1 value, and baseline-by-visit interaction.  An 
unstructured correlation matrix will be used to model the within-patient errors.  
Parameters will be estimated using restricted maximum likelihood method 
with the Newton-Raphson algorithm.  Statistical inferences on treatment 
comparisons for the key secondary endpoint, percentage change from 
baseline in FEV1 at each visit, will be derived from the mixed-effect model.  
The change from baseline for continuous endpoints will be analyzed using a 
MMRM in the same fashion as for the change in FEV1.  Data up to Week 24 
will be included as response variables.  Age, sex, and height will be included 
as covariates in the models for spirometry parameters only. 
The safety variables, including AEs, laboratory parameters, vital signs, ECG 
and physical examinations will be summarized using descriptive statistics. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 13 
Interim analysis 
No interim analysis is planned for this study. The primary analysis is planned 
when the last patient completes the week 24 visit or discontinues from the 
study before week 24. 
Data base lock 
The primary database lock will be based on the date when the last patient 
completes the week 24 visit or discontinues from the study before week 24.  
Analyses will be based on all data collected up to this database lock and will 
be considered as the final analyses in the CSR (Clinical Study Report). 
Additional data between database lock and last patient completing last visit 
will be summarized in a CSR addendum. 
DURATION OF STUDY PERIOD (per 
patient)  
Total duration of study (per patient) is expected to be up to 46 weeks: 
x
Up to 10 weeks for screening 
x
24 weeks of  treatment 
x
12 weeks of post-treatment follow-up 
(electronic 










Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 18 
h
At Visit 1, perform chest X-ray or magnetic resonance imaging (MRI) if no chest imaging (X-ray, computed tomography [CT], MRI) available within the previous year. At Visit 10, it is only 
applicable for patients who plan to roll over into a long-term study and available chest imaging is over 1 year from rolling over into a long-term study. 
i
Prior to screening, patients must be on a stable high-dose ICS (fluticasone propionate >500 μg total daily or equivalent) plus a second controller (LABA, LTRA, etc) for 1 month prior 
to  Visit 1.  Patients requiring a third controller are considered eligible for this study.  Patients should be on well-documented, regular prescribed treatment of maintenance systemic 
corticosteroids in the 6 months prior to Visit 1 and using a stable OCS dose for 4 weeks prior to Visit 1.  Patients must be taking 5 to 35 mg/day of prednisone or equivalent at Visit 1. 
j
Investigational product administrations (q2w) must be separated by at least 11 days.  The randomized Treatment Period visits occur every 2 weeks up to Week 8 and then every 4 weeks, 
alternating with q2w home administration of IMP (patient, caregiver, or health care professional) without study visit up to the end of treatment period at Week 24.  After Visit 7 (Week 8), if the 
patient or Investigator decides not to administer IMP at home, the IMP injections can be performed at the site by way of unscheduled visits.  Patients will be monitored at the study site for a 
minimum of 30 minutes after injections. 
k
Electronic diary/PEF meter is used for daily recording of salbutamol/albuterol or levosalbutamol/levalbuterol use, ICS, LABA, LAMA, LTRA, and other controller use, OCS requirements, 
nocturnal awakenings, morning and evening asthma symptom scores, and AM and PM PEF.  The device is dispensed at Visit 1. The eDiary data must be reviewed on a weekly basis by the 
Investigator during the Optimization Period and prior to OCS dose reduction during the OCS Reduction Phase of the study, including Visit 5. 
l
During the OCS Optimization period, the ACQ-5 will be completed weekly in the patient’s electronic diary. During the Treatment and Post-treatment periods, the ACQ-7 will be performed at 
clinic visits and the ACQ-5 will be completed on a weekly basis for those weeks that the patient does not have a scheduled clinic visit. 
m FeNO assessment is conducted prior to spirometry and following a fast of 1 hour. 
n
Vital signs, including blood pressure (mmHg), heart rate (beats per minute), respiratory rate (breaths per minute), body temperature (degrees Celsius) and body weight (kg) will be measured 
at the Screening and Randomization visits (Visits 1, 2 and 3) and every subsequent visit.  Height (cm) will be measured at screening (Visit 1) only.  Vital signs will be measured in the sitting 
position using the same arm at each visit, and will be measured prior to receiving investigational product at the clinic visits. 
o
OCS dose adjustments can be made during scheduled phone visits or scheduled in-clinic visits. 
p
Patients who  do not meet the criteria for OCS reduction at Visit 5 may begin reduction at a later visit. 
q
OCS titration during the OCS Optimization Phase can occur weekly following Visit 2 until the optimal OCS dose is determined and every 4 weeks during the OCS Reduction Phase but is not 
necessarily required to occur during a scheduled in-clinic visit. 
r
At the EOT visit (Visit 11), the final OCS dose the patient is receiving needs to be documented; no adjustments to the OCS dose will be permitted (except for those patients who experience an 
asthma exacerbation). 
s
Serum pregnancy test at Visit 1 and urine pregnancy tests at other visits.  A negative result must be obtained at Visits 1 and 3 prior to randomization. 
t
Hematology: hemoglobin, hematocrit, platelet count, total white blood cell count with 5-part differential count, and total red blood cell count. Serum chemistry: creatinine, blood urea nitrogen, 
glucose (only at Visits 3, 8,.and 11), HbA1c, uric acid, total cholesterol, total protein, albumin, total bilirubin (reflex testing will be triggered by elevated bilirubin), alanine aminotransferase, 
aspartate aminotransferase, alkaline phosphatase, lactate dehydrogenase, electrolytes (sodium, potassium, chloride), bicarbonate, and creatine phosphokinase.  Clinical laboratory testing at 
Visit 1 and Visit 10 (only for patients who planned roll over into a long-term study)  includes hepatitis screen (HBsAg, HBsAb, IgM and IgG/total-HBcAb, and HCVAb), HIV screen (anti-HIV-1 
and anti-HIV-2 antibodies), and ANA. Patients who are IgG/Total-HBc Ab positive and  HBs Ag negative at Visit 1 must undergo HBV DNA testing prior to randomization to determine eligibility 
(only applicable for patients who plan to roll over into  a long term study).  Note: Anti-ds DNA antibody will be tested if ANA is positive (1:160 titer).  At Visits 3 (randomization), 8, and 11, the 
blood sample should be taken with the patient in fasting state which means no intake of any food or drink except for water for at least 8 hours.  If the visit can only be done at a different time of 
the day and the patient is not fasting, then he/she should be advised to eat a light meal and the site should document that serum chemistry was not obtained under fasting conditions. 
u
Urine dipstick analysis, including specific gravity, pH, glucose, ketones, blood protein, nitrate, leukocyte esterase, urobilinogen, and bilirubin. If any parameter on the dipstick is abnormal, a 
urine sample should be sent to the central laboratory for testing.  If positive for proteins, microscopic analysis will be performed by central laboratory. 
v
Pharmacokinetic samples will be collected prior to dosing.   
w Systemic drug concentration and ADA samples are to be collected prior to dosing. In the event of any SAE or any adverse event of special interest (AESI) of anaphylaxis or systemic allergic 
reaction related to IMP and requiring treatment, or severe injection site reaction lasting longer than 24 hours, samples will be collected near the onset and resolution of the event for any 
additional analysis if required or for archival purposes. See Section 9.2.5 for more details. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 19 
x
ADA samples are to be collected prior to dosing.  
y
Archival serum will be collected for potential use in retrospective safety follow-up or additional biomarker analysis. Collection of archival serum is optional and requires the patient to sign 
consent.  
z
Optional sampling for exploratory analysis of DNA and RNA, requiring separate pharmacogenetics informed consent. Blood for DNA can be collected any time during the study;  blood for RNA 
must be collected prior to any IMP administration. 
aa For those patients with bilateral nasal polyposis/chronic rhinosinusitis. 
bb Sputum and additional blood samples will be collected at selected Canadian sites as an optional assessment.  At Visits 3 and 11, both sputum and blood will be collected.  At Visit 14, only a 
sputum sample will be collected (for patients who have not rolled over into a long-term study).  In addition, sputum collection will be obtained when a patient experiences symptoms of an 
asthma exacerbation (collected during an unscheduled visit). 
cc An optional assessment to be done in selected Canadian sites (only for patients with a FEV170% of predicted). 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 20 
2 
TABLE OF CONTENTS 
 
AMENDED CLINICAL TRIAL PROTOCOL 02 ..............................................................................................1
1
FLOW CHARTS.............................................................................................................................14
1.1
STUDY FLOW CHART ..................................................................................................................15
2
TABLE OF CONTENTS ................................................................................................................20
2.1
LIST OF TABLES...........................................................................................................................27
3
LIST OF ABBREVIATIONS ..........................................................................................................28
4
INTRODUCTION AND RATIONALE.............................................................................................30
4.1
INTRODUCTION............................................................................................................................30
4.2
RATIONALE...................................................................................................................................31
4.2.1
Rational for study design ...............................................................................................................31
4.2.2
Rationale for dose selection...........................................................................................................32
5
STUDY OBJECTIVES ...................................................................................................................34
5.1
PRIMARY.......................................................................................................................................34
5.2
SECONDARY ................................................................................................................................34
5.3
EXPLORATORY ............................................................................................................................34
6
STUDY DESIGN ............................................................................................................................35
6.1
DESCRIPTION OF THE PROTOCOL...........................................................................................35
6.2
DURATION OF STUDY PARTICIPATION ....................................................................................35
6.2.1
Duration of study participation for each patient .............................................................................35
6.2.2
Determination of end of clinical trial (all patients) ..........................................................................35
6.3
INTERIM ANALYSIS......................................................................................................................36
6.4
STUDY COMMITTEES..................................................................................................................36
6.4.1
Data monitoring committee ............................................................................................................36
6.5
DISCUSSION OF STUDY DESIGN AND CHOICE OF CONTROL GROUPS .............................36
7
SELECTION OF PATIENTS..........................................................................................................37
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 21 
7.1
INCLUSION CRITERIA..................................................................................................................37
7.2
EXCLUSION CRITERIA ................................................................................................................37
7.2.1
Exclusion criteria related to study methodology ............................................................................38
7.2.2
Exclusion criteria related to the active comparator and/or mandatory background therapies.......39
7.2.3
Exclusion criteria related to the current knowledge of Sanofi compound......................................39
7.2.4
Additional exclusion criteria during or at the end of the Screening period/OCS optimization 
period before randomization ..........................................................................................................41
8
STUDY TREATMENTS .................................................................................................................42
8.1
INVESTIGATIONAL MEDICINAL PRODUCTS.............................................................................42
8.1.1
Dupilumab......................................................................................................................................42
8.1.2
Placebo ..........................................................................................................................................42
8.1.3
Preparation of investigational product............................................................................................42
8.1.4
Dosing schedule.............................................................................................................................42
8.2
NONINVESTIGATIONAL MEDICINAL PRODUCTS.....................................................................43
8.2.1
Inhaled corticosteroid with a second or third controller..................................................................43
8.2.2
Oral corticosteroids ........................................................................................................................44
8.2.2.1
Screening Period/Oral Corticosteroid Optimization Phase (Visits 1 and 2)...................................44
8.2.2.2
Randomized Treatment Period......................................................................................................46
8.2.3
Posttreatment/Follow-up Period.....................................................................................................48
8.2.4
Reliever Medication........................................................................................................................48
8.2.5
Treatment of severe asthma exacerbations ..................................................................................48
8.2.6
Treatment after the end of the study..............................................................................................48
8.3
BLINDING PROCEDURES............................................................................................................48
8.3.1
Methods of blinding........................................................................................................................48
8.3.2
Randomization code breaking during the study.............................................................................49
8.4
METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP ..............................................49
8.5
PACKAGING AND LABELING ......................................................................................................50
8.6
STORAGE CONDITIONS AND SHELF LIFE................................................................................50
8.7
RESPONSIBILITIES ......................................................................................................................51
8.7.1
Treatment accountability and compliance......................................................................................51
8.7.2
Return and/or destruction of treatments ........................................................................................52
8.8
CONCOMITANT MEDICATION.....................................................................................................52
9
ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT ..............................................54
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 22 
9.1
PRIMARY ENDPOINT ...................................................................................................................54
9.1.1
Primary efficacy endpoint...............................................................................................................54
9.1.1.1
Oral corticosteroid dose adjustments.............................................................................................54
9.2
ADDITIONAL EFFICACY ENDPOINTS.........................................................................................55
9.2.1
Secondary efficacy endpoints related to adjustments in oral corticosteroid dosing ......................55
9.2.2
Disease-specific efficacy measures...............................................................................................55
9.2.2.1
Severe asthma exacerbation events..............................................................................................56
9.2.2.2
Spirometry......................................................................................................................................56
9.2.2.3
Electronic diary/peak expiratory flow meter ...................................................................................58
9.2.2.4
Asthma Control Questionnaire.......................................................................................................59
9.2.2.5
Health care resource utilization......................................................................................................60
9.2.2.6
Airway hyperresponsiveness (optional; only for patients enrolled in select sites in Canada) .......60
9.2.3
Safety and tolerability endpoints ....................................................................................................60
9.2.3.1
Adverse events ..............................................................................................................................61
9.2.3.2
Vital signs.......................................................................................................................................61
9.2.3.3
Physical examination .....................................................................................................................61
9.2.3.4
ECG ...............................................................................................................................................61
9.2.3.5
Clinical laboratory tests..................................................................................................................62
9.2.3.6
Pregnancy test ...............................................................................................................................63
9.2.4
Patient Reported Outcomes (Health-related Quality of Life/health economic variables/other 
endpoints) ......................................................................................................................................63
9.2.4.1
Asthma Quality of Life Questionnaire ............................................................................................63
9.2.4.2
SNOT-22........................................................................................................................................64
9.2.4.3
Hospital Anxiety and Depression Scale.........................................................................................64
9.2.4.4
EQ-5D-5L .......................................................................................................................................64
9.2.4.5
Asthma symptom score .................................................................................................................65
9.2.5
Systemic drug concentration and anti-drug antibodies..................................................................65
9.2.5.1
Sampling time ................................................................................................................................65
9.2.5.2
Handling procedures......................................................................................................................66
9.2.5.3
Bioanalytic method.........................................................................................................................66
9.2.6
Pharmacodynamics........................................................................................................................67
9.2.6.1
Whole blood biomarkers ................................................................................................................67
9.2.6.2
Plasma biomarkers ........................................................................................................................67
9.2.6.3
Serum biomarkers..........................................................................................................................67
9.2.6.4
Fractional exhaled nitric oxide .......................................................................................................68
9.2.6.5
ILC2 and CD34 cells and cytokines in sputum and blood (optional; only for patients 
enrolled in select sites in Canada).................................................................................................68
9.2.7
Pharmacogenetic assessment.......................................................................................................68
9.3
FUTURE USE OF SAMPLES ........................................................................................................69
9.4
APPROPRIATENESS OF MEASUREMENTS ..............................................................................69
10
STUDY PROCEDURES ................................................................................................................70
10.1
VISIT SCHEDULE..........................................................................................................................70
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 23 
10.1.1
Screening and Oral Corticosteroid Optimization Period ................................................................71
10.1.1.1 Visit 1 (Week -8 to -3) ....................................................................................................................71
10.1.1.2 Visit 2 (Week -7 to -2) ....................................................................................................................74
10.1.1.3 Weekly phone calls to optimize oral corticosteroid dose ...............................................................75
10.1.2
Randomized Treatment Period......................................................................................................76
10.1.2.1 Visit 3/Randomization (Week 0).....................................................................................................76
10.1.2.2 Induction Phase (4 weeks).............................................................................................................77
10.1.2.3 OCS Reduction Phase (16 weeks) ................................................................................................80
10.1.2.4 Maintenance Phase .......................................................................................................................86
10.1.3
Post-treatment Period ....................................................................................................................88
10.1.3.1 Visits 12 and 13 (Week 28 ± 3 days and Week 32 ± 3 days, respectively)...................................88
10.1.3.2 Visit 14 (Week 36 ± 3 days; end-of-study visit)..............................................................................89
10.2
DEFINITION OF SOURCE DATA..................................................................................................90
10.3
HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT 
DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION.......................................91
10.3.1
Temporary treatment discontinuation with investigational medicinal products..............................91
10.3.2
Permanent treatment discontinuation with investigational medicinal product(s) ...........................91
10.3.3
List of criteria for permanent treatment discontinuation.................................................................91
10.3.4
Handling of patients after permanent treatment discontinuation ...................................................92
10.3.5
Procedure and consequence for patient withdrawal from study....................................................92
10.4
OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING ..........................93
10.4.1
Definitions of adverse events.........................................................................................................93
10.4.1.1 Adverse event ................................................................................................................................93
10.4.1.2 Serious adverse event ...................................................................................................................94
10.4.1.3 Adverse event of special interest...................................................................................................95
10.4.2
Serious adverse events waived from expedited regulatory reporting to regulatory 
authorities.......................................................................................................................................96
10.4.3
General guidelines for reporting adverse events ...........................................................................96
10.4.4
Instructions for reporting serious adverse events ..........................................................................97
10.4.5
Guidelines for reporting adverse events of special interest...........................................................98
10.4.6
Guidelines for management of specific laboratory abnormalities ..................................................98
10.5
OBLIGATIONS OF THE SPONSOR .............................................................................................98
10.6
SAFETY INSTRUCTIONS .............................................................................................................99
10.6.1
Hypersensitivity..............................................................................................................................99
10.6.2
Severe injection site reactions .....................................................................................................100
10.6.3
Infections......................................................................................................................................100
10.6.4
Elevated liver function tests .........................................................................................................101
10.7
ADVERSE EVENTS MONITORING............................................................................................101
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 24 
11
STATISTICAL CONSIDERATIONS............................................................................................102
11.1
DETERMINATION OF SAMPLE SIZE.........................................................................................102
11.2
DISPOSITION OF PATIENTS .....................................................................................................102
11.3
ANALYSIS POPULATIONS.........................................................................................................102
11.3.1
Efficacy populations .....................................................................................................................102
11.3.1.1 Intent-to-treat population..............................................................................................................103
11.3.2
Safety population .........................................................................................................................103
11.3.3
Systemic drug concentration population......................................................................................103
11.3.4
Anti-drug antibody population ......................................................................................................103
11.4
STATISTICAL METHODS ...........................................................................................................103
11.4.1
Extent of study treatment exposure and compliance...................................................................103
11.4.1.1 Extent of investigational medicinal product exposure..................................................................103
11.4.1.2 Compliance ..................................................................................................................................104
11.4.2
Analyses of efficacy endpoints.....................................................................................................104
11.4.2.1 Analysis of primary efficacy endpoint...........................................................................................104
11.4.2.2 Analyses of secondary efficacy endpoints...................................................................................105
11.4.2.3 Analyses of other efficacy endpoints ...........................................................................................106
11.4.2.4 Multiplicity considerations ............................................................................................................107
11.4.3
Analyses of safety data................................................................................................................107
11.4.3.1 Adverse events ............................................................................................................................107
11.4.3.2 Clinical laboratory evaluation, vital signs, and electrocardiogram data.......................................108
11.4.4
Analyses of systemic drug concentration, anti-drug antibodies, and pharmacodynamics 
variables.......................................................................................................................................109
11.4.4.1 Drug concentration analysis.........................................................................................................109
11.4.4.2 Anti-drug antibodies analysis .......................................................................................................109
11.4.4.3 Pharmacodynamic analysis .........................................................................................................109
11.4.5
Analyses of patient-reported outcomes (health-related quality of life/health economics 
variables.......................................................................................................................................109
11.5
INTERIM ANALYSIS....................................................................................................................110
12
ETHICAL AND REGULATORY CONSIDERATIONS.................................................................111
12.1
ETHICAL AND REGULATORY STANDARDS ............................................................................111
12.2
INFORMED CONSENT ...............................................................................................................111
12.3
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) ............112
13
STUDY MONITORING.................................................................................................................114
13.1
RESPONSIBILITIES OF THE INVESTIGATOR(S).....................................................................114
13.2
RESPONSIBILITIES OF THE SPONSOR...................................................................................114
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 25 
13.3
SOURCE DOCUMENT REQUIREMENTS..................................................................................115
13.4
USE AND COMPLETION OF CASE REPORT FORMS AND ADDITIONAL REQUESTS.........115
13.5
USE OF COMPUTERIZED SYSTEMS........................................................................................115
14
ADDITIONAL REQUIREMENTS.................................................................................................116
14.1
CURRICULUM VITAE..................................................................................................................116
14.2
RECORD RETENTION IN STUDY SITES ..................................................................................116
14.3
CONFIDENTIALITY .....................................................................................................................116
14.4
PROPERTY RIGHTS...................................................................................................................117
14.5
DATA PROTECTION...................................................................................................................117
14.6
INSURANCE COMPENSATION..................................................................................................118
14.7
SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES ...............................118
14.8
PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF 
A SITE..........................................................................................................................................118
14.8.1
By the Sponsor.............................................................................................................................118
14.8.2
By the Investigator .......................................................................................................................119
14.9
CLINICAL TRIAL RESULTS ........................................................................................................119
14.10
PUBLICATIONS AND COMMUNICATIONS ...............................................................................119
15
CLINICAL TRIAL PROTOCOL AMENDMENTS ........................................................................121
16
REFERENCES.............................................................................................................................122
17
APPENDICES..............................................................................................................................124
APPENDIX A.
CORTICOSTEROID TABLES ..........................................................................................125
APPENDIX B.
LIST OF PROHIBITED LIVE ATTENUATED VACCINES................................................127
APPENDIX C.
EXAMPLES OF CYP SUBSTRATES WITH A NARROW THERAPEUTIC RANGE.......128
APPENDIX D.
ASTHMA CONTROL QUESTIONNAIRE, 5-QUESTION VERSION................................129
APPENDIX E.
ASTHMA CONTROL QUESTIONNAIRE, 7-QUESTION VERSION................................131
APPENDIX F.
GENERAL GUIDANCE FOR THE FOLLOW-UP OF LABORATORY 
ABNORMALITIES BY SANOFI....................................................................................................134
APPENDIX G.
ASTHMA QUALITY OF LIFE QUESTIONNAIRE ............................................................139
APPENDIX H.
22-ITEM SINO NASAL OUTCOME TEST .......................................................................145
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 26 
APPENDIX I.
HOSPITAL ANXIETY AND DEPRESSION SCALE...........................................................147
APPENDIX J.
EUROQUAL QUESTIONNAIRE .......................................................................................149
APPENDIX K.
DEFINITION OF ANAPHYLAXIS .....................................................................................152
APPENDIX L.
LIST OF OPPORTUNISTIC INFECTIONS.......................................................................153
APPENDIX M.
COMMONLY USED ASTHMA CONTROLLER THERAPIES..........................................154
 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 27 
2.1 
LIST OF TABLES 
Table 1  Oral corticosteroid optimization titration schedule...........................................................................46
Table 2  Oral corticosteroid titration schedule during the Oral Corticosteroid Reduction phase ..................47
Table 3 - Summary of handling procedures for dupilumab ...........................................................................66
Table 4  Summary of bioanalytical methods for dupilumab and anti-dupilumab antibody............................67
Table 5  Summary of adverse event reporting instructions...........................................................................97
 
 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 28 
3 
LIST OF ABBREVIATIONS 
 
ACQ-5: 
Asthma Control Questionnaire-5 question version 
ADA: 
anti-drug antibodies 
AE: 
adverse event 
AESI: 
adverse events of special interest 
ANA: 
anti-nuclear antibody 
ANCOVA: 
analysis of covariance 
AQLQ: 
Asthma Quality of Life Questionnaire 
ATS: 
American Thoracic Society 
BMI: 
body mass index 
CDMS: 
clinical data management system 
CI: 
confidence interval 
COPD: 
chronic obstructive pulmonary disease 
CT: 
computed tomography 
CV%: 
coefficient of variation 
CYP: 
cytochrome P450 
DMC: 
data monitoring committee 
DRF: 
Discrepancy Resolution Form 
ECG: 
electrocardiogram 
e-CRF: 
electronic case report form 
ELISA: 
enzyme linked immunosorbent assay 
EOT: 
end-of-treatment 
ER: 
emergency room 
ERS: 
European Respiratory Society 
FEF25-75%: 
forced expiratory flow from 25% to 75% of the vital capacity 
FEV1: 
forced expiratory volume in 1 second 
FVC: 
forced vital capacity 
GCP: 
good clinical practice 
GINA: 
Global Initiative for Asthma 
GSO: 
Global Safety Officer 
HADS: 
Hospital Anxiety and Depression Scale 
HbA1c: 
hemogobin A1c 
HBsAb: 
hepatitis B surface antibody 
HCV: 
hepatitis C virus 
HCVAb: 
hepatitis C virus antibody 
HIV: 
human immunodeficiency virus 
HLGT: 
high-level group term 
HLT: 
high level term 
ICH: 
International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
ICS: 
inhaled corticosteroids 
IEC: 
Institutional Ethics Committee 
Ig: 
immunoglobulin 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 29 
IL: 
interleukin 
IL-4RĮ: 
interleukin-4 receptor alpha subunit 
IMP: 
investigational medicinal product 
IRB: 
Institutional Review Board 
ISR: 
injection site reaction 
ITT: 
intent-to-treat 
IVRS: 
interactive voice response system 
IWRS: 
interactive web response system 
KM: 
Kaplan Meier 
LABA: 
long-acting beta agonist 
LS: 
least squares 
LTRA: 
leukotriene receptor antagonist 
MCID: 
minimal clinically important difference 
MDI: 
metered dose inhaler 
MMRM: 
mixed effect model with repeated measures 
MRI: 
magnetic resonance imaging 
mRNA: 
messenger ribonucleic acid 
OCS: 
oral corticosteroids 
PC20: 
provocative concentration that causes a positive reaction 
PCR: 
polymerase chain reaction 
PCSA: 
potentially clinically significant abnormality 
PEF: 
peak expiratory flow 
PK: 
pharmacokinetic 
Pop: 
population 
PROs: 
patient-reported outcomes 
PT: 
preferred term 
Q1: 
first quartile 
q2w: 
every 2 weeks 
Q3: 
third quartile 
q4w: 
every 4 weeks 
RNA: 
ribonucleic acid 
SAE: 
serious adverse event 
SC: 
subcutaneous 
SD: 
standard deviation 
SEM: 
standard error of the mean 
SNOT-22: 
22-item Sino Nasal Outcome Test 
SOC: 
system organ class 
SUSAR: 
suspected unexpected serious adverse reactions 
TARC: 
thymus and activation-regulated chemokine 
TEAE: 
treatment-emergent adverse event 
Th-2: 
T-helper cell-2 
TSLP: 
thymic stromal lymphopoietin 
ULN: 
upper limit of normal 
VAS: 
visual analogue scale 
WBC: 
white blood cells 
ȕ-HCG: 
beta-human chorionic gonadotropin 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 30 
4 
INTRODUCTION AND RATIONALE 
4.1 
INTRODUCTION 
Asthma is a chronic inflammatory disease of the airways characterized by airway 
hyperresponsiveness, acute and chronic bronchoconstriction, airway edema, and mucus plugging.  
The inflammatory component of asthma involves many cell types, including mast cells, 
eosinophils, T-lymphocytes, neutrophils, and epithelial cells and their biological products.  For 
most asthma patients, a regimen of controller therapy and reliever therapy provides adequate 
long-term control.  However, it is estimated that 5% to 10% of asthma patients have symptomatic 
disease despite maximum recommended treatment with combinations of anti-inflammatory and 
bronchodilator drugs.  These patients account for up to 50% of the total health cost through 
hospital admissions, use of emergency services, and unscheduled physician visits (1). 
Although asthma is well controlled with inhaled therapy in most patients, approximately 10% of 
the patients have severe asthma that is associated with considerable morbidity and mortality.  
Severe asthma is a heterogeneous syndrome with multiple distinct phenotypes based on several 
clinical, functional, and inflammatory parameters (2,3).  From a clinical perspective, severe 
asthma has been divided into 3 subgroups (1,4):  
x
Frequent asthma exacerbations with relatively stable periods in between 
x
Asthma with fixed airway obstruction 
x
Corticosteroid-dependent asthma 
Corticosteroids are highly effective in patients with severe asthma; however, the regular use of 
systemic steroids can result in serious deleterious side effects affecting numerous body systems 
(eg, formation of cataracts, muscle weakening, central nervous system disorders, and 
osteoporosis) (5,6).  There is a clear need for safe corticosteroid sparing therapies for these 
patients. Current available options do not offer a positive benefit-risk ratio.  The consequences of 
unresponsiveness to therapy or lack of compliance with therapy is loss of asthma control and 
ultimately, asthma exacerbation. The poor response of some patients with asthma may reflect the 
number of cellular and molecular mechanisms operative in asthma. There is increasing interest in 
distinct phenotypes because targeted therapy is more likely to be successful in patients with 
similar underlying pathobiologic features (4). 
In a recently published trial involving 135 patients with severe eosinophilic asthma, treated with 
oral corticosteroids (OCS) for more than 6 months in addition to high dose inhaled corticosteroids 
(ICS) in combination with a second controller, received mepolizumab (an anti-interleukin [IL]-5 
monoclonal antibody) or placebo for 24 weeks.  Patients treated with mepolizumab were 2.4 times 
more likely to have a dose reduction in their OCS daily dose.  The median percentage reduction 
was 50% for the actively treated patients (7). 
Recent therapeutic approaches in asthma have been focused on trying to control the T-helper 
cell-2 (Th-2) response.  Up-regulation of IL-4 and IL-13 activity has been implicated as an 45 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 31 
important inflammatory component of asthma disease progression.  Dupilumab is under 
development as a potential novel treatment for asthma.  Dupilumab, a fully human monoclonal 
antibody, is directed against the IL-4 receptor alpha subunit (IL-4RĮ), which is a component of 
IL-4 receptors Type I and Type II, as well as the IL-13 receptor.  The binding of dupilumab to 
IL-4RĮ results in blockade of downstream signaling initiated by both IL-4 and IL-13.  Recently 
published clinical data from a Phase 2 clinical trial, demonstrated that dupilumab had a significant 
clinical effect in reducing asthma exacerbations, improving lung function and asthma control in 
patients with moderate to severe uncontrolled asthma in comparison with placebo (8).  For 
complete information regarding the preclinical and clinical evaluation of dupilumab to date, see 
the Investigator’s Brochure. 
4.2 
RATIONALE 
4.2.1 Rational for study design 
This Phase 3 study will investigate the efficacy and tolerability of dupilumab, in comparison with 
placebo, in reducing the use of OCS while maintaining asthma control in patients with severe 
refractory asthma.  The study will also investigate the effects of dupilumab on clinical markers of 
asthma control, including asthma exacerbation rate, quality of life, and lung function (eg, forced 
expiratory volume in 1 second [FEV1]).  The study will enroll patients with severe asthma and 
well-documented, regular prescribed treatment of maintenance systemic corticosteroids  in the 
6 months prior to screening.  The clinical trial will be divided into 3 periods: 
x
Screening and OCS optimization period (from 3 to up to 8 weeks [up to 10 weeks for those 
patients who experience an asthma exacerbation that requires a change in OCS dose to 
allow for 2 weeks of stabilization prior to randomization]). 
x
Treatment period (24 weeks): includes a 4-week induction phase, a 16-week OCS 
reduction phase, and a 4-week maintenance phase. 
x
Post-treatment period (12 weeks): to monitor the patients’ status following completion of 
study drug treatment.  This period only applies for those patients not rolling over into a 
long-term  study. 
The presence of a placebo arm is appropriate for the objectives of this study, since it will provide 
the most robust assessment of the efficacy and safety of dupilumab while still providing patients 
access to standard of care. 
The OCS adjustments (increase or decrease) during the Optimization phase and the length of the 
Optimization phase are deemed suitable because the patients have been managed on a stable dose 
of OCS for a significant period of time prior to the start of the study (as per by the inclusion 
criteria).  A similar optimization approach was successfully employed in 3 published OCS 
reduction studies (7,9,10). 
The proposed study design provides the opportunity to better understand the efficacy of 
dupilumab on multiple asthma domains including lung function, prevention of severe asthma 
exacerbations, and symptom control while reducing the dose of OCS over a period of 24 weeks. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 32 
4.2.2 Rationale for dose selection 
The dose regimen of subcutaneous (SC) dupilumab selected for this study is 300 mg every 
2 weeks (q2w).  All patients randomized to receive treatment with dupilumab will get an initial 
loading dose of 600 mg on Day 1.  The administration of the loading dose of dupilumab will 
allow systemic concentrations to reach steady-state faster, potentially reducing the time to onset of 
clinical effect.  
Proof of concept has been established in the ACT11457 study at 300 mg weekly.  One hundred 
and four patients with persistent, moderate-to-severe asthma and a blood eosinophil count of at 
least 300 cells/PL or a sputum eosinophil level of at least 3%, partially controlled or uncontrolled 
by medium-to-high doses of ICS plus long-acting beta agonist (LABA; fluticasone/salmeterol, 
budesonide/formoterol, or mometasone/formoterol) were randomized to the study.  The study 
showed unprecedented efficacy in a population of mostly severe asthmatics with poor asthma 
control and decreased lung function inadequately controlled with mostly high doses of ICS in 
combination with a LABA. 
In addition, in the Phase 2b study DRI12544, 776 patients were randomized in a 1:1:1:1:1 ratio to 
1 of 4 dupilumab regimens or placebo.  The doses tested were: 200 mg every 4 weeks (q4w), 
300 mg q4w, 200 mg q2w, 300 mg q2w, and placebo.  Patients on the 300 mg regimens received 
a 600 mg loading dose on Day 1, whereas those treated with 200 mg doses received a loading 
dose of 400 mg.  Study treatment was administered for 24 weeks.  A prespecified interim analysis, 
based upon all available data at that time, was performed when the last patient completed 
12 weeks of treatment.  The assessment, change from baseline in FEV1 at Week 12, was the final 
analysis of the primary endpoint.  The analysis of annualized rate of severe asthma exacerbation 
included all events that occurred during the treatment period, adjusted by the treatment duration.  
At the time of this analysis, the average observed treatment duration was approximately 21.4 out 
of 24 weeks (approximately 89% of study information), with 70% of patient having completed 
24 weeks of treatment, and 30% of patients had completed the 16-week off-treatment follow-up.   
Compared with placebo, treatment with dupilumab demonstrated dose-dependent improvement in 
FEV1 and reduction in the annualized severe asthma exacerbation rate.  In general, the q2w dosing 
regimens demonstrated greater efficacy than the q4w dosing regimen.  Both the 200 mg q2w and 
300 mg q2w dose regimens demonstrated statistically significant improvements in FEV1 and a 
significant reduction in the annualized rate of severe asthma exacerbations versus placebo in the 
overall intent-to-treat (ITT) population, patients with a baseline high eosinophil count (300 
cells/μL), and patients with a lower baseline blood eosinophil (<300 cells/μL).  In contrast to the 
q2w regimen, the q4w dosing regimens demonstrated a consistently lower improvement in FEV1 
from baseline compared with placebo than the q2w dosing regimens and the 200 mg q4w dose did 
not reach a statistically significant improvement in FEV1 in all patients as well as those with high 
baseline blood eosinophils. Secondary efficacy analysis)on endpoints such as patient reported 
outcomes (Asthma Control Questionnaire-5 question version [ACQ-5] and Asthma Quality of 
Life Questionnaire [AQLQ]) also support the superiority of the q2w regimens compared with the 
q4w dosing.  
Although the results of the Phase 2b study didn't show a clear differentiation between the 
2 biweekly regimens, modeling and simulation data suggest that the 300 mg q2w may exhibit 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 33 
better clinical efficacy.  Because this trial will enroll patients with greater asthma severity than 
those randomized in the Phase 2b and in the planned pivotal Phase 3 trial, the Sponsor prefers to 
optimize the chances for these patients for exhibiting the best clinical response to dupilumab.  For 
these reasons, the 300 mg q2w dose regimen has been selected for this trial. 
A population pharmacokinetic (PK) model prediction demonstrated that exposure in adolescents 
at the dose 300 mg q2w is not expected to exceed the observed adult exposure at the dupilumab 
dose regimen of 300 mg once weekly, which was observed to be generally well tolerated in adults. 
Therefore, adolescent dosing at 300 mg q2w regimen is expected to yield dupilumab exposure 
that is expected to result in efficacious exposures and unlikely to be associated with a heightened 
safety risk in this age population. 
Dupilumab has been safe and well-tolerated in all clinical trials completed in healthy volunteers, 
patients with atopic dermatitis, nasal polyposis with chronic sinusitis, or asthma dosed for up to 
16 weeks with a maximum dose of 300 mg administered every week.  No important identified 
risks have been established during the dupilumab clinical program.  A low discontinuation rate 
has been observed across the completed clinical trials in dupilumab treated patients.  Furthermore, 
patients on placebo demonstrated a higher discontinuation rate in comparison to those on 
dupilumab.  The reported rate of suspected unexpected serious adverse reactions (SUSARs) has 
also been low.  In addition, no imbalance in the frequency of treatment-emergent adverse events 
(TEAEs) between patients treated with dupilumab versus those treated with placebo has been 
observed, with the exception of injection site reactions (ISRs).  In summary, the safety data 
observed so far in completed and currently ongoing studies in patients with atopic dermatitis, 
asthma, or nasal polyps with chronic sinusitis have demonstrated a very positive profile for 
dupilumab in comparison with placebo. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 34 
5 
STUDY OBJECTIVES 
5.1 
PRIMARY 
The primary objective of this study is to evaluate the efficacy of dupilumab, compared with 
placebo, for reducing the use of maintenance OCS in patients with severe steroid-dependent 
asthma. 
5.2 
SECONDARY 
Secondary objectives of the study include: 
x
To evaluate the safety and tolerability of dupilumab 
x
To evaluate the effect of dupilumab in improving patient-reported outcomes (PROs)  
x
To evaluate dupilumab systemic exposure and the incidence of treatment-emergent 
anti-drug antibodies (ADA) 
5.3 
EXPLORATORY 
The following objectives will be exploratory: 
x
To evaluate baseline and on-treatment levels of biomarkers in association with treatment 
response and for their potential to predict treatment responses 
x
To evaluate patient genetic profiles and their potential to predict treatment responses 
x
To evaluate the effect of dupilumab on airway markers of inflammation (at select study 
sites within Canada) 
 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 35 
6 
STUDY DESIGN 
6.1 
DESCRIPTION OF THE PROTOCOL 
This is a multinational, multicenter, randomized, double-blind, placebo-controlled study assessing 
the effect of dupilumab administered SC for a maximum of 24 weeks in patients with severe 
steroid-dependent asthma.  Patients will be treated on an outpatient basis and will be stratified by 
optimized OCS dose at Week 0 (10 mg/day, >10 mg/day) and country. 
6.2 
DURATION OF STUDY PARTICIPATION 
6.2.1 Duration of study participation for each patient 
Screening is from signed informed consent to randomization and the study observation period 
starts at randomization and lasts until the end of the study.   
The total duration of the study (per patient) is expected to be up to 44 weeks (or up to 46 weeks in 
patients who experience an asthma exacerbation that requires a change in OCS dose to allow for 
2 weeks of stabilization prior to randomization) and consists of: 
x
Up to 10 weeks for the Screening period/OCS Optimization phase 
x
24 weeks for the Treatment period 
x
12 weeks for the Post-treatment period (for patients not rolling over into a long-term 
study) 
Patients who discontinue early from treatment or patients who choose not to roll over into a 
long-term study may be asked to return to the clinic to have additional ADA samples collected for 
analysis based on the overall assessment of antibody titers and clinical presentation. 
Patients who permanently discontinue the study medication will be asked and encouraged to 
return to the clinic for all remaining study visits. 
6.2.2 Determination of end of clinical trial (all patients) 
The last patient last visit will occur when the last patient either completes the end-of-treatment 
(EOT) visit (Visit 11) and rolls over into long-term study, or at the end of the 12-week safety 
follow-up period if the patient completes treatment and elects not to roll over into long-term study 
or discontinues treatment early, or withdraws during the Post-treatment period for any reason, 
whichever occurs last. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 36 
6.3 
INTERIM ANALYSIS 
No interim analysis is planned for this study. The primary analysis is planned when the last 
patient completes the week 24 visit or discontinues from the study before week 24. 
The primary database lock will be based on the date when the last patient completes the week 24 
visit or discontinues from the study before week 24.  Analyses will be based on all data collected 
up to this database lock and will be considered as the final analyses in the CSR (Clinical Study 
Report). Additional data between database lock and last patient completing last visit will be 
summarized in a CSR addendum. 
6.4 
STUDY COMMITTEES 
6.4.1 Data monitoring committee  
A data monitoring committee (DMC) is independent from the Sponsor and is commissioned for 
the dupilumab clinical development program.  This committee is comprised of externally-based 
individuals with expertise in the diseases under study, biostatistics, or clinical research.  The 
primary responsibilities of the DMC are to review and evaluate the safety data during the course 
of the trial and make appropriate recommendations regarding the conduct of the clinical trial to 
the Sponsor. 
The DMC procedures and safety data to be reviewed by the DMC are described in the DMC 
charter.  In the above capacities, the DMC is advisory to the Sponsor.  The Sponsor is responsible 
for promptly reviewing and for taking into account in a timely manner the recommendations of 
the DMC in terms of trial continuation with or without alterations or of potential trial termination. 
6.5 
DISCUSSION OF STUDY DESIGN AND CHOICE OF CONTROL GROUPS 
The study design (including reductions in OCS dosing) and choice of a control group is based on 
similar optimization approach of studies that have been successfully employed in 3 published 
OCS reduction studies (7,9,10). 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 37 
7 
SELECTION OF PATIENTS 
7.1 
INCLUSION CRITERIA 
I 01.
Adult and adolescent (12 years of age and older) patients with a physician diagnosis of 
asthma for 12 months, based on the Global Initiative for Asthma (GINA) 2014 guidelines 
and the following criteria: 
A) Patients with severe asthma and well-documented, regular prescribed treatment of 
maintenance systemic corticosteroids in the 6 months prior to Visit 1 and using a stable 
OCS dose (ie, no change of OCS dose) for 4 weeks prior to Visit 1.  Patients must be 
taking 5-35 mg/day of prednisone/ prednisolone, or the equivalent, at Visit 1 and at the 
Randomization visit.  In addition, patients must agree to switch to study-required 
prednisone/prednisolone as their OCS at Visit 1 (see Section 10.1.1) and use it per 
protocol for the duration of the study (see Appendix A for a steroid conversion chart). 
B) Existing treatment with high dose ICS (>500 Pg total daily dose of fluticasone propionate 
or equivalent) in combination with a second controller (ie, LABA, leukotriene receptor 
antagonist [LTRA]) for at least 3 months with a stable dose of ICS for 1 month prior to 
Visit 1.  In addition, patients requiring a third controller for their asthma will be 
considered eligible for this study, and it should also be used for at least 3 months with a 
stable dose 1 month prior to Visit 1 (see Appendix A for a steroid conversion chart). 
C) An FEV1 <80% of predicted normal for adults and 90% of predicted normal for 
adolescents at Visit 1. 
D) Evidence of asthma as documented by either: 
-
Reversibility of at least 12% and 200 mL in FEV1 after the administration of 200 to 
400 Pg (2 to 4 puffs of albuterol/salbutamol or levalbuterol/levosalbutamol, or of a 
nebulized solution of albuterol/salbutamol or levalbuterol/levosalbutamol, if 
considered as a standard office practice) before randomization or documented in the 
12 months prior to Visit 1 
OR 
-
Airway hyperresponsiveness (methacholine: provocative concentration that causes a 
positive reaction [PC20] of <8 mg/mL) documented in the 12 months prior to Visit 1. 
I 02.
Signed written informed consent. 
7.2 
 EXCLUSION CRITERIA 
Patients who have met all the above inclusion criteria listed in Section 7.1  will be screened for 
the following exclusion criteria which are sorted and numbered in the following 4 subsections:  
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 38 
7.2.1 Exclusion criteria related to study methodology 
E 01. Patients <12 years of age or the minimum legal age for adolescents in the country of the 
investigative site, whichever is higher (for those countries where local regulations permit 
enrollment of adults only, patient recruitment will be restricted to those who are 18 years 
of age). 
E 02. Patients who weigh <30 kg. 
E 03. Chronic obstructive pulmonary disease (COPD) or other lung diseases (eg, idiopathic 
pulmonary fibrosis, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis, 
cystic fibrosis) which may impair pulmonary function tests. 
E 04. Clinical evidence or imaging (eg, chest X-ray, computed tomography, magnetic resonance 
imaging) within 12 months of Visit 1 with clinically significant findings of lung disease(s) 
other than asthma, as per local standard of care. 
E 05. A patient who experiences a deterioration of asthma that results in emergency treatment or 
hospitalization within 4 weeks of Screening Visit 1. 
E 06. A patient who requires 12 puffs or more of rescue medication (eg, metered dose inhaler) 
on any 1 day in the week prior to Visit 1. 
E 07. A patient who has experienced an upper or lower respiratory tract infection within the 
4 weeks prior to Screening. 
E 08. Current smoker or cessation of smoking within 6 months prior to Visit 1. 
E 09. Previous smoker with a smoking history >10 pack-years. 
E 10. Comorbid disease that might interfere with the evaluation of the investigational medicinal 
product (IMP) (an example being, but not limited to, neuromuscular disease, etc). 
E 11. Known or suspected alcohol and/or drug abuse. 
E 12. Inability to follow the procedures of the study (eg, due to language problems or 
psychological disorders). 
E 13. Patients requiring non-selective beta-1 adrenergic receptor blockers for any reason, or 
initiation or change in dose of a selective beta-1 adrenergic receptor blocker within 
1 month prior to Visit 1 or plan to initiate or change in dose of a selective beta-1 
adrenergic receptor blocker during the screening period or the randomized treatment 
period. 
E 14. Anti-immunoglobulin (Ig) E therapy (omalizumab) within 130 days of Visit 1. 
E 15. Initiation of allergen immunotherapy within 3 months prior to Visit 1 or a plan to begin 
therapy or change dose during the Screening period or the Randomized Treatment period. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 39 
E 16. Patients on or initiation of bronchial thermoplasty within 3 years prior to Visit 1 or plan to 
begin therapy during the Screening period or the Randomized Treatment period. 
E 17. Exposure to another investigative antibody within a time period prior to Visit 1 that is less 
than 5 half-lives of the antibody.  In case the half-life is not known, then the minimum 
interval since exposure to the prior investigative antibody is 3 months.  The minimum 
interval since exposure to any other (non-antibody) investigative study medication is 
30 days prior to Visit 1. 
E 18. Patients receiving medications that are prohibited as concomitant medications (See 
Section 8.8). 
E 19. Patients who have previously been treated in any clinical trial of dupilumab. 
E 20. The patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, 
study coordinator, other staff or relative thereof directly involved in the conduct of the 
study. 
7.2.2 Exclusion criteria related to the active comparator and/or mandatory background 
therapies  
E 21. A patient with a history of clinically significant renal, hepatic, cardiovascular, metabolic, 
neurologic, hematologic, ophthalmologic, respiratory, gastrointestinal, cerebrovascular or 
other significant medical illness or disorder which, in the judgment of the Investigator, 
could interfere with the study or require treatment that might interfere with the study.  
Specific examples include but are not limited to insulin-dependent diabetes, uncontrolled 
hypertension, active hepatitis, active or latent untreated tuberculosis, bronchiectasis.  Other 
conditions that are well controlled and stable will not prohibit participation if deemed 
appropriate per the Investigator’s judgment. 
7.2.3 Exclusion criteria related to the current knowledge of Sanofi compound  
E 22. Pregnant or breastfeeding woman 
E 23. Women of childbearing potential (pre-menopausal female biologically capable of 
becoming pregnant) who do not fulfill: 
x
A confirmed negative serum beta-human chorionic gonadotropin test at Visit 1. 
And either: 
x
An established use of an acceptable contraceptive method: 
-
Oral, injected, inserted, or implanted hormonal contraceptive. 
-
Intrauterine device with or intrauterine system with progestogen. 
-
Barrier contraceptive (condom, diaphragm, or cervical/vault caps) used with 
spermicide (foam, gel, film, cream, or suppository). 
Or: 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 40 
-
Female sterilization (eg, tubal occlusion, hysterectomy, or bilateral salpingectomy). 
-
Male sterilization with post-vasectomy documentation of the absence of sperm in the 
ejaculate; for female patients, the vasectomized male partner should be the sole partner 
for that patient. 
-
True abstinence; periodic abstinence (eg, calendar, ovulation, symptothermal, 
post-ovulation methods) is not an acceptable method of contraception. 
-
Postmenopausal women (defined as at least 12 consecutive months without menses) 
are not required to use additional contraception. 
E 24. Deleted 
E 25. Diagnosed active parasitic infection (helminthes); suspected or high risk of parasitic 
infection, unless clinical and (if necessary) laboratory assessments have ruled out active 
infection before randomization. 
E 26. Positive for human immunodeficiency virus (HIV) infection or HIV serology at Visit 1. 
E 27. Known or suspected history of immunosuppression, including history of invasive 
opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, 
penumocystosis, or aspergillosis), despite infection resolution; or unusually frequent, 
recurrent or prolonged infections, per the Investigator’s judgment.  Tuberculosis testing 
will be performed on a country by country basis according to local guidelines, if required 
by regulatory authorities or ethic committees.  
E 28. Evidence of acute or chronic infection requiring treatment with antibacterials, antivirals, 
antifungals, antiparasitics, or antiprotozoals within 4 weeks before Visit 1, significant viral 
infections within 4 weeks before Visit 1 that may not have received antiviral treatment (eg, 
influenza receiving only symptomatic treatment).  Exceptions may be considered for 
uncomplicated mild viral or fungal infections requiring antiviral or antifungal therapy 
respectively only after discussion with the Investigator and approval by the Sponsor. 
E 29. Live, attenuated vaccinations within 4 weeks prior to Visit 1 or planned live, attenuated 
vaccinations during the study; see Appendix B for list of prohibited live, attenuated 
vaccines. 
E 30. Patients with active autoimmune disease or patients using immunosuppressive therapy 
(including OCS) for an autoimmune disease (eg inflammatory bowel disease, primary 
biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis) or patients with high 
titer of autoantibodies at Screening who are suspected by the Investigator or the Sponsor of 
having a high risk for developing an autoimmune disease. 
E 31. History of malignancy within 5 years before the Screening visit, except completely treated 
in situ carcinoma of the cervix, completely treated and resolved nonmetastatic squamous or 
basal cell carcinoma of the skin. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 41 
E 32. Patients with a history of systemic hypersensitivity reaction, other than localized injection 
site reaction, to any biologic drug. 
E 33. Patients with: 
x
Positive (or indeterminate) test for hepatitis B surface antigen (HBs-Ag),  
x
Positive IgM hepatitis B core antibody, 
x
Positive IgG/total hepatitis B core antibody confirmed by positive hepatitis B virus DNA 
(HBV DNA) 
x
Positive hepatitis C virus antibody (HCVAb) confirmed by positive hepatitis C virus RNA 
(HCV RNA) 
E 34. Patient has evidence of liver injury, as defined by any of the following criteria:  
x
Clinically significant/active hepatobiliary disease 
x
Alanine aminotransferase >3 × upper limit of normal (ULN) 
E 35. Patient has any of the following abnormal lab values at Screening: 
x
Creatine phosphokinase >10 × ULN 
x
Platelets <100,000 cells/mm3 
x
Eosinophils >1500 cells/mm3 
7.2.4 Additional exclusion criteria during or at the end of the Screening period/OCS 
optimization period before randomization 
E 36. Patient who has withdrawn consent before enrollment/randomization. 
E 37. Despite screening of the patient, enrolment/randomization is stopped at the study level. 
E 38. Patient did not experience an increase in ACQ-5 0.5 during the OCS optimization phase. 
E 39. Noncompliance with completion of the electronic diary (eDiary) defined as : 
x
Documented use of each asthma controller medication (including OCS, ICS/LABA, etc) 
dose as instructed during the OCS Optimization phase for at least 80% of the duration of 
that period. 
x
Completion of weekly ACQ-5 scores. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 42 
8 
STUDY TREATMENTS 
8.1 
INVESTIGATIONAL MEDICINAL PRODUCTS 
8.1.1 Dupilumab 
Sterile dupilumab will be provided in 150 mg/mL in glass prefilled syringes (2.25 mL total 
volume) to deliver 300 mg in 2 mL. 
8.1.2 Placebo 
Sterile placebo for dupilumab will be provided in identically matched glass prefilled syringes to 
deliver 2 mL. 
8.1.3 Preparation of investigational product 
Dupilumab or matching placebo in glass prefilled syringes will be dispensed to the patients.  
Additional information will be provided in the Pharmacy manual. 
8.1.4 Dosing schedule 
The IMP will be administered every 14 ± 3 days (ie, q2w).  The doses of the IMP must be 
separated by 11 days to avoid an overdose.   
Patients will receive q2w SC injections of 300 mg dupilumab or placebo following a loading dose 
of 600 mg on Day 1 during the 24-week Treatment period. 
Prophylactic treatment/premedication for an ISR is not permitted. 
Patients will have the option to self-administer the study drug (or have a caregiver administer 
study drug) outside the study site during weeks in which no clinic visit is scheduled.  The study 
staff will train the patient/caregiver on the preparation and administration of study drug on Day 1 
and will administer the first of the 2 injections required for the loading dose.  The 
patient/caregiver will administer the second injection required for the loading dose under the 
supervision of the clinic staff.  This training must be documented in the patient’s study file.  At 
subsequent study visits, patients are trained to self-inject the IMP, and the patients are allowed to 
self-inject IMP at home after 5 injections at the investigational site (starting on Week 10). 
When the patient has a study visit, the IMP will be administered following clinic procedures and 
blood collection.  Patients will be monitored for signs or symptoms of a hypersensitivity reaction 
at the study site for a minimum of 30 minutes.  
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 43 
For doses not given at the study site, a Home Dosing Diary will be provided to record information 
related to the injections.  The diary will be kept as source data in the patient’s study file and the 
information will be recorded in the eCRF. 
If the patient (or caregiver) is unable or unwilling to administer IMP, arrangements must be made 
for qualified site personnel and/or health care professionals (eg, visiting nurse service) to 
administer the IMP for the doses that are not scheduled to be given at the study site.  Patients who 
prefer to have the clinic staff administer study drug may choose to have injections administered in 
the clinic. 
If the study visit is not performed at the site as scheduled, the dose will be administered by the 
patient and/or their caregiver/health care professional, or arrangements must be made for an 
unscheduled visit at the site to administer the IMP.  When the IMP is administered at home, the 
patients must be advised by the site staff to self-monitor for potential signs and symptoms that 
may suggest a hypersensitivity reaction for at least 30 minutes after administration. 
If the patient, or caregiver does not develop the comfort to inject the investigational drug at home, 
or the Investigator determines that the patient (or caregiver) injection at home is not appropriate, 
injections can be performed at the site by way of unscheduled visits. 
Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen 
(avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not 
injected twice consecutively.  Injection in the upper arms could be done only by a trained person 
(parent/ caregiver trained by Investigator or delegate) or health care professional but not the 
patient themselves.  This instruction pertains to the day that the loading dose is injected as well as 
the administration of q2w injections.  For each injection, the anatomic site of administration will 
be recorded in the electronic case report form (e-CRF) and, as applicable, the home diary. 
Detailed instructions for transport, storage, preparation, and administration of the IMP are 
provided to the patient.  Patients will complete a Home Dosing Diary to document compliance 
with self-injection (or caregiver) injection of IMP. 
8.2 
NONINVESTIGATIONAL MEDICINAL PRODUCTS 
Oral corticosteroids will be provided by each investigational site. 
8.2.1 Inhaled corticosteroid with a second or third controller 
Prior to and during the Screening period, patients must be on a stable dose of high dose ICS with a 
second controller medication (LABA, LTRA, theophylline, etc).  Patients requiring a third 
controller for their asthma will be considered eligible for this study, and it should also be used for 
at least 3 months with a stable dose 1 month prior to Visit 1. 
During the Randomized Treatment period and Post-treatment period (for those patients not rolling 
over into a long-term study), patients will continue taking their controller medication(s). 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 44 
The recognized controllers in this study will include the following 5 classes: ICS, LABA, LAMA, 
anti-leukotrienes and methylxanthine. For examples of commonly used asthma controller 
therapies, refer to Appendix M for a list of controller medications approved for this study. 
8.2.2 Oral corticosteroids 
During the course of the study, patients will receive variable doses of OCS 
(prednisone/prednisolone).  Prednisone/prednisolone use will be captured on a daily basis by the 
patient using an eDiary. 
8.2.2.1 Screening Period/Oral Corticosteroid Optimization Phase (Visits 1 and 2) 
Patients who meet eligibility criteria at the Screening visit will enter the OCS Optimization Phase.  
Prednisone or prednisolone will be the only OCS used.  At the Screening visit (V1), patients 
currently using other forms of maintenance OCS will have their corticosteroids switched to either 
of these corticosteroids at a dose clinically equivalent to their current stable OCS maintenance 
dose.  The definition of stable OCS maintenance dose in EFC13691 is no change of OCS dose 
within 4 weeks of Screening Visit 1 
OCS optimization phase interruption criteria 
The lowest effective or optimized OCS dose will be defined during this phase as the lowest dose a 
patient can tolerate without experiencing any of the following criteria: 
x
Increase in ACQ-5 of 0.5 from the last ACQ-5 score recorded in the e-diary 
x
Severe asthma exacerbation 
x
Clinically significant event, based on investigator judgment that requires treatment by 
OCS dose adjustment 
In general, the investigator can refer to the ACQ-5 score at Screening Visit 1 to guide the OCS 
dose adjustments made during the optimization phase of the study; however, the decision to titrate 
can be based on the investigator’s clinical judgement.  Once determined, the optimized dose must 
remain stable for 2 consecutive weeks along with baseline medications without meeting any of the 
OCS optimization phase interruption criteria in order to be eligible for randomization.   
Investigators should adjust the OCS dose according to a prespecified titration schedule (Table 1) 
based on the OCS optimization phase interruption criteria, and in accordance with their clinical 
judgement.  The decision rule of the titration schedule will be based on changes in the patient’s 
asthma control, assessed by the above criteria.  In the absence of a severe asthma exacerbation or 
a clinically significant event, the change in OCS dose should be guided directly by the ACQ-5 
score. 
A severe asthma exacerbation event during the study is defined as a deterioration of asthma 
requiring: 
x
Use of systemic corticosteroids for 3 days (at least double the dose currently used) and/or  
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 45 
x
Hospitalization or emergency room (ER) visit because of asthma requiring intervention 
with a systemic corticosteroid treatment (at least double the dose currently used) 
No change in OCS dose will be made at Visit 1.  One week after the Screening visit (Visit 1), 
patients will return to the clinic for Visit 2.  At Visit 2, and weekly throughout the Optimization 
phase, patient stability will be assessed by the above outlined criteria.   
If at Visit 2, the patient’s asthma status remains controlled (ie, none of the above criteria are met), 
the Investigator should down titrate the patient’s OCS dose.  The downward titration will continue 
until a point when at least 1 of the OCS optimization phase interruption criteria are met.  If the 
down-titration is stopped, the investigator should up-titrate the OCS dose by 1 step per Table 1, 
unless the patient’s medical condition requires treatment with a higher dose of OCS. 
Deterioration is defined as an increase in the ACQ-5 score of 0.5 from the last ACQ-5 score 
recorded in the e-diary, the occurrence of a severe asthma exacerbation, or a clinically significant 
event, based on investigator judgment that requires treatment by OCS dose adjustment.  In these 
cases, the patient will return to the prior OCS dose at which none of the OCS optimization phase 
interruption criteria were met.   
If at Visit 2, or weekly thereafter, the patient's asthma status deteriorates as outlined above their 
OCS dose should be increased by 1 step (Table 1).  In this manner, the Screening/OCS 
Optimization phase can range from 3 to 8 weeks until an optimized dose of OCS is achieved 
(Note: If an asthma exacerbation occurs that requires a change in OCS dose, this period can be 
extended up to 10 weeks to allow for 2 weeks of stabilization prior to randomization.)  
In cases where the stable OCS dose for 4 weeks prior to Visit 1 does not conform to a dose found 
on Table 1, the initial dose reduction should be the most conservative decrease that approximates 
the Table 1 protocol guidance.  As an example, 6 mg could be reduced to 5 mg and then per 
protocol to 2.5 mg thereafter, or 8 mg to 7.5 mg and then 5 mg, depending upon the individual 
patient and the investigator’s judgment.  In the event of any uncertainty, the Investigator will 
discuss the therapy directly with the Sponsor prior to the first OCS dose reduction. 
Those patients who are able to down titrate their OCS dose to 2.5 mg during the OCS 
Optimization phase without meeting any of the above criteria, will be considered screen failures 
and will not be randomized. 
(electronic 






Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 48 
4 weeks and continue with dose reductions as per Table 2 at the following visit.  If a second 
exacerbation occurs, the OCS dose should be increased 1 step; however, no further OCS dose 
reductions will be allowed. 
8.2.3 Posttreatment/Follow-up Period 
During this follow-up period, patients will continue treatment with their stable dose of OCS.  The 
dose of OCS can be modified based on their level of asthma control, as determined by the 
Investigator. 
8.2.4 Reliever Medication 
Patients may administer albuterol/salbutamol or levalbuterol/levosalbutamol metered dose inhaler 
(MDI) as reliever medication as needed during the study.  Nebulizer solutions may be used as an 
alternative delivery method. 
8.2.5 Treatment of severe asthma exacerbations 
Severe asthma exacerbations will be treated with the use of oral or parenteral corticosteroids at a 
dose at least equivalent to double the dose of current maintenance dose of OCS for a minimum of 
3 days to a maximum of 7 days, this is to ensure that exacerbations are managed in a timely 
manner and consistently, when possible, for all patients participating in this study.  If the 
exacerbation is not resolved after 7 days, the treatment of the exacerbation may continue at the 
discretion of the Investigator. 
8.2.6 Treatment after the end of the study 
The Investigator is responsible for ensuring that consideration has been given to the post study 
care of the patient’s medical condition.  
Patients who complete the 24-week treatment period, and return for the EOT visit at Week 24, 
may be eligible to roll over into a long-term study. 
At the end of the study, patients who do not roll over into a long-term study may be prescribed 
appropriate alternative asthma therapy if needed and as determined by the study Investigator. 
8.3 
BLINDING PROCEDURES 
8.3.1 Methods of blinding 
Dupilumab and placebo will be provided in identically matched 2 mL prefilled syringes.  To 
protect the blind, each treatment kit of 2 mL (dupilumab or placebo) glass prefilled syringe will be 
prepared such that the treatments (dupilumab or placebo) are identical and indistinguishable and 
will be labeled with a treatment kit number.  The randomized treatment kit number list will be 
generated by Sanofi. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 49 
Both the patient and the Investigator will be blinded to the assigned active drug or placebo.  Study 
patients, Investigators, and study site personnel will not have access to the randomization 
(treatment codes) except under circumstances described in Section 8.3.2. 
Patients, Investigators, and site personnel will not have access to assay results for 
immunoglobulins (IgG, IgG subclasses, IgA, and IgM) after the first administration of IMP 
because these values have the potential for unblinding.  Furthermore, neither patients, 
investigators, nor site personnel will have access to eotaxin-3, antigen-specific IgE, thymus and 
activation-regulated chemokine (TARC), or periostin while the study is ongoing or upon study 
completion, as the related data are not essential for patient care and have the potential for 
unblinding.   
The DMC will receive blinded results by treatment group or unblinded (if necessary) confidential 
reports from an independent statistician for review, which have to be handled 
 
  None of these reports can be delivered to unauthorized persons. 
8.3.2 Randomization code breaking during the study 
In case of an adverse event (AE), the code should only be broken in circumstances when 
knowledge of the IMP is required for treating the patient.  
Code breaking can be performed at any time by using the proper module of the interactive voice 
response system (IVRS)/interactive web response system (IWRS) and/or by calling any other 
phone number provided by the Sponsor for that purpose.  If the blind is broken, the Investigator 
should document the date, time of day, and reason for code breaking.   
Patient withdrawal will only occur when the code break call is made at the site level, not the study 
level.  This means that if the emergency unblinding transaction is performed by the Investigator 
(ie, at the site level), then the patient will be withdrawn from treatment.  However, if the 
emergency unblinding transaction is performed by the Global Safety Officer (GSO; ie, at the 
study level, as the GSO is not site based), then the patient will not be withdrawn from treatment.  
At the facilities where the systemic drug concentration measurements, ADA, and selected 
biomarkers are determined, the samples will be analyzed prior to data base lock leading to 
unblinding of responsible bioanalysts.  Bioanalysts are excluded from the clinical trial team. 
8.4 
METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP 
A randomized treatment kit number list will be generated centrally by Sanofi.  The investigational 
product (dupilumab or placebo) will be packaged in accordance with this list.   
The Sanofi Clinical Supplies team will provide the randomized treatment kit number list and the 
Study Biostatistician will provide the randomization scheme to the centralized treatment 
allocation system.  This centralized treatment allocation system will generate the patient 
randomization list according to which it will allocate the treatments to the patients. 
Patients who meet the entry criteria will be randomized to receive either dupilumab or placebo.   
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 50 
Patients who meet any exclusion criteria may be rescreened once during the open enrollment of 
the study.  A different patient identification will be issued for these patients.  Rescreening is not 
permitted if the patient fails to meet all inclusion criteria.  There is no requirement for a waiting 
period between the screen-failure date and the rescreening date.  The IVRS/IWRS report will flag 
rescreened patients.  Patients that are rescreened must sign a new consent form and all Visit 1 
procedures must be repeated. 
The Investigator obtains treatment kit numbers at randomization and subsequent scheduled visits 
via an IVRS/IWRS that will be available 24 hours a day. 
Patients will be randomized using a 1:1 randomization ratio for dupilumab 300 mg q2w and 
placebo q2w.  Randomization will be stratified by the optimized OCS dose (10 mg/day and 
>10 mg/day) at Week 0 and country.  
Recruitment of patients whose eosinophil level is <150 cells/μL will stop when approximately 46 
(25% of the total sample size) of such patients are randomized.  Recruitment will continue with 
patients whose eosinophil level is 150 cells/μL until reaching the total sample size of 180.  In 
addition, the number of patients receiving 5 mg OCS at Visit 3 will be limited to approximately 
54 patients (approximately 30% of the study population). 
A randomized patient is defined as a patient who is registered and assigned with a treatment kit 
number from the centralized treatment allocation system, as documented from its log file.  A 
patient cannot be randomized more than once in the study. 
8.5 
PACKAGING AND LABELING 
Dupilumab and placebo will be supplied as 1 glass prefilled syringe packed in a patient kit box.  
Both glass prefilled syringe and box will be labeled. 
Packaging is in accordance with the administration schedule.  The content of the labeling is in 
accordance with the local regulatory specifications and requirements. 
8.6 
STORAGE CONDITIONS AND SHELF LIFE 
All investigational products should be stored at a temperature between 2°C and 8°C in an 
appropriate, locked room under the responsibility of the Investigator or other authorized persons 
(eg, pharmacists) in accordance with local regulations, policies, and procedures. 
Control of investigational product storage conditions, especially control of temperature (eg, 
refrigerated storage), information on in-use stability, and instructions for handling the Sanofi 
compound should be managed according to the rules provided by the Sponsor. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 51 
8.7 
RESPONSIBILITIES 
The Investigator, the hospital pharmacist, or other personnel allowed to store and dispense the 
IMP will be responsible for ensuring that the IMP used in the clinical trial is securely maintained 
as specified by the Sponsor and in accordance with applicable regulatory requirements. 
All IMPs will be dispensed in accordance with the Investigator's prescription and it is the 
Investigator's responsibility to ensure that an accurate record of IMP issued and returned is 
maintained. 
Any quality issue noticed with the receipt or use of an IMP (deficiency in condition, appearance, 
pertaining documentation, labeling, expiration date, etc) should be promptly notified to the 
Sponsor.  Some deficiencies may be recorded through a complaint procedure. 
A potential defect in the quality of IMP may be patient to initiation of a recall procedure by the 
Sponsor.  In this case, the Investigator will be responsible for promptly addressing any request 
made by the Sponsor, in order to recall IMP and eliminate potential hazards. 
Under no circumstances will the Investigator supply IMP to a third party, allow the IMP to be 
used other than as directed by this clinical trial protocol, or dispose of IMP in any other manner. 
8.7.1 Treatment accountability and compliance 
Measures taken to ensure and document treatment compliance and accountability include: 
x
Proper recording of treatment kit number as required on the appropriate e-CRF page for 
accounting purposes. 
x
All medication treatment kits (whether empty or unused) are returned by the patient at 
each visit when a treatment dispensing is planned. 
-
The completed patient injection diary (returned to the site at each visit), returned 
treatment kit boxes, and any unused prefilled syringes will be used for drug 
accountability purposes. 
x
The Investigator or designee tracks treatment accountability/compliance, either by diary, 
or by counting the number of used treatment kits, and provides this information in the 
treatment log. 
x
Patients will record IMP dosing self-administered through the use of a Home Dosing 
Diary.  Site personnel will review the diary at each clinic visit and follow up with the 
patient accordingly. 
x
Prednisone/prednisolone use will be captured on a daily basis by the patient (or caregiver) 
through the use of a daily eDiary.  The Investigator or designee will review the eDiary at 
each clinic visit and follow up with the patient accordingly. 
The monitor in charge of the study then checks the data entered on the IMP administration page 
by comparing them with the IMP that has been retrieved and the patient treatment log form. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 52 
Prednisone/prednisolone, tracking and reconciliation has to be completed by the Investigator or 
designee according to the system proposed by the Sponsor. 
8.7.2 Return and/or destruction of treatments 
All partially used or unused treatment kits will be retrieved by the Sponsor or destroyed at study 
site.  All used prefilled syringes should be kept in a sharps container by the patients and be 
returned to sites for destroy.  A detailed treatment log of the returned IMP will be established with 
the Investigator (or the pharmacist) and countersigned by the Investigator and the monitoring 
team.  The Investigator will not destroy the unused IMP unless the Sponsor provides written 
authorization. 
8.8 
CONCOMITANT MEDICATION 
A concomitant medication is any treatment received by the patient concomitantly to any IMP(s).  
All concomitant medications taken during the study will be recorded in the eCRF, including the 
drug name and the dates of administration. 
The following concomitant treatments are not permitted during the Screening Period or the 
Randomized Treatment period: 
x
Anti-immunoglobulin E (IgE) therapy (eg, omalizumab)  
x
Other biologic therapies such as mepolizumab, benralizumab, anti-TNF, anti-IL-17, or 
other intravenous Ig therapies 
x
Systemic immunosuppressant  
x
Bronchial thermoplasty  
x
Beta-adrenergic receptor blockers (beta-blockers)  
x
Investigational drugs  
x
Live/attenuated vaccines: refer to Appendix B  
x
Asthma relievers other than salbutamol/albuterol or levosalbutamol/levalbuterol: their use 
is not recommended during the study period. In case of use in exceptional circumstances 
(eg, prescribed by a physician not participating in the study), their use will be documented 
in the patient's file and reported in the eCRF. 
Of note, the following medications will be permitted during the study 
x
Antihistamines 
x
Ocular, topical, or intranasal corticosteroids 
x
Continuous positive airway pressure for the treatment of obstructive sleep apnea, if 
initiated prior to the Screening visit. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 53 
Cytochrome P450 substrates: 
The impact of dupilumab on cytochrome P450 (CYP) enzyme activity has not been studied and 
the effect of dupilumab on levels of IL-4 and IL-13 has not been fully characterized.  However, 
IL-4 was reported to upregulate CYP2E1, 2B6, 3A4 messenger ribonucleic acid (mRNA) 
expression or down regulate CYP1A2 mRNA in human hepatocyte or human peripheral blood 
mononuclear cell culture (11,12).  Human peripheral blood mononuclear cells incubated with 
various Th-2 cytokines showed that IL-13 increased mRNA expression of CYP2B6 and CYP3A4 
(13).  Since the clinical significance of the limited in vitro findings for IL-4 and IL-13 
involvement in CYP regulation and the impact of dupilumab on CYP enzymes is not fully 
understood, during the study treatment and at least up to the end of follow-up, caution should be 
used for drugs which are metabolized via these CYP isoforms and which have a narrow 
therapeutic index.  This means that close clinical observation and/or laboratory monitoring as 
applicable are required in order to enable early detection of toxic manifestations or lack of 
activity/efficacy of these drugs, followed by dose adjustment or their withdrawal if needed 
(11,12,13).  Some examples of CYP450 substrates with narrow therapeutic index are provided in 
Appendix C. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 54 
9 
ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT 
9.1 
PRIMARY ENDPOINT 
9.1.1 Primary efficacy endpoint 
The primary efficacy endpoint for this study is the percentage reduction of OCS dose at Week 24 
compared with the baseline dose, while maintaining asthma control.  The percent reduction in 
OCS dose will be calculated as: (optimized OCS dose – final OCS dose at Week 24)/optimized 
OCS dose × 100.  A patient will be considered as having maintained asthma control between 
Week 20 and Week 24 if he/she does not have a clinically significant event, based on investigator 
judgment that requires treatment by OCS dose adjustment during this period.  For those patients 
who experience an exacerbation, the final OCS dose will be considered to be 1 step higher than 
the dose they were receiving at the time of the exacerbation.  Patients who permanently 
discontinue the study medication will be asked and encouraged to return to the clinic for all 
remaining study visits and the Investigator will continue to prescribe OCS at the dose specified 
for OCS titration.  The off-treatment OCS dose at Week 24 will be used in the primary analysis. 
9.1.1.1 Oral corticosteroid dose adjustments 
The dose adjustment of OCS through the OCS Reduction phase of the study will be based on the 
following: 
x
Asthma symptom data collected through the eDiary (ACQ-5 score) 
x
Clinically significant asthma exacerbation(s) 
x
Mean morning PEF <70% of baseline stability limit as assessed in the week prior to the 
clinical visit 
x
FEV1 20% reduction from baseline stability limit 
x
Rescue medication use requiring 4 or more puffs/day above the mean baseline value for 
any 2 consecutive days in the prior week, or 12 puffs on any 1 day in the week prior to 
the clinical visit 
x
Clinically significant event, based on Investigator judgment that requires treatment by 
OCS dose adjustment 
The patient will complete the ACQ-5 on a weekly basis and record the score in the eDiary 
(starting with Visit 1 onwards).  The Investigator will review the eDiary data on a weekly basis 
during the OCS Optimization phase and monthly during the Randomized Treatment period. 
Daily OCS dose will be recorded using the eDiary. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 55 
9.2 
ADDITIONAL EFFICACY ENDPOINTS 
9.2.1 Secondary efficacy endpoints related to adjustments in oral corticosteroid dosing 
The key secondary endpoint is: 
x
Proportion of patients achieving a reduction of 50% or greater in their OCS dose compared 
with baseline at Week 24 while maintaining asthma control.  The relative reduction for 
each patient will be calculated as (optimized OCS dose – final OCS dose at 
Week 24)/optimized OCS dose × 100. 
Other secondary efficacy endpoints include: 
x
Absolute reduction of OCS dose at Week 24 compared with the baseline dose while 
maintaining asthma control 
x
Proportion of patients achieving a reduction of OCS dose to <5 mg/day at Week 24 while 
maintaining asthma control 
x
Proportion of patients no longer requiring OCS at Week 24 while maintaining asthma 
control 
x
Proportion of patients achieving their maximum possible reduction of OCS dose per 
protocol at Week 24 while maintaining asthma control. 
9.2.2 Disease-specific efficacy measures 
The following additional disease-specific efficacy endpoints will be evaluated: 
Annualized rate of severe asthma exacerbation events (see Section 9.2.2.1) 
x
Time to first severe asthma exacerbation event 
x
Change from baseline in pre-bronchodilator FEV1 at Weeks 2, 4, 8, 12, 16, 20, and 24 
x
Percent change from baseline in pre-bronchodilator FEV1 at Weeks 2, 4, 8, 12, 16, 20, and 
24 
x
Change from baseline in other lung function measurements (percent predicted FEV1, 
morning/evening PEF, forced vital capacity [FVC], forced expiratory flow from 25% to 
75% of the vital capacity [FEF25-75%]), at Weeks 2, 4, 8, 12, 16, 20, and 24 
x
Absolute change from baseline in post-bronchodilator FEV1 at Weeks 12 and 24 
x
Change from baseline in ACQ-5 score at Weeks 2, 4, 8, 12, 16, 20, and 24 
x
Change from baseline in AQLQ score at Weeks 12, and 24  
x
Annualized rate of severe asthma exacerbations requiring hospitalization or ER visit 
x
Time to first severe asthma exacerbation requiring hospitalization or ER visit 
x
Change from baseline at Weeks 12 and 24 in: 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 56 
-
22-item Sino Nasal Outcome Test (SNOT-22) in patients with bilateral nasal 
polyposis/chronic rhinosinusitis 
-
Hospital Anxiety and Depression Scale (HADS) 
-
EQ-5D-5L 
x
Change from baseline at Weeks 2, 4, 8, 12, 16, 20, and 24 in: 
-
Morning/evening asthma symptom score and nocturnal awakenings (eDiary) 
-
Use of rescue medication 
-
Health Care Resource Utilization 
x
Change from baseline in airway hyperresponsiveness at Week 24 (for select study sites in 
Canada) 
9.2.2.1 Severe asthma exacerbation events 
A severe asthma exacerbation event during the study is defined as a deterioration of asthma 
requiring: 
x
Use of systemic corticosteroids for 3 days (at least double the dose currently used); 
and/or 
x
Hospitalization because of asthma symptoms or emergency room visit because of asthma 
requiring intervention with additional systemic corticosteroid treatment 
Two events will be considered as different if the interval between their start dates is equal or 
greater than 28 days. 
The period of time for which severe asthma exacerbation information will be included in the 
endpoint analysis will be from randomization until the Week 24 visit.   
For safety reasons, alerts will be programmed into the eDiary that will notify both the patient and 
the site to monitor the clinical situation closely in case the patient’s asthma worsens.  However, an 
alert in itself will not be classified as a clinically significant asthma exacerbation.  
The reasons (eg, infections including viral and bacterial, allergen exposure, exercise, or others) of 
the severe asthma exacerbation events will be collected on the eCRF. 
9.2.2.2 Spirometry 
The following parameters will be measured using spirometry:  FEV1 (pre- and post-
bronchodilator), percent predicted FEV1, FVC, and FEF25-75%. 
A spirometer that meets the 2005 American Thoracic Society (ATS)/European Respiratory 
Society (ERS) recommendations will be used.  Spirometry should be performed in accordance 
with the ATS/ERS guidelines (3).  For pre-bronchodilator measured parameters, including FEV1, 
FVC, and FEF25-75%, spirometry will be performed after withholding the last dose of 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 57 
salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and withholding the last 
dose of LABA for at least 12 hours and withholding the last dose of LAMA for at least 24 hours. 
For post-bronchodilator FEV1, the measure should follow the steps described for reversibility 
validation. 
At all visits, spirometry should be performed in the morning if possible, but if the test can only be 
done at a different time of the day, the testing should be done at approximately the same time of 
the day at each visit throughout the study.  The same spirometer and standard spirometric 
techniques, including calibration, will be used to perform spirometry at all visits and, whenever 
possible, the same person should perform the measurements.  Please refer to the Operational 
Manual for additional information. 
Pulmonary function tests will be measured in the sitting position; however, if necessary to 
undertake the testing with the patient standing or in another position, this should be noted on the 
spirometry report.  For any patient, the position should be consistent throughout the study. 
Three measurements fulfilling the ATS acceptability and repeatability criteria should be obtained 
at every visit, if possible.  The acceptability criteria must be applied before the repeatability 
criteria.  Unacceptable maneuvers must be discarded before applying the repeatability criteria.  If 
a patient fails to provide repeatable and/or acceptable maneuvers, an explanation should be 
documented.   
The largest FEV1 and largest FVC should be recorded after the data are examined from all of the 
acceptable curves, even if they do not come from the same curve.  The FEF25-75% should be 
obtained from the single curve that meets the acceptability criteria and gives the largest sum of 
FVC plus FEV1 (best performance). 
Automated best efforts, which combine FEV1 and FVC are not acceptable. 
The spirometer must be calibrated following the principles of the ATS/ERS guidelines every day 
that a study patient is seen and spirometry is carried out.  The calibration records should be kept in 
a reviewable log.  It is preferred that the calibration equipment (ie, 3-liter syringe) that is used to 
calibrate the spirometer be subjected to a validated calibration according to the manufacturer’s 
specifications. 
Reversibility/post-bronchodilator FEV1 
Reversibility, which is defined as an increase in absolute FEV1 of 12% over the baseline value, 
with an absolute increase of at least 200 mL, must be demonstrated within 30 minutes of 
bronchodilator administration.   
A reversibility test will be administered (if not done and documented within 12 months of Visit 1) 
following pulmonary function testing after asthma medications have been withheld for the 
appropriate intervals.  Patients will receive 2 to up to 4 puffs of albuterol/salbutamol.  
Alternatively, and only if it is consistent, with usual office practice (to be documented), 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 58 
reversibility may be performed using inhalation of nebulized albuterol/salbutamol.  Spirometry 
may be repeated several times within 30 minutes after administration of bronchodilator.   
If the patient does not meet the reversibility at Visit 1, 2 additional assessments can be performed 
at any time (ie, unscheduled visits) prior to randomization (Visit 3). 
Further details on spirometry will be available in a separate operational manual provided to the 
sites. 
9.2.2.3 Electronic diary/peak expiratory flow meter 
On a daily basis throughout the study, the patient uses an electronic diary/PEF meter to: 
x
Measure morning and evening PEF 
x
Respond to the morning and evening asthma symptom scale questions 
x
Record daily prednisone/prednisolone usage 
x
Indicate the number of puffs/day of salbutamol/albuterol or levosalbutamol/levalbuterol 
for symptom relief 
x
Record the use of daily controller medications  
x
Record the number of nocturnal awakenings due to asthma symptoms 
x
Record oral steroids use for asthma exacerbation event 
At Screening (Visit 1), patients will be issued an eDiary/PEF.  Patients will be instructed on the 
use of the device, and written instructions on the use of the electronic PEF meter will be provided 
to the patients.  In addition, the Investigator will instruct the patients on how to record the 
following variables in the electronic PEF meter: 
x
Morning PEF performed within 15 minutes after arising (between 5:30 AM and 10 AM) 
prior to taking any albuterol or levalbuterol 
x
Evening PEF performed in the evening (between 5:30 PM and 10 PM) prior to taking any 
albuterol or levalbuterol 
x
Patients should try to withhold albuterol/salbutamol or levalbuterol/levosalbutamol for at 
least 6 hours prior to measuring their PEF 
x
Three PEF efforts will be performed by the patient; all 3 values will be recorded by the 
electronic PEF meter, and the highest value will be used for evaluation 
Baseline morning PEF will be the mean AM measurement recorded for the 7 days prior to 
randomization, and baseline evening PEF will be the mean PM measurement recorded for the 
7 days prior to randomization.  Period stability limit is defined as the respective mean morning or 
evening PEF obtained over the last 7 days prior to Day1.  There should be at least 4 days’ 
measurement for setting up the stability limit, and the first dosing visit should be rescheduled until 
data for 4 days are available.  Please refer to the Operational Manual for additional information. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 59 
Information derived from the electronic PEF meter will be evaluated by the Investigator at study 
visits. 
9.2.2.4 Asthma Control Questionnaire 
The ACQ was designed to measure both the adequacy of asthma control and change in asthma 
control which occurs either spontaneously or as a result of treatment.  During the OCS 
Optimization period, the ACQ-5 will be completed weekly in the patient’s eDiary.  During the 
treatment period, the ACQ-7 will be performed at clinic visits and the ACQ-5 will be completed 
on a weekly basis for those weeks that the patient does not have a scheduled clinic visit. 
9.2.2.4.1 Asthma Control Questionnaire-5 question version 
The ACQ-5 is a 5-item questionnaire, which has been developed as a measure of patients’ asthma 
control that can be quickly and easily completed in clinical practice (14).  The questions are 
designed to be self-completed by the patient.  The 5 questions enquire about the frequency and/or 
severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, 
shortness of breath, and wheezing).  The response options for all these questions consist of a 0 (no 
impairment/limitation) to 6 (total impairment/ limitation) scale (Appendix D).  The ACQ-5 score 
is a mean of the values recorded for the individual questions. 
Throughout the study patients should complete the ACQ-5 on a weekly basis using their eDiary.  
The results from the ACQ-5 will be used as a part of the assessment to determine patient 
eligibility for OCS dose adjustment.  The patient should complete the questionnaire within the 
eDiary.  The patient should be instructed to complete the questions as accurately as possible.  The 
patient should be reassured that there are no right or wrong answers.  If the patient requests help 
or clarification with any of the questions, he/she will be asked to reread the instructions and give 
the answer that best reflects how he/she felt over the previous week.  The Investigator should not 
provide the patient with any answer or attempt to interpret any portion of a question. 
If the ACQ-5 is completed through the eDiary while the patient is at a scheduled in-clinic visit, it 
is recommended that the ACQ-5 be administered at the same time during the visit.  To avoid 
biasing responses, the patients should not be told the results of diagnostic tests prior to completing 
the questionnaire and should be completed before any procedures are performed on the patient to 
avoid influencing the patient’s response.  Adequate time should be allowed to complete all items 
on the ACQ-5. 
9.2.2.4.2 Asthma Control Quesionnaire-7 question version 
The ACQ-7 consists of 7 questions.  The first 5 questions assess the most common asthma 
symptoms: 1. frequency in past week awoken by asthma during the night, 2. severity of asthma 
symptoms in the morning, 3. limitation of daily activities due to asthma, 4. shortness of breath due 
to asthma and 5. wheeze, plus 6. short-acting bronchodilator use and 7. FEV1 (pre-bronchodilator 
use, % and % predicted use).  Patients are asked to recall how their asthma has been during the 
previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 
6= maximum impairment; Appendix E). 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 60 
Clinic staff scores the FEV1% predicted on a 7-point scale.  The questions are equally weighted 
and the ACQ score is the mean of the 7 questions and therefore between 0 (totally controlled) and 
6 (severely uncontrolled). 
A global score is calculated: the questions are equally weighted and the ACQ-7 score is the mean 
of the 7 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled).  
Higher score indicates lower asthma control.  Patients with a score below 1.0 reflect adequately 
controlled asthma and patients with scores above 1.0 reflect inadequately controlled asthma.  On 
the 7-point scale of the ACQ-7, a change or difference in score of 0.5 is the smallest change that 
can be considered clinically important, corresponding to the minimal clinically important 
difference (MCID) defined by the developer. 
Measurement properties such as reliability and ability to detect change have been documented in 
the literature (14). 
9.2.2.5 Health care resource utilization 
A questionnaire of health care resource utilization (reliever medication, specialist visit, 
hospitalization, emergency or urgent medical care facility visit, outcome, sick leaves, school days’ 
loss, etc) will be administered at each visit. 
9.2.2.6 Airway hyperresponsiveness (optional; only for patients enrolled in select sites in 
Canada)
Airway hyperresponsiveness will be assessed through a bronchial provocation test using 
methacholine (to be done only if the patient’s FEV1 is 70% of predicted).  A 20% decrease in the 
FEV1 will be considered as a positive test and the PC20 of agonist to cause this decrease is 
calculated by interpolation from the dose-response curve.  
9.2.3 Safety and tolerability endpoints  
The same safety assessments will be applied across both arms.  Adverse events, including serious 
adverse events (SAEs) and AEs of special interest (AESI), will be collected at every visit.  The 
Investigator will ask the patient how he/she has felt since the last study visit.  To assure the 
continuing safety of patients in this study, an independent DMC will be responsible for reviewing 
the safety data on a periodic basis throughout the course of the study as outlined in Section 6.4.1. 
Safety observations 
x
The Investigator should take all appropriate measures to ensure the safety of the patients.  
Notably, he/she should follow up the outcome of SAEs /AESI until clinical recovery is 
complete and laboratory results have returned to normal or until progression has been 
stabilized or death.  In all cases, this may imply that observations will continue beyond the 
last planned visit per protocol, and that additional investigations may be requested by the 
Sponsor. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 61 
x
When treatment is prematurely discontinued, the patient’s observations will continue until 
the end of the study as defined by the protocol for that patient. 
x
In case of any SAE/AESI with immediate notification brought to the attention of the 
Investigator at any time after the end of the study for the patient and considered by him/her 
to be caused by the investigational product with a reasonable possibility, this should be 
reported to the Sponsor. 
9.2.3.1 Adverse events 
Adverse events for each patient will be monitored and documented from the time the patient gives 
informed consent at Visit 1 until the End-of-Study visit (Visit 14) or until the rollover to a 
long-term study, except for: 
x
Serious AEs 
x
Adverse events that are ongoing at database lock 
Adverse events, AESI, and SAEs will be reported as described in Section 10.4. 
9.2.3.2 Vital signs 
Vital signs, including blood pressure (mmHg), heart rate (beats per minute), respiratory rate 
(breaths per minute), body temperature (degrees Celsius) and body weight (kg) will be measured 
at every visit.  Height (cm) will be measured at the Screening visit (Visit 1) only.  
Vital signs will be measured in the sitting position using the same arm at each visit, and will be 
measured prior to receiving investigational product at the clinic visits.  
Refer to Section 1.1 for the schedule of vital signs performed throughout this study. 
9.2.3.3 Physical examination 
Physical examinations will include an assessment of general appearance, skin, eyes, 
ear/nose/throat, heart, chest, abdomen, reflexes, lymph nodes, spine, and extremities.  All 
deviations from normal will be recorded, including those attributable to the patient’s disease. 
Refer to Section 1.1 for the schedule of physical examinations performed throughout this study. 
9.2.3.4 ECG 
One recording of a standard 12-lead electrocardiogram (ECG) will be performed centrally.  Refer 
to Section 1.1 for the schedule of ECGs performed throughout this study.  At the 
post-randomization visits in which an ECG is scheduled, the ECG will be performed prior to 
investigational product administration.   
All measurements will be made from a single lead: lead II, lead I (if lead II is not possible), or 
lead V5 (if leads II and I are not possible).  A minimum of 3 complexes in an appropriate lead 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 62 
(lead II) will be averaged to determine the PR-interval, QT/QTc-interval, QRS-complex and heart 
rate will be measured for each ECG. 
Please refer to the Operational Manual for additional information. 
The ECGs will be manually read at a central reading vendor.   
9.2.3.5 Clinical laboratory tests 
The clinical laboratory tests will be conducted by an accredited (College of American Pathologists 
or equivalent) central laboratory with national and regional clinical licenses as required for 
diagnostic testing and must provide evidence of participation in proficiency testing, as 
appropriate.  After reviewing the laboratory report and evaluating any results that are outside the 
normal range, the Investigator must sign and date the laboratory report.   
Abnormal laboratory values that are considered to be clinically significant by the Investigator 
must be repeated as soon as possible after receiving the laboratory report to rule out laboratory 
error.  Persistent abnormal laboratory values should be repeated until they return to normal or 
until an etiology of the persistent abnormality is determined. 
Refer to Section 1.1 for the description of the clinical laboratory evaluations and the schedule of 
laboratory evaluations performed throughout this study. 
The clinical laboratory parameters that will be measured are: 
x
Hematology: To include hemoglobin, hematocrit, platelet count, total white blood cell 
(WBC) count with 5-part differential count, and total red blood cell count. 
x
Serum chemistry: To include creatinine, blood urea nitrogen, glucose, hemoglobin A1c 
(HbA1c), uric acid, total cholesterol, total protein, albumin, total bilirubin (in case of 
values above the normal range, differentiation in conjugated and non-conjugated 
bilirubin), alanine aminotransferase (ALT), AST, alkaline phosphatase, lactate 
dehydrogenase, electrolytes (sodium, potassium, chloride), bicarbonate, and creatine 
phosphokinase.  At Visits 3 (randomization), 8, and 11, the blood sample should be taken 
with the patient in fasting state which means no intake of any food or drink except for 
water for at least 8 hours.  If the visit can only be done at a different time of the day and 
the patient is not fasting, then he/she should be advised to eat a light meal and the site 
should document that the serum chemistry was not obtained under fasting conditions. 
x
Urine dipstick analysis: To include specific gravity, pH, glucose, ketones, blood, protein, 
nitrate, leukocyte esterase, urobilinogen and bilirubin (by dipstick).  If any parameter on 
the dipstick is abnormal, a urine sample should be sent to the central laboratory for testing. 
If positive for proteins, microscopic analysis is performed by central laboratory. 
x
Serum immunoglobulins: quantitative immunoassays for total IgG, IgG subclasses 1-4, 
IgM, and IgA (after the first administration of IMP, results are blinded to the sites and 
sponsor study team). 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 63 
x
Clinical laboratory testing at Visit 1 and Visit 10 adds hepatitis screen including HBsAg, 
HBsAb, IgM and IgG/total-HBcAb, HCVAb, HIV screening (anti-HIV-1 and anti-HIV-2 
antibodies), and anti-nuclear antibody (ANA).  Note: anti-double-stranded DNA antibody 
will be tested if ANA is positive (1:160 titer). Patients who are IgG/total-HBcAb positive 
and HBsAg negative at Visit 1 must undergo HBV DNA testing prior to randomization to 
determine eligibility (only applicable for patients who plan to roll over into a long term 
study). In case of results showing HCVAb positive, HCV RNA testing must be negative 
prior to randomization.   
Decision trees for the management of certain laboratory abnormalities by Sanofi are provided in 
Appendix F. 
9.2.3.6 Pregnancy test 
A serum pregnancy test (ȕ-human chorionic gonadotropin) will be performed at Screening 
(Visit 1) in women of childbearing potential, and a urine dipstick pregnancy test will be 
performed at Visit 3 prior to randomization and other visits prior to investigational product 
administration.  A negative result must be obtained at Visits 1 and 3 prior to randomization.  
Refer to Section 1.1 for the schedule of pregnancy test performed throughout this study. 
9.2.4 Patient Reported Outcomes (Health-related Quality of Life/health economic 
variables/other endpoints) 
Patients should complete PROs before undergoing spirometry testing. 
9.2.4.1 Asthma Quality of Life Questionnaire 
The AQLQ was designed as a self-administered PRO to measure the functional impairments that 
are most troublesome to patients as a result of their asthma (see Appendix G).  The instrument is 
comprised of 32 items, each rated on a 7-point Likert scale (from 1 to 7).  The AQLQ has 4 
domains.  The domains and the number of items in each domain are as follows: 
x
Symptoms (12 items) 
x
Activity limitation (11 items) 
x
Emotional function (5 items) 
x
Environmental Stimuli (4 items) 
A global score is calculated ranging from 1 to 7 and a score by domain.  Higher scores indicate 
better quality of life. 
The instrument has been used in many clinical trials, and it has been shown to be reliable, valid 
(patient interviews), and sensitive to change.  The MCID for the AQLQ is 0.5 (15). 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 64 
9.2.4.2 SNOT-22 
The SNOT-22 is a validated questionnaire to assess the impact of chronic rhinosinusitis on health 
related quality of life (see Appendix H).  The SNOT-22 has 22 items, 5 domains and a global 
score.  The 5 domains include: 
x
Nasal (range 0-30) with a MCID of -2.5 
x
Ear (range 0-15) with a MCID of -1.25 
x
Sleep (0-20) with a MCID of -1.67 
x
General and practical (0-30) with a MCID of -2.50 
x
Emotional (0-15) with a MCID of -1.25.  
The range of the global score is 0-110 and an MCID of 8.9 (16).  Lower scores indicate less 
impact.  The recall period of the assessment is within the past 2 weeks. 
9.2.4.3 Hospital Anxiety and Depression Scale 
The HADS is a general scale used to detect states of anxiety and depression and has been 
validated in patients with asthma (see Appendix I).  The instrument is comprised of 14 items: 
7 items each related to anxiety and depression.  Each item on the questionnaire is scored from 0-3; 
with a score for either anxiety or depression ranging between 0 and 21. 
The minimal important difference for the HADS-A (anxiety) has been reported to be in the range 
of 0.41 (anxious and depressed patients in active treatment controlled studies) to 1.32 (COPD 
patients), in the range of 0.50 (anxious and depressed patients in active treatment controlled 
studies) to 1.40 (COPD patients) for HADS-D (depression) and approximately 1.5 (COPD 
patients) for the HADS total score (17,18). 
Alternatively, a significant improvement in treatment versus placebo group was defined as the 
percentage of patients who moved from a defined category of moderate to severe depression or 
anxiety (8) to not having the disease (<8) (19).  Using this methodology Stelara (Ustekinumab) 
was able to make the claim in summary of product characteristics that “HADS was significantly 
improved in the treatment group compared with placebo” (20). 
9.2.4.4 EQ-5D-5L 
The EQ-5D-5L is a standardized health-related quality of life questionnaire developed by the 
EuroQol Group in order to provide a simple, generic measure of health for clinical and economic 
appraisal (21).  The EQ-5D is designed for self-completion by patients. 
The EQ-5D essentially consists of 2 pages – the EQ-5D descriptive system and the EQ visual 
analogue scale (VAS; see Appendix J).  The EQ-5D descriptive system comprises 5 dimensions: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.  Each dimension has 
5 levels: no problems, slight problems, moderate problems, severe problems, and extreme 
problems.  The EQ VAS records the respondent’s self-rated health on a vertical visual analogue 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 65 
scale.  The EQ VAS ‘thermometer’ has endpoints of 100 (best imaginable health state) at the top 
and 0 (worst imaginable health state) at the bottom.  The MCID for the EQ-5D in asthma patients 
has been reported to be in the range of 0.001 to 0.074 (22,23). 
9.2.4.5 Asthma symptom score 
Patients will record overall symptom scores in an eDiary twice a day prior to measuring their 
PEF.  Symptoms experienced during the night will be recorded upon arising (AM symptom 
score).  The patient’s overall asthma symptoms experienced during the waking hours will be 
recorded in the evening (PM symptom score).  Baseline symptom scores will be the mean AM 
and mean PM scores recorded for the 7 days prior to randomization.  Scores can range between 
0-4 with 0 indicating more mild symptoms and 4 indicating more severe symptoms.  There is no 
global score, just an AM score and a PM score.  An MCID of 0.35 will be used. 
9.2.5 Systemic drug concentration and anti-drug antibodies 
9.2.5.1 Sampling time 
Blood samples of serum functional dupilumab and anti-dupilumab antibodies will be collected as 
designated in the study flow chart (Section 1.1).  Patients who discontinue early from treatment or 
patients who choose not to roll over into a long-term study may be asked to return to the clinic to 
have additional ADA samples collected for analysis based on the overall clinical presentation at 
that time.  
In the event of an SAE or any AESI of anaphylaxis or systemic allergic reaction related to IMP 
and requiring treatment, or severe injection site reaction lasting longer than 24 hours, samples will 
be collected near the onset and resolution of the event for any additional analysis if required or for 
archival purposes. An unscheduled systemic drug concentration page in the e-CRF must be 
completed as well. 
Pre-existing anti-drug antibodies are defined as:  
x
An ADA positive response in the assay at baseline with all post treatment ADA results 
negative, OR 
x
An ADA positive response at baseline with all post treatment ADA responses less than 4-
fold over baseline titer levels. 
Treatment-emergent anti-drug antibodies are defined as:  
x
An ADA positive response in the assay post first dose, when baseline results are negative 
or missing. 
x
Treatment-boosted anti-drug antibodies are defined as:   
x
An ADA positive response in the assay post first dose that is greater-than or equal to 4-
fold over baseline titer levels, when baseline results are positive. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 66 
Treatment-emergent (TE) ADA responses are further classified as Transient, Persistent or 
Indeterminate 
x
Persistent Response- defined as a treatment-emergent response with two or more 
consecutive ADA positive sampling time points, separated by more than 12-week period 
(with no ADA negative samples in between). 
x
Indeterminate Response- defined as a treatment-emergent response with only the last 
collected sample positive in the ADA assay  
x
Transient Response - defined as a treatment-emergent response that is not considered 
persistent OR indeterminate 
Unused samples collected for drug concentration or ADA analyses may be used for exploratory 
analyses. 
9.2.5.2 Handling procedures 
Special procedures for collection, storage, and shipping of serum are described in separate 
operational manuals.  An overview of handling procedure for samples used in the determination 
of systemic drug concentration and ADA is provided in Table 3. 
Table 3 - Summary of handling procedures for dupilumab 
Sample type 
Functional dupilumab 
Anti-dupilumab antibody 
Matrix 
Serum 
Serum 
Blood sample volume 
5 mL 
5 mL 
Anticoagulant 
None 
None 
Blood handling procedures 
See operational manual 
See operational manual 
Serum aliquot split 
2 aliquots 
2 aliquots 
Storage conditions 
<6 months: below -20°C 
<24 months: below -80°C (preferred) 
<6 months: below -20°C 
<24 months: below -80°C (preferred) 
Serum shipment condition 
In dry ice 
In dry ice 
 
9.2.5.3 Bioanalytic method 
Serum PK and ADA samples will be assayed using validated methods as described in Table 4. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 67 
Table 4  Summary of bioanalytical methods for dupilumab and anti-dupilumab antibody 
Analyte 
Functional dupilumab 
Anti-dupilumab antibody 
Matrix 
Serum 
Serum 
Analytical technique 
ELISA 
Electrochemiluminescence 
Lower limit of quantification 
0.078 mg/L 
Not applicable 
Site of bioanalysis 
Regeneron 
Regeneron 
ELISA=enzyme-linked immunosorbent assay. 
9.2.6 Pharmacodynamics 
Pharmacodynamics is an exploratory endpoint. 
Several biomarkers related to asthmatic inflammation and Th2 polarization will be assessed for 
their value in predicting therapeutic response and/or in documenting the time course of drug 
response.  In 2 prior asthma trials (ACT11457 and DRI12544), treatment with dupilumab 
significantly suppressed systemic levels of serum TARC (CCL17; a ligand of CCR4 receptors that 
attracts Th2 cells), plasma eotaxin-3 (CCL26; a ligand of CCR3 receptors that attracts eosinophils 
and lung mast cells), and serum total IgE (a product of immunoglobulin class switching driven by 
IL-4), as well as reduced the concentrations of FeNO (a marker of airway inflammation).  
Periostin (a protein reported to be elevated at baseline in patients responsive to treatment with 
anti-IL-13 antibodies) is included to differentiate dupilumab from the anti-IL-13 therapeutic class. 
Assay methodologies are briefly summarized below.  More detailed information on the collection, 
handling, transport and preservation of samples (eg, minimum volumes required for blood 
collection and for aliquots for each biomarker assay) will be provided in a separate laboratory 
manual. 
9.2.6.1 Whole blood biomarkers 
Blood eosinophil count will be measured as part of the standard 5-part WBC differential cell 
count on a hematology autoanalyzer. 
9.2.6.2 Plasma biomarkers 
Eotaxin-3 will be measured in heparinized plasma with a validated enzyme immunoassay (Human 
Eotaxin-3 Quantikine ELISA kit; R&D Systems). 
9.2.6.3 Serum biomarkers 
Antigen-specific IgE will be detected using panels of antigens appropriate to the location of the 
clinical site (ImmunoCAP test; Phadia). 
Total IgE will be measured with a quantitative method (eg, ImmunoCAP) approved for diagnostic 
testing. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 68 
A validated immunoassay will be used to quantify levels of TARC and periostin. 
9.2.6.4 Fractional exhaled nitric oxide 
Exhaled nitric oxide will be analyzed using a NIOX instrument (Aerocrine AB, Solna, Sweden), 
or similar analyzer using a flow rate of 50 mL/s, and reported in parts per billion (ppb).  This 
assessment should be conducted prior to spirometry and following a fast of at least 1 hour.  
Further details on the procedure for measuring exhaled nitric oxide with NIOX will be provided in 
a separate instruction manual. 
9.2.6.5 ILC2 and CD34 cells and cytokines in sputum and blood (optional; only for 
patients enrolled in select sites in Canada) 
Innate lymphoid type 2 cells (ILC2) secrete IL-5 and IL-13, and to a lesser extent IL-4, when 
stimulated by several factors released from inflamed respiratory epithelium such as IL-25, IL-33, 
and thymic stromal lymphopoietin (TSLP) and are thought to have a pivotal role in perpetuating 
asthma.  CD34+ eosinophil progenitor cells are known to be elevated in the sputum of patients 
with asthma and may participate in asthmatic inflammation.  To assess the effect of IL-4R 
blockade on the trafficking of ILC2 and CD34+ cells into the airway, these cells will be measured 
in the blood and induced sputum using flow cytometry.  Cytokines will be assayed in the sputum 
and blood using immunoassays. 
Please refer to the Operational Manual for additional information regarding sputum and blood 
collection. 
9.2.7 Pharmacogenetic assessment 
Pharmacogenetic testing is optional and voluntary. 
For those patients who sign the optional pharmacogenetic informed consent form, blood samples 
for exploratory genetic analysis of DNA or RNA will be collected at the study visit as specified in 
the study flow chart and these samples will be stored up to 15 years after completion of the final 
report of the main clinical trial or as appropriate according to local regulations.  Specific 
procedures for collection, storage, and shipping of pharmacogenetic samples will be provided in a 
lab manual. 
The DNA or RNA samples may be used to determine a possible relationship between genes and 
response to treatment with dupilumab, possible adverse reactions to dupilumab, and to study the 
genetics of asthma.  The DNA may be subjected to a genome-wide association study by whole 
genome array (common single nucleotide polymorphisms) analysis and/or to whole exome 
sequencing or whole genome analysis in order to thoroughly explore genetic associations with 
disease progression or treatment response.  The RNA may be subjected to discrete panels of 
polymerase chain reaction (PCR) analyses, microarray analyses, or RNA sequencing analyses. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 69 
The blood DNA sample, and the DNA or RNA that is extracted, will be assigned a second 
number, a Genetic ID (de-identification code) that is different from the Patient ID.  This “double 
coding” is performed to separate a patient’s medical information and DNA data. 
The clinical study data (coded by Patient ID) will be stored in the clinical data management 
system (CDMS), which is a distinct database in a separate environment from the database 
containing the pharmacogenetic data (coded by Genetic ID).  The key linking Patient ID and 
Genetic ID will be maintained by a third party, under appropriate access control.  The matching of 
clinical data and pharmacogenetic data, for the purpose of data analysis, will be possible only by 
using this key, which will be under strict access control.  All data will be reported only in coded 
form in order to maintain confidentiality. 
9.3 
FUTURE USE OF SAMPLES 
Not all of the samples collected during this study may be required for the tests planned in this 
clinical trial.  For patients who have consented to it, the samples that are archived, unused or left 
over after planned testing may be used for additional research purposes (excluding genetic 
analysis, patient to sign additional consent per Section 9.2.6).  For patients who have consented to 
it, archival blood samples will be collected at the visit specified in the study flow chart, 15 mL 
each, will be collected into a dry, red topped tube with clot activator (or into smaller tubes of 
equivalent total volume) kept at room temperature for 30 minutes and then centrifuged at 
approximately 1500 × g for 10 minutes at room temperature.  The serum will then be transferred, 
in equal portions, into 3 storage tubes, which will be immediately capped and frozen in an upright 
position at -20°C or colder. 
These archived serum samples, and any residual or leftover serum, plasma or blood remaining 
from planned laboratory work, may be used for research purposes related to asthma (eg, 
exploratory biomarkers of disease or drug effect), additional drug safety assessments, or 
development and validation of bioassay methods beyond those defined in the present protocol.  
These samples will remain labeled with the same identifiers as the ones used during the study (ie, 
patient ID, sample ID).  They will be transferred to a Sanofi site (or a subcontractor site) which 
can be located outside of the country where the study is conducted.  The Sponsor has included 
safeguards for protecting patient confidentiality and personal data (see Section 14.3 and 
Section 14.5). 
9.4 
APPROPRIATENESS OF MEASUREMENTS  
The efficacy and safety assessments used in this study are standard for the evaluation of therapy in 
patients with asthma 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 70 
10 
STUDY PROCEDURES 
10.1 
VISIT SCHEDULE 
The clinical study consists of 3 periods:  
1. Screening and OCS Optimization Period (from 3 to up to 8 weeks for those patients who 
experience an asthma exacerbation that requires a change in OCS dose this period can be 
extended to 10 weeks to allow for 2 weeks of stabilization prior to randomization; Visits 1 
and 2) 
2. Treatment Period (24 weeks): includes the randomization visit (Visit 3) and a 4-week 
induction phase (Visits 4 and 5), a 16-week OCS reduction phase (Visits 6-10), and a 
4-week maintenance phase (Visit 11)  
3. Post-treatment Period (12 weeks; Visits 12-14) 
The study visits occur on the planned dates (relative to the first injection), as scheduled. After 
randomization, the visit schedule should be adhered to within the ± 3 day visit window. 
Patients who permanently discontinue the study medication will be asked and encouraged to 
return to the clinic for all remaining study visits and participate in follow-up assessments 
according to the visit schedule.  Under exceptional circumstances when a patient cannot come to 
the site for the scheduled visit/s, a phone contact can be made after sponsor approval is given. 
During the phone contact information about AEs, concomitant medications and exacerbation 
events should be collected. 
Patients should be reminded that sexually active female patients of reproductive potential are 
required to practice effective contraception during the entire study duration, while taking 
dupilumab and for 12 weeks post last IMP dose. 
Prior to all screening assessments, after discussion of participation in the study, the written 
consent form (including voluntary participation in pharmacogenetic testing/future use of blood 
samples) must be signed and dated. 
Although the screening assessments for this study are grouped under the heading of 2 visits in this 
protocol, it is possible for them to be performed over more than the 2 scheduled site visits if 
necessary, as long as the screening window prior to randomization (Day 1) is respected.  If certain 
dynamic laboratory tests do not meet the eligibility criteria, these laboratory assessments may be 
repeated, at the discretion of the Investigator, if it is judged to be likely to return to acceptable 
range for study inclusion within the screening visit window prior to Day 1.  These patients do not 
need to sign a new ICF and be allocated a new patient number within this same screening 
window. 
Patients that fail the initial screening for exclusion criteria, eg, concomitant medications, may be 
rescreened for study eligibility 1 additional time.  Patients that are rescreened must sign a new 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 71 
consent form and all of the Visit 1 procedures must be repeated (refer to Section 8.4 for further 
instructions related to rescreening) unless a prior assessment is performed within the time frame 
permitted prior to study entry. 
Patients who fail the Screening Visit because of eDiary/spirometry equipment malfunction, or 
patient-related/site personnel-related unintentional errors may be rescreened 1 time after approval 
is granted by the Sponsor’s clinical study director. In every case of rescreen allowance due to 
technical equipment malfunction and/or unintentional human error(s), the Study Investigator must 
document receipt of Sponsor approval and, when applicable, document the site’s corrective action 
plan to prevent future occurrences. 
All clinical assessments and blood samples should be performed/collected prior to the 
administration of the IMP, unless otherwise specified.  
For patients at select sites in Canada who have agreed to participate in the optional assessment, a 
sputum sample will be collected at the time of an asthma exacerbation during an unscheduled 
visit. 
10.1.1 Screening and Oral Corticosteroid Optimization Period 
Patients who meet eligibility criteria at the Screening visit (Visit 1) will enter the OCS 
Optimization phase.  The Screening/OCS Optimization Period will be from 3 to up to 8 weeks (if 
an asthma exacerbation occurs that requires a change in OCS dose this period can be extended to 
10 weeks to allow for 2 weeks of stabilization prior to randomization) in duration, dependent upon 
the length of time the patient requires to optimize their OCS dose. 
Prednisone or prednisolone will be used as the OCS.  At the Screening visit, patients currently 
using other forms of maintenance OCS must have their corticosteroids switched to the 
corresponding equivalent daily dose of prednisone/prednisolone.  
Follow up visits/phone calls may be added during this period depending on the patient’s response 
to OCS dose changes. 
10.1.1.1 Visit 1 (Week -8 to -3) 
Following a discussion of participation in the clinical trial, informed consent must be obtained and 
documented.  These steps precede any study procedures.  In patients who experience an asthma 
exacerbation during the OCS Optimization phase, this visit may occur at Week -9 or -10. 
The following procedures will then be performed: 
x
Call IVRS/IWRS to assign patient number and register screening visit 
x
Interview to collect patient demographic information including gender, ethnic origin, race, 
date of birth, height, weight, and body mass index (BMI). 
x
Collect other medical history and surgical history, and prior and concomitant medications  
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 72 
-
Medical history will include smoking status; history of diabetes, hypertension, 
sinusitis, polyposis, osteoporosis, cataracts, aspirin sensitivity, previous intubations, 
asthma exacerbations in the previous years, gastrointestinal bleeding, myopathy, signs 
of adrenal insufficiency/crisis, and susceptibility to infections; and triggers of 
worsening asthma. 
-
Therapy history should include current treatments for asthma including the duration of 
prior use of maintenance OCS for the treatment of asthma, coursed of rescue 
corticosteroid (oral or parenteral). 
x
Review entry criteria to assess eligibility, with special attention to verify the following: 
-
Patients must be on a stable dose high-dose ICS (fluticasone propionate >500 Pg total 
daily or equipotent) plus a second controller (LABA, LTRA, etc.) for 1 month prior 
to Visit 1.  In addition, patients requiring a third controller for their asthma are 
considered eligible for this study.  The third controller should also be used for at least 
3 months with a stable dose 1 month prior to Visit 1. 
-
Patients should be on a well-documented, regular prescribed treatment of maintenance 
systemic corticosteroids in the 6 months prior to Visit 1 with a stable OCS dose for the 
4 weeks prior to Visit 1.  Patients must be taking 5-35 mg/day of prednisone or 
equivalent at Visit 1. 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg], height [cm]) 
x
Perform physical examination including an assessment for any clinically significant 
adverse effects associated with the use of maintenance OCS. 
x
Perform a nasal exam to check for the presence/absence of nasal polyps. 
x
Dispense eDiary and PEF meter, provide instructions for daily use, and remind patient to 
bring the eDiary to the next visit. 
x
Instruct the patient on how to complete the ACQ-5.  The first ACQ-5 will be collected at 
Visit 1 and then weekly thereafter throughout the duration of the study. 
x
Administer the following PROs: 
-
AQLQ 
-
HADS 
-
EQ-5D-5L 
-
SNOT-22 (only for patients with bilateral nasal poilyposis/chronic rhinosinusitis) 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 73 
Entry criteria at Visit 1 include the requirement of a specific FEV1 and demonstration of 
reversibility as specified in Section 7.1.  See below for additional directions. 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
-
Pre-bronchodilator FEV1 must be <80% predicted normal for adults and 90% of 
predicted normal for adolescents. 
x
Establish reversibility 
-
Reversibility must be at least 12% and 200 mL in FEV1 after 200 Pg to 400 Pg (2 to 
4 puffs of albuterol/salbutamol, or levalbuterol/levosalbutamol, or of a nebulized 
solution of albuterol/salbutamol or levalbuterol/levosalbutamol.  (Note: This is only 
required if reversibility or airway responsiveness was not performed within 12 months 
prior to Visit 1.) 
-
Three total attempts may be made during the Screening Period to meet the qualifying 
criteria for reversibility. 
x
Perform 12-lead ECG 
x
Perform chest X-ray or magnetic resonance imaging (MRI), as per local standard of care, 
if no chest imaging (X-ray, computed tomagraphhy [CT], MRI) is available from the 
previous year or if there is local requirement. 
x
Obtain blood samples for screening clinical laboratory determinations: 
Hematology (see Section 9.2.3.5 for details) 
-
Serum chemistry (see Section 9.2.3.5 for details) 
x
Obtain blood samples for hepatitis screen (HBsAg, HBsAb, IgM and IgG/total-HBcAb, 
and HCVAb), HIV screen (anti-HIV-1 and anti-HIV-2 antibodies), and anti-nuclear 
antibody (ANA).  Patients who are IgG/total-HBcAb positive and HBsAg negative at Visit 
1 must undergo HBV DNA testing prior to randomization to determine eligibility (only 
applicable for patients who plan to roll over into a long term study).  In case of results 
showing HCVAb positive, HCV RNA testing must be negative/not detected prior to 
randomization.   
x
Obtain blood sample for serum immunoglobulins (total IgG, IgM, and IgA) 
x
Perform parasitic screening if there is a clinical suspicion per Investigator judgment (to be 
done using local testing as per local guidelines). 
x
Obtain serum ȕ-human chorionic gonadotropin (ȕ-HCG) pregnancy test if female of 
childbearing potential 
x
Obtain urine for urinalysis (dipstick). If any parameter on the dipstick is abnormal, a urine 
sample should be sent to the central laboratory for testing. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 74 
x
Record any AEs/SAEs 
x
For those patients who were previously receiving an OCS other than prednisone or 
prednisolone, switch their OCS to the equivalent daily dose of prednisone/prednisolone 
(see Appendix A). 
x
Dispense salbutamol/albuterol or levosalbutamol/levalbuterol for use as reliever 
medication throughout the study.  Instruct patient to record usage in the electronic diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.1.2 Visit 2 (Week -7 to -2) 
Visit 2 will occur 1 week after Visit 1.  Visit 2 will then occur over 2 weeks which are designated 
as Visit 2A (complete with all procedures), and 1 week later, Visit 2B (will consist of a review of 
the eDiary with the patient).    For both Visit 2A and 2B, patients must report to the clinical site 
and will be instructed on completing the ACQ-5 which will be collected at both visits; however, 
all other procedures will be performed only at Visit 2A. 
The following procedures will be performed during this visit: 
x
Complete and review the ACQ-5 – recommended to be completed at the visit, when 
possible, prior to other procedures being performed 
x
Review entry criteria to confirm continued eligibility 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning, if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 75 
x
Establish reversibility (Note: This is only required if reversibility or airway responsiveness 
was not performed within 12 months prior to Visit 1 or established at Visit 1.) 
-
Reversibility must be at least 12% and 200 mL in FEV1 after 200 Pg to 400 Pg (2 to 
4 puffs of albuterol/salbutamol or of a nebulized solution of albuterol/salbutamol), if 
considered as a standard office practice. 
-
Three total attempts may be made during the Screening Period to meet the qualifying 
criteria for reversibility for those patients who do not have documented reversibility in 
the previous year. 
x
Record any AEs/SAEs 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit. 
x
Review ACQ-5 score and asthma exacerbations and determine appropriate OCS dose 
adjustment according to the schedule provided in Table 1. 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.1.3 Weekly phone calls to optimize oral corticosteroid dose 
Patients will continue to assess their ACQ-5 score on a weekly basis reducing their OCS dose in 
accordance with Table 1 until they achieve their optimal OCS dose.  The lowest effective OCS 
dose will be identified as the OCS dose that the patient was taking just before the ACQ 5 score 
increased by 0.5.  Once the optimized dose is determined, the patient must be able to remain on 
the optimized prednisone/prednisolone dose, along with their baseline ICS plus second (or third) 
controller medication, for 2 consecutive weeks prior to randomization. 
The following procedures will be performed during the weekly phone calls: 
x
Review ACQ-5 score and determine appropriate OCS dose adjustment according to the 
schedule provided in Table 1. 
x
Review any asthma exacerbations that have occurred. 
x
Review compliance with OCS and controller medications. 
x
Record any AEs/SAEs that occurred during the previous week. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 76 
10.1.2 Randomized Treatment Period 
10.1.2.1 Visit 3/Randomization (Week 0) 
At Visit 3 (Week 0), patients who meet the entry and randomization eligibility criteria will be 
randomized in a 1:1 ratio to receive a 600 mg loading dose (2 injections of 300 mg) followed by 
300 mg q2w of dupilumab or matching placebo, respectively. 
During this visit, the following procedures will be performed prior to randomization: 
x
Review inclusion/exclusion criteria to confirm continued eligibility 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Administer the following PROs: 
-
ACQ-5 
-
AQLQ 
-
HADS 
-
EQ-5D-5L 
-
SNOT-22 (only for patients with bilateral nasal polyposis/chronic rhinosinusitis) 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning, if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Measure post-bronchodilatory FEV1 
x
Perform 12-lead ECG 
x
Obtain (fasting) blood samples for the following: 
-
Clinical laboratory determinations (hematology and serum chemistry) 
-
Serum immunoglobulins (total IgG, IgM, and IgA) 
-
Pharmacokinetic sample 
-
ADA 
-
Biomarkers 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 77 
-
Archival serum 
x
Pharmacogenetics (optional, for those patients who sign the Pharmacogenetic informed 
consent form)Perform urine dipstick pregnancy test if female of childbearing potential 
x
Obtain urine for urinalysis (dipstick). If any parameter on the dipstick is abnormal, a urine 
sample should be sent to the central laboratory for testing. 
x
Collect sputum and additional blood sample (only for those patients enrolled in the 
optional assessment at selected sites within Canada) 
x
Perform methacholine challenge (only for those patients enrolled in the optional 
assessment at selected sites within Canada if the patient’s FEV1 is 70% predicted normal) 
x
Record any AEs/SAEs 
x
Record any concomitant medications 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit 
x
Review OCS reduction criteria (ACQ-5 score and asthma exacerbations) and determine 
optimized OCS dose at baseline 
x
Call IVRS/IWRS to register visit and to randomize the patient to IMP (dupilumab or 
placebo) 
After randomization: 
x
Administer IMP SC (dupilumab 300 mg or placebo). Two injections of IMP will be 
administered. The patient or caregiver receives training on administering the second 
injection, if the patient or caregiver is willing to self-inject. 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.2.2 Induction Phase (4 weeks)  
The Induction Phase of the Randomized Treatment Period will consist of 4 weeks (V4 and V5).  
During this period, patients will remain on their optimized dose of OCS along with their baseline 
asthma medications and return to the clinic for 2 visits.  Visit 5 is the end of the 4 week period.  
Patients will be assessed and, if determined appropriate, will begin OCS dose adjustment at 
visit 5. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 78 
10.1.2.2.1 Visit 4 (Week 2 ± 3 days) 
The following procedures will be performed during this visit: 
x
Call IVRS/IWRS to register visit 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Administer the ACQ-7 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Record any AEs/SAEs 
x
Administer IMP SC (dupilumab 300 mg or placebo). For those patients or caregivers 
willing to perform self-injection, the patient or caregiver will perform the injection under 
the supervision of the investigator or designee. 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit. 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.2.2.2 Visit 5 (Week 4 ± 3 days) 
The following procedures will be performed during this visit: 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 79 
x
Call IVRS/IWRS to register visit 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Administer the ACQ-7 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Obtain blood samples for the following: 
-
Clinical laboratory determinations (hematology and serum chemistry) 
-
Pharmacokinetic sample 
-
Biomarkers 
x
Perform urine dipstick pregnancy test if female of childbearing potential 
x
Record any AEs/SAEs 
x
Review OCS reduction criteria (ACQ-5 score, asthma exacerbations, PEF, rescue 
medication use, and signs of adrenal insufficiency) and determine appropriate OCS dose 
adjustment according to the schedule provided in Table 2. 
x
Administer IMP SC (dupilumab 300 mg or placebo). For those patients or caregivers 
willing to perform self-injection, the patient or caregiver will perform the injection under 
that supervision of the investigator or designee. 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit. 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 80 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.2.3 OCS Reduction Phase (16 weeks) 
During the OCS Reduction Phase, patients will return to the clinic once every 4 weeks.  
The OCS dose will be titrated during this phase following a predetermined schedule (Table 2) and 
based on the starting optimized OCS dose.  Dose reductions should be attempted every 4 weeks.  
The last possible dose reduction can occur at Week 20 with no further dose adjustments beyond 
this time point.   
During Weeks 10, 14, and 18, patients will self-administer the IMP.  They do not need to return to 
the clinic during these weeks.  Study personnel will follow-up with the patient with a phone call. 
For patients, or those with caregivers, who are not comfortable with self-administering the IMP, 
they will return to the study clinic for these visits. 
10.1.2.3.1 Visit 6 (Week 6 ± 3 days) 
The following procedures will be performed during this visit: 
x
Call IVRS/IWRS to register visit 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Administer the ACQ-7 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Record any AEs/SAEs 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 81 
x
Administer IMP SC (dupilumab 300 mg or placebo). For those patients or caregivers 
willing to perform self-injection, the patient or caregiver will perform the injection under 
that supervision of the investigator or designee. 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit. 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.2.3.2 Visit 7 (Week 8 ± 3 days) 
The following procedures will be performed during this visit: 
x
Call IVRS/IWRS to register visit 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Administer the ACQ-7 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Obtain blood samples for the following: 
-
Clinical laboratory determinations (hematology and serum chemistry) 
-
Pharmacokinetic sample 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 82 
x
Perform urine dipstick pregnancy test if female of childbearing potential 
x
Record any AEs/SAEs 
x
Review ACQ-5 score, if any asthma exacerbations occurred, morning PEF, use of rescue 
medications, and signs of adrenal insufficiency.  Determine appropriate OCS dose 
adjustment according to the schedule provided in Table 2. 
x
Administer IMP SC (dupilumab 300 mg or placebo).  For those patients or caregivers 
willing to perform self-injection, the patient or caregiver will perform the injection under 
that supervision of the investigator or designee. 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit. 
x
Review/dispense Home Dosing Diary. 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.2.3.3 Visit 8 (Week 12 ± 3 days) 
The following procedures will be performed during this visit: 
x
Call IVRS/IWRS to register visit 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, 
weight [kg] 
x
Administer the following PROs: 
-
ACQ-7 
-
AQLQ 
-
HADS 
-
EQ-5D-3L 
-
SNOT-22 (only for patients with bilateral nasal polyposis/chronic rhinosinusitis) 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 83 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Measure post-bronchodilatory FEV1 
x
Perform 12-lead ECG 
x
Obtain fasting blood samples for the following: 
-
Clinical laboratory determinations (hematology and serum chemistry) 
-
Pharmacokinetic sample 
-
Biomarkers 
-
Serum immunoglobulins (total IgG, IgM, and IgA) 
-
Archival serum 
x
Perform urine dipstick pregnancy test if female of childbearing potential 
x
Obtain urine for urinalysis (dipstick).  If any parameter on the dipstick is abnormal, a urine 
sample should be sent to the central laboratory for testing. 
x
Record any AEs/SAEs 
x
Review ACQ-5 score, if any asthma exacerbations occurred, morning PEF, use of rescue 
medications, and signs of adrenal insufficiency.  Determine appropriate OCS dose 
adjustment according to the schedule provided in Table 2. 
x
Administer IMP SC (dupilumab 300 mg or placebo) 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit. 
x
Review and dispense the Home Dosing Diary 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 84 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.2.3.4 Visit 9 (Week 16 ± 3 days) 
The following procedures will be performed during this visit: 
x
Call IVRS/IWRS to register visit 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Administer the ACQ-7 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Obtain blood samples for the following: 
-
Clinical laboratory determinations (hematology and serum chemistry) 
x
Perform urine dipstick pregnancy test if female of childbearing potential 
x
Record any AEs/SAEs 
x
Review ACQ-5 score, if any asthma exacerbations occurred, morning PEF, use of rescue 
medications, and signs of adrenal insufficiency.  Determine appropriate OCS dose 
adjustment according to the schedule provided in Table 2. 
x
Administer IMP SC (dupilumab 300 mg or placebo) 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit. 
x
Review and dispense the Home Dosing Diary 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 85 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.2.3.5 Visit 10 (Week 20 ± 3 days) 
Week 20 is the last week that the patient’s OCS dose can be changed.  The following procedures 
will be performed during this visit: 
x
Call IVRS/IWRS to register visit 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Administer the ACQ-7 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Obtain blood samples for the following: 
-
Clinical laboratory determinations (hematology, serum chemistry) 
-
For patients who plan to roll over into a long-term study, obtain blood samples for HIV 
screen (anti-HIV-1 and anti-HIV-2 antibodies), ANA, and hepatitis screen (HBsAg, 
HBsAb, IgM and IgG/total-HBcAb, HCVAb).  Patients who are IgG/total-HBcAb 
positive and HBsAg negative must undergo HBV DNA testing prior to randomization 
to determine eligibility (only applicable for patients who plan to roll over into a 
long-term study). In case of results showing HCVAb positive, HCV RNA testing must 
be “not detected” prior to randomization. 
-
Biomarkers 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 86 
x
Perform chest x-ray or MRI if chest imaging (x-ray, CT, MRI) is over 1 year from entry 
into a long-term study as per local standard of care or if there is local requirement (only 
applicable for patients who plan to roll over into a long-term study) 
x
Perform urine dipstick pregnancy test if female of childbearing potential 
x
Record any AEs/SAEs 
x
Review ACQ-5 score, if any asthma exacerbations occurred, morning PEF, use of rescue 
medications, and signs of adrenal insufficiency.  Determine appropriate OCS dose 
adjustment according to the schedule provided in Table 2. 
x
Administer IMP SC (dupilumab 300 mg or placebo) 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit. 
x
Review/dispense Home Dosing Diary 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.2.4 Maintenance Phase  
The Maintenance Phase consists of 4 weeks.  During this phase, patients will be maintained on the 
same OCS dose established at Week 20. 
During Week 22, patients do not need to return to the clinic and can self-administer the IMP.   
10.1.2.4.1 Visit 11 (Week 24 ± 3 days; end-of-treatment visit) 
The following procedures will be performed during this visit: 
x
Call IVRS/IWRS to register visit 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Perform physical examination 
x
Administer the following PROs: 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 87 
-
ACQ-7 
-
AQLQ 
-
HADS 
-
EQ-5D-5L 
-
SNOT-22 (only for patients with bilateral nasal polyposis/chronic rhinosinusitis) 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Measure post-bronchodilator FEV1 
x
Perform 12-lead ECG 
x
Obtain fasting blood samples for the following: 
-
Clinical laboratory determinations (hematology and serum chemistry) 
-
Pharmacokinetic sample 
-
ADA sample 
-
Biomarkers 
-
Serum immunoglobulins (total IgG, IgM, and IgA) 
-
Archival serum 
x
Perform urine dipstick pregnancy test if female of childbearing potential 
x
Obtain urine for urinalysis (dipstick).  If any parameter on the dipstick is abnormal, a urine 
sample should be sent to the central laboratory for testing. 
x
Collect sputum and additional blood sample (only for those patients enrolled in the 
optional assessment at selected sites within Canada) 
x
Perform methacholine challenge (only for those patients enrolled in the optional 
assessment at selected sites within Canada, if the patient’s FEV1 is 70% predicted 
normal) 
x
Record any AEs/SAEs 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 88 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit. 
x
Review ACQ-5 score, if any asthma exacerbations occurred, morning PEF, use of rescue 
medications, and signs of adrenal insufficiency and document the final OCS dose that the 
patient is receiving.   
x
Review Home Dosing Diary 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.3 Post-treatment Period 
After completing the treatment period, patients will be evaluated for 12 weeks in the Post-
treatment Period.  During this follow-up period, patients will continue treatment with their stable 
dose of controller medication that can be modified based on their level of asthma control, as 
determined by the Investigator. 
Eligible patients completing the treatment period will be offered the opportunity to roll over into a 
long-term study with dupilumab.  Patients subsequently enrolled in this long-term study will not 
participate in the off-treatment safety phase of this trial. 
Patients who discontinue early from treatment or patients who choose not to roll over into a 
long-term study may be asked to return to the clinic to have additional ADA samples collected for 
analysis based on the overall assessment of antibody titers and clinical presentation. 
10.1.3.1 Visits 12 and 13 (Week 28 ± 3 days and Week 32 ± 3 days, respectively) 
The following procedures will be performed during each of these visits: 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Administer the ACQ-7 
x
Complete the Health Resource Utilization questionnaire 
x
Measure FeNO 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 89 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Record any AEs/SAEs 
x
Download electronic diary/PEF meter, provide instructions for daily use, and remind 
patient to bring the device to the next visit. 
x
Dispense and resupply salbutamol/albuterol or levosalbutamol/levalbuterol for use as 
reliever medication throughout the study.  Instruct patient to record usage in the electronic 
diary. 
x
Remind patient to continue their controller medication (including OCS and ICS in 
combination with 1 or 2 other controllers) and instruct patient to record daily usage in the 
electronic diary. 
x
Remind patient to withhold last dose of salbutamol/albuterol or 
levosalbutamol/levalbuterol for at least 6 hours and withhold last dose of LABA for at 
least 12 hours and withholding the last dose of LAMA for at least 24 hours prior to next 
visit. 
10.1.3.2 Visit 14 (Week 36 ± 3 days; end-of-study visit) 
The following procedures will be performed during this visit: 
x
Call IVRS/IWRS to register visit 
x
Collect concomitant medications 
x
Measure vital signs (blood pressure, heart rate, respiration rate, body temperature, weight 
[kg]) 
x
Administer the following PROs: 
-
ACQ-7 
-
AQLQ 
-
HADS 
-
EQ-5D-5L 
-
SNOT-22 (only for patients with bilateral nasal polyposis/chronic rhinosinusitis) 
x
Complete the Health Resource Utilization questionnaire 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 90 
x
Measure FeNO 
-
Exhaled nitric oxide assessment is conducted prior to spirometry and following a fast 
of 1 hour 
x
Perform spirometry 
-
Spirometry will be performed in the morning if possible, but if the testing can only be 
done at a different time of the day, the testing should be done at approximately the 
same time of the day at each visit throughout the study, after withholding the last dose 
of salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and 
withholding the last dose of LABA for at least 12 hours and withholding the last dose 
of LAMA for at least 24 hours. 
x
Measure post-bronchodilator FEV1 
x
Perform 12-lead ECG 
x
Obtain blood samples for the following: 
-
Clinical laboratory determinations (hematology and serum chemistry) 
-
Pharmacokinetic sample 
-
ADA 
-
Serum immunoglobulins (total IgG, IgM, and IgA) 
x
Perform urine dipstick pregnancy test if female of childbearing potential 
x
Obtain urine for urinalysis (dipstick).  If any parameter on the dipstick is abnormal, a urine 
sample should be sent to the central laboratory for testing. 
x
Collect sputum sample (only for those patients enrolled in the optional assessment at 
selected sites within Canada) 
x
Record any AEs/SAEs 
x
Download and collect the eDiary. 
10.2 
DEFINITION OF SOURCE DATA 
Source data is all information in original records and certified copies of original records of clinical 
findings, observations, or other activities in a clinical trial necessary for the reconstruction and 
evaluation of the trial.  Source data are contained in source documents.  Source documents are 
original documents, data and records such as hospital records, clinic and office charts, laboratory 
notes, memoranda, pharmacy dispensing records, recorded data from automated instruments, etc.  
All the data collected in the e-CRF should be transcribed directly from source documents.  Data 
downloaded from the study-associated central laboratories, spirometry, nitric oxide measurement, 
ECG, patient electronic diary/PEF meter, and the Home Dosing Diary will be considered source 
data. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 91 
10.3 
HANDLING OF PATIENT TEMPORARY OR PERMANENT TREATMENT 
DISCONTINUATION AND OF PATIENT STUDY DISCONTINUATION  
The IMP should be continued whenever possible.  In case the IMP is stopped, it should be 
determined whether the stop can be made temporarily; permanent IMP discontinuation should be 
a last resort.  Any IMP discontinuation should be fully documented in the eCRF.  In any case, the 
patient should remain in the study as long as possible. 
10.3.1 Temporary treatment discontinuation with investigational medicinal products 
Temporary treatment discontinuation may be considered by the Investigator because of AEs.  
Re-initiation of treatment with the IMP will be done under close and appropriate clinical and/or 
laboratory monitoring once the Investigator will have considered according to his/her best medical 
judgment that the AE is sufficiently resolved and unlikely to recur after resuming therapy with 
IMP.   
In addition, the following conditions(s) will be cause for temporary treatment discontinuation: 
x
Infections or infestations that do not respond to medical treatment. 
x
Any laboratory abnormality that meets temporary treatment discontinuation criteria as per 
Appendix F. 
10.3.2 Permanent treatment discontinuation with investigational medicinal product(s) 
Permanent treatment discontinuation is any treatment discontinuation associated with the 
definitive decision from the Investigator or the patient not to re-expose the patient to the IMP at 
any time. 
10.3.3 List of criteria for permanent treatment discontinuation 
The patients may withdraw from treatment with the IMP if they decide to do so, at any time and 
irrespective of the reason, or this may be the Investigator’s decision.  All efforts should be made 
to document the reasons for treatment discontinuation and this should be documented in the 
e-CRF. 
Patients must be withdrawn from treatment (ie, from any further investigational treatment) for the 
following reasons: 
x
At their own request or at the request of their legally authorized representative (legally 
authorized representative means an individual or judicial or other body authorized under 
applicable law to consent on behalf of a prospective patient to the patient’s participation in 
the procedure(s) involved in the research). 
x
If, in the Investigator’s opinion, continuation in the study would be detrimental to the 
patient’s well-being. 
x
At the specific request of the Sponsor. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 92 
x
In the event of a protocol deviation, at the discretion of the Investigator or the Sponsor. 
x
Any code breaking requested by the Investigator will lead to permanent treatment 
discontinuation. 
x
Pregnancy  
x
Anaphylactic reactions or systemic allergic reactions that are related to IMP and require 
treatment. 
x
Diagnosis of a malignancy during study, excluding carcinoma in situ of the cervix, or 
squamous or basal cell carcinoma of the skin. 
x
Any opportunistic infection, such as tuberculosis or other infections whose nature or 
course may suggest an immunocompromised status (Appendix L). 
x
Serum ALT >3 ULN and total bilirubin > 2ULN (Appendix F). 
x
Serum ALT > 5 ULN if baseline ALT < 2 ULN, or ALT >8 ULN if baseline 
ALT > 2 ULN (Appendix F). 
10.3.4 Handling of patients after permanent treatment discontinuation 
Patients will be followed-up according to the study procedures as specified in this protocol up to 
the scheduled date of study completion, or up to recovery or stabilization of any AE to be 
followed-up as specified in this protocol, whichever comes last. Study investigators should 
continue OCS dose adjustment after treatment discontinuation, as guided by their medical 
judgment, including up-titration and down-titration in accordance with Table 2 (Titration schedule 
for oral corticosteroids during the OCS Reduction Phase of the Randomized Period). 
All cases of permanent treatment discontinuation should be recorded by the Investigator in the 
appropriate pages of the CRF when considered as confirmed.   
Patients who discontinue early from treatment may be asked to return to the clinic to have 
additional ADA samples collected based on the overall assessment of antibody titers and clinical 
presentation. 
Patients who permanently discontinue the study medication will be asked and encouraged to 
return to the clinic for remaining study visits and participate in follow-up assessments according 
to the visit schedule. 
Under exceptional circumstances when a patient  cannot come to the site for the scheduled visit/s, 
a phone contact can be made after sponsor approval is given. During the phone contact 
information about AEs, concomitant medications and exacerbation events should be collected. 
10.3.5 Procedure and consequence for patient withdrawal from study  
The patients may withdraw from the study before study completion if they decide to do so, at any 
time and irrespective of the reason. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 93 
Withdrawal of consent for follow-up should be accompanied by documentation of the reason for 
withdrawal. Withdrawal of consent for treatment should be distinguished from withdrawal of 
consent for follow-up visits and from withdrawal of consent for non-patient contact follow-up, eg, 
medical records checks. Patients requesting withdrawal should be informed that withdrawal of 
consent for follow-up will jeopardize the public health value of the study. 
Patients who withdraw should be explicitly asked about the contribution of possible adverse 
events to their decision to withdraw consent, and any adverse event information elicited should be 
documented.  
Patients may withdraw consent verbally or in writing and, if verbal, then the site needs to 
document in source records that patient withdrew consent verbally.  All study withdrawals should 
be recorded by the investigator in the appropriate screens of the e-CRF and in the patient’s 
medical records when considered as confirmed. In the medical record, at least the date of the 
withdrawal and the reason should be documented. 
If possible, the patients are assessed using the procedure normally planned for the end-of-study 
visit including a systemic drug concentration sample, if appropriate, and three Post treatment 
Period Visits. 
For patients who fail to return to the site, the Investigator should make the best effort to re-contact 
the patient (eg, contacting patient’s family or private physician, reviewing available registries or 
health care databases), and to determine his/her health status, including at least his/her vital status. 
Attempts to contact such patients must be documented in the patient’s records (eg, times and dates 
of attempted telephone contact, receipt for sending a registered letter). 
A patient should only be designated as lost to follow-up if the site is unable to establish contact 
with the patient after 3 documented attempts via 2 different methods (phone, text, e-mail, certified 
letter, etc). 
The statistical analysis plan (SAP) will specify how these patients lost to follow-up for their 
primary endpoints will be considered. Patients who have withdrawn from the study cannot be 
rerandomized (treated) in the study. Their inclusion and treatment numbers must not be reused. 
10.4 
OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING 
10.4.1 Definitions of adverse events  
10.4.1.1 Adverse event 
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with this treatment. 
Asthma exacerbations should only be reported as AEs if they fulfill a seriousness criterion.   
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 94 
For this study, asthma exacerbations should be managed by the Investigators based on their 
medical judgment and applicable national/international asthma management guidelines. 
10.4.1.2 Serious adverse event 
A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 
x
Results in death, or 
x
Is life-threatening, or 
Note: The term “life-threatening” in the definition of “serious” refers to an event in which 
 
the patient was at risk of death at the time of the event; it does not refer to an event which 
 
hypothetically might have caused death if it were more severe. 
x
Requires inpatient hospitalization or prolongation of existing hospitalization, or 
x
Results in persistent or significant disability/incapacity, or 
x
Is a congenital anomaly/birth defect 
x
Is a medically important event 
x
Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is appropriate in other situations, such as important medical events that may not 
be immediately life-threatening or result in death or hospitalization but may jeopardize the 
patient or may require medical or surgical intervention (ie, specific measures or corrective 
treatment) to prevent one of the other outcomes listed in the definition above. 
Note: The following list of medically important events is intended to serve as a guideline for 
determining which condition has to be considered as a medically important event. The list is 
not intended to be exhaustive: 
-
Intensive treatment in an emergency room or at home for: 
-
Allergic bronchospasm  
-
Anaphylaxis (refer to Appendix K for the definition of anaphylaxis) 
-
Blood dyscrasias (ie, agranulocytosis, aplastic anemia, bone marrow aplasia, 
myelodysplasia, pancytopenia, etc),  
-
Convulsions (seizures, epilepsy, epileptic fit, absence, etc). 
-
Development of drug dependence or drug abuse 
-
ALT >3 × ULN + total bilirubin >2 × ULN or asymptomatic ALT increase >10 × ULN 
-
Suicide attempt or any event suggestive of suicidality 
-
Syncope, loss of consciousness (except if documented as a consequence of blood 
sampling) 
-
Bullous cutaneous eruptions 
-
Cancers diagnosed during the study  
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 95 
-
Chronic neurodegenerative diseases (newly diagnosed)  
10.4.1.3 Adverse event of special interest 
An adverse event of special interest (AESI) is an AE (serious or non-serious) of scientific and 
medical concern specific to the Sponsor’s product or program, for which ongoing monitoring and 
immediate notification by the Investigator to the Sponsor is required. Such events may require 
further investigation in order to characterize and understand them. Adverse events of special 
interest may be added or removed during a study by protocol amendment. 
For these AESIs, the Sponsor will be informed immediately (ie, within 24 hours), per SAE 
notification described Section 10.4.2, even if not fulfilling a seriousness criterion, using the 
corresponding pages in the CRF (to be sent) or screens in the e-CRF.  
x
Anaphylactic reactions or systemic allergic reactions that are related to IMP and require 
treatment (refer to Appendix K for the definition of anaphylaxis) 
x
Severe injection site reactions that last longer than 24 hours 
x
Any infection meeting at least 1 of the following criteria: 
-
Any serious infection (SAE) 
-
Requires parenteral (intravenous, intramuscular, subcutaneous) antimicrobial therapy 
-
Requires oral antimicrobial therapy for longer than 2 weeks 
-
Is a parasitic infection  
-
Is an opportunistic infection (Appendix L) 
Note:  Antimicrobial therapy refers to antibiotic, antiviral, and antifungal agents 
x
Significant ALT elevation 
-
ALT >5 x the upper limit of normal (ULN) in patients with baseline ALT 2 x ULN; 
or 
-
ALT >8 x ULN if baseline ALT >2 x ULN 
x
Pregnancy of a female patient entered in a study as well as pregnancy occurring in a 
female partner of a male patient entered in a study with IMP/noninvestigational medicinal 
product (NIMP);  
-
Pregnancy occurring in a female patient entered in the clinical trial or in a female 
partner of a male patient entered in the clinical trial. It will be qualified as an SAE only 
if it fulfills one of the seriousness criteria (see Section 10.4.1.2). 
-
In the event of pregnancy in a female participant, IMP should be discontinued.  
-
Follow-up of the pregnancy in a female participant or in a female partner of a male 
participant is mandatory until the outcome has been determined. 
x
Symptomatic overdose (serious or non-serious) with IMP/NIMP 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 96 
-
An overdose (accidental or intentional) with the IMP is an event suspected by the 
Investigator or spontaneously notified by the patient and defined as at least twice the 
intended dose  during an interval of less than 11 days. The circumstances (ie, 
accidental or intentional) should be clearly specified in the verbatim and symptoms, if 
any, entered on separate AE forms. 
-
An overdose (accidental or intentional) with any NIMP is an event suspected by the 
Investigator or spontaneously notified by the patient and defined as at least twice the 
intended dose within the intended therapeutic interval. The circumstances (ie, 
accidental or intentional) should be clearly specified in the verbatim and symptoms, if 
any, entered on separate AE forms. 
Of note, asymptomatic overdose has to be reported as a standard AE. 
10.4.2 Serious adverse events waived from expedited regulatory reporting to regulatory 
authorities 
Not applicable. 
10.4.3 General guidelines for reporting adverse events 
x
All AEs, regardless of seriousness or relationship to IMP/NIMP, spanning from the 
signature of the informed consent form until the end of the study as defined by the 
protocol for that patient, are to be recorded on the corresponding page(s) or screen(s) of 
the e-CRF. 
x
Protocol defined asthma exacerbation events are collected as efficacy endpoints via the 
asthma exacerbation form.  These events should not be reported as AEs unless they fulfill 
a seriousness criterion.   
x
Whenever possible, diagnosis or single syndrome should be reported instead of symptoms. 
The Investigator should specify the date of onset, intensity, action taken with respect to 
IMP, corrective treatment/therapy given, additional investigations performed, outcome, 
and his/her opinion as to whether there is a reasonable possibility that the AE was caused 
by the IMP or by the study procedure(s).  In studies that require the use of 
combined/multiple IMPs/NIMPs, the GSO with input from other appropriate study team 
members must determine if the causal relationship will either be assessed for the combined 
product as a regimen or as distinct entities.  The GSO must communicate this decision to 
the study team for inclusion in the protocol and AE CRF. 
x
The Investigator should take appropriate measures to follow all AEs until clinical recovery 
is complete and laboratory results have returned to normal, or until progression has been 
stabilized, or until death, in order to ensure the safety of the patients.  This may imply that 
observations will continue beyond the last planned visit per protocol, and that additional 
investigations may be requested by the monitoring team up to as noticed by the Sponsor.  
Patients who experience an ongoing SAE or an AESI, at the prespecified study end-date, 
should be followed until resolution, stabilization, or death and related data will be 
collected. The duration of poststudy follow-up and reporting of AEs will be specified (eg, 
until recovery). 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 97 
x
When treatment is prematurely discontinued, the patient’s observations will continue until 
the end of the study as defined by the protocol for that patient. 
x
Laboratory, vital signs or ECG abnormalities are to be recorded as AEs only if:  
-
Symptomatic and/or  
-
Requiring either corrective treatment or consultation, and/or  
-
Leading to IMP discontinuation or modification of dosing, and/or  
-
Fulfilling a seriousness criterion, and/or  
-
Defined as an AESI 
Table 5 summarizes the reporting timelines for select AEs and laboratory abnormalities. 
Table 5  Summary of adverse event reporting instructions 
Adverse event/laboratory abnormality 
Reporting timeframe 
Serious adverse event 
 
Within 24 hours 
Pregnancy 
 
Within 24 hours 
Overdose 
Symptomatic 
Within 24 hours 
 
Asymptomatic 
Routine 
ALT elevation 
ALT >5 ULN if baseline ALT is 2 ULN 
Within 24 hours 
 
ALT >8 ULN if baseline ALT is >2 ULN 
Within 24 hours 
Anaphylactic or systemic allergic reactions that are related to IMP and require treatment. 
Within 24 hours 
Severe injection site reactions that last longer than 24 hours. 
Within 24 hours 
Infections as defined in Section 10.4.1.3. 
Within 24 hours 
ALT=alanine aminotransaminase; ULN=upper limit of normal. 
10.4.4 Instructions for reporting serious adverse events 
In the case of occurrence of an SAE, the Investigator must immediately: 
-
ENTER (within 24 hours) the information related to the SAE in the appropriate 
screens of the e-CRF; the system will automatically send a notification to the 
monitoring team after approval of the Investigator within the e-CRF or after a standard 
delay. 
-
SEND (preferably by fax or e-mail) a photocopy of all examinations carried out and 
the dates on which these examinations were performed, to the representative of the 
monitoring team whose name, fax number, and email address appear on the clinical 
trial protocol. Care should be taken to ensure that the patient's identity is protected and 
the patient's identifiers in the clinical trial are properly mentioned on any copy of a 
source document provided to the Sponsor. For laboratory results, include the 
laboratory normal ranges. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 98 
-
All further data updates should be recorded in the e-CRF as appropriate, and further 
documentation as well as additional information (for laboratory data, concomitant 
medications, patient status, etc) should be sent (by fax or e-mail) to the monitoring 
team within 24 hours of knowledge of the SAE. In addition, every effort should be 
made to further document any SAE that is fatal or life threatening within a week 
(7 days) of the initial notification. 
-
A back-up plan (using a paper CRF process) is available and should be used when the 
e-CRF system does not work. 
Any SAE brought to the attention of the Investigator at any time after the end of the study for the 
patient and considered by him/her to be caused by the IMP with a reasonable possibility, should 
be reported to the monitoring team. 
10.4.5 Guidelines for reporting adverse events of special interest   
For AESIs, the Sponsor must be informed immediately (ie, within 24 hours), as per SAE 
notification guidelines described in Section 10.4.4, even if not fulfilling a seriousness criterion, 
using the corresponding pages of the CRF (to be sent) or screens in the e-CRF. 
10.4.6 Guidelines for management of specific laboratory abnormalities 
Decision trees for the management of certain laboratory abnormalities by Sanofi are provided in 
Appendix F.   
The following laboratory abnormalities should be monitored, documented, and managed 
according to the related flow chart in protocol appendices.  
x
Neutropenia 
x
Thrombocytopenia 
x
Increase in ALT 
x
Acute renal insufficiency 
x
Suspicion of rhabdomyolysis 
In addition, on treatment eosinophil counts >3000 cells/μL (3.0 giga/L) are to be reported as AEs. 
10.5 
OBLIGATIONS OF THE SPONSOR 
During the course of the study, the Sponsor will report in an expedited manner: 
-
All SAEs that are both unexpected and at least reasonably related to the IMP 
(SUSAR), to the regulatory authorities, Institutional Ethics Committees 
(IECs)/Institutional Review Boards (IRBs) as appropriate and to the Investigators.    
-
All SAEs that are expected and at least reasonably related to the IMPs to the regulatory 
authorities, according to local regulations. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 99 
In this study, some AEs are considered related to the underlying condition and thus will not be 
considered unexpected (eg, wheezing related to asthma). 
Any other AE not listed as an expected event in the Investigator’s Brochure or in this protocol 
will be considered unexpected. 
For safety, the treatment code will be unblinded by the Sponsor for reporting to the Health 
Authority of any suspected unexpected adverse drug reaction (SUSAR) and reasonably associated 
with the use of the IMP according to either the judgment of the Investigator and/or the Sponsor. 
In case of a SUSAR, Sanofi Global Pharmacovigilance and Epidemiology will utilize XGRID to 
reveal medication assignment for regulatory reporting requirements for the particular case. 
The Sponsor will report all safety observations made during the conduct of the trial in the clinical 
study report. 
10.6 
SAFETY INSTRUCTIONS 
10.6.1 Hypersensitivity 
Allergic reaction is a potential risk associated with the administration of most therapeutic 
monoclonal antibodies. 
Allergic reactions may be defined as immunologically-mediated responses to a pharmaceutical 
and/or formulation agent in a sensitized person. Signs and symptoms are often experienced during 
or shortly after therapeutic administration.  These reactions may present in a variety of ways, 
including dizziness, headache, anxiety, dyspnea, hypotension, tachycardia, pruritus, rash, 
urticaria/angioedema, flushing, nausea, or vomiting.  Refer to Appendix K “Definition of 
Anaphylaxis”, which describes the clinical criteria for the diagnosis of anaphylaxis.  
Patients should be monitored for at least 30 minutes after each study-site administered 
investigational product administration for any signs or symptoms of a hypersensitivity reaction. 
Trained personnel and medications should be available to treat anaphylaxis or any severe allergic 
reaction if it occurs.  Furthermore, the patients will be advised, when the IMP is administered at 
home, to self-monitor for potential signs and symptoms that may suggest a hypersensitive reaction 
for at least 30 minutes after administration.  
Anaphylactic reactions or systemic allergic reactions that are related to IMP and require treatment 
must be reported as an adverse event of special interest (AESI) (within 24 hours; for further 
details, see AESI definition in Section 10.4.1.3 and Appendix K) and study medication must be 
permanently discontinued. ADA and PK samples will be collected near the onset and resolution of 
the AESI for any additional analysis. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 100 
10.6.2 Severe injection site reactions 
Based on the SC mode of administration of high doses of protein and on a higher incidence of 
local injection site reactions observed at the highest dose level (300 mg weekly), severe injection 
site reactions, are considered as a potential risk.  Patients who experience an injection site reaction 
must be closely monitored for the possibility of a more intense injection site reaction with a future 
injection.  Any severe injection reaction that lasts over 24 hours will be reported as an AESI with 
immediate notification. ADA and PK samples will be collected near the onset and resolution of 
the AESI for any additional analysis. 
Prophylactic treatment/premedication for an injection site reaction is not permitted. 
10.6.3 Infections 
Some biologic therapies have been associated with an increased risk of infection, including 
opportunistic infection.  As a precautionary measure, the Investigator is required to carefully 
monitor for any signs or symptoms of infection such as, but not limited to, increased body 
temperature, malaise, weight loss, sweats, cough, dyspnea, pulmonary infiltrates, or serious febrile 
systemic illness. 
Since dupilumab binds to IL-4RĮ, preventing IL-4 and IL-13 activation of their respective 
receptors, it inhibits the T-helper 2 (Th2) cytokines production. Infections with a diversity of 
helminthic parasites elicit eosinophilia via stimulation of Th2-like lymphocyte responses. The Th2 
response is characterized by production of IL-4, IL-13 and IL-5, subsequently generating IgG1 
and IgE-secreting cells, and eliciting eosinophilia.  Eosinophilia is prominent in a number of 
helminthic parasitic diseases. The eosinophilic response to helminths is determined both by the 
host's immune response and by the parasite, including its distribution, migration, and development 
within the infected host. Therefore, patients treated with dupilumab may potentially have an 
increased risk of parasitic infection. 
Section 10.4.1.3 defines infections that should be reported as AESIs (ie, within 24 hours). 
A complete diagnostic work-up should be performed (ie, cultures, histopathological or cytological 
evaluation, antigen detection, and serum antibody titers).  Patients should be referred to an 
infectious disease specialist if deemed necessary for diagnostic work up and appropriate 
treatment. 
Infections or infestations that do not respond to medical treatment should have study drug 
discontinued until the infection is resolved. 
For any opportunistic infection, such as TB or other infections whose nature or course may 
suggest an immunocompromised status (Appendix L), patients must be permanently discontinued 
from study medication. 
In order to minimize this risk, any patient with an active parasitic infection should be excluded 
from the study. Similarly, patients with suspected parasitic infection, or those at high risk of 
parasitic infection are also excluded, unless clinical and (if necessary) laboratory assessments 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 101 
have ruled out active infection before randomization. During the study, appearance of signs or 
symptoms (such as abdominal pain, cough, diarrhea, fever, fatigue hepatosplenomegaly) that 
could be associated with a parasitic infection should be carefully evaluated, especially if there is a 
history of parasitic exposure through recent travel to/ or residence in endemic areas, especially 
when conditions are conducive to infection (eg, extended stay, rural or slum areas, lack of running 
water, consumption of uncooked, undercooked, or otherwise potentially contaminated food, close 
contact with carriers and vectors, etc). Subsequent medical assessments (eg, stool exam, blood 
tests, etc) must be performed in order to rule out parasitic infection/infestation.   Patients with 
confirmed parasitic infections during the study should be reported as AESI with immediate 
notification.  
10.6.4 Elevated liver function tests 
No preclinical and clinical data has suggested any hepatic toxicity of dupilumab; however, as a 
general consideration of clinical development, the administration of immunosuppressant or 
immunomodulating agents may represent an additional risk factor for hepatotoxicity. 
In order to closely follow potential liver function abnormalities, assessment of total protein, 
albumin, total bilirubin, ALT, aspartate aminotransferase, and alkaline phosphatase are measured 
as part of the clinical laboratory testing.  Clinical laboratory testing at Visit 1 and Visit 10 (only 
applicable for patients who planned to roll over into a long-term study) adds hepatitis screen 
(HBsAg, HBsAb, IgM and IgG/total-HBcAb, and HCVAb).  Patients who are IgG/total-HBcAb 
positive and HBsAg negative at Visit 1 or Visit 10 must undergo HBV DNA testing prior to 
randomization to determine eligibility (only applicable for patients who plan to roll over into a 
long-term study).  Furthermore, it is recommended that patients who are receiving potentially 
immunosuppressive therapy and are IgG HBcAb positive and HBV DNA negative undergo 
surveillance HBV DNA studies every 1 to 3 months depending upon the individual potential 
therapeutic risk and comorbidities.  If necessary, a hepatologist should be consulted on a 
case-by-case basis. 
Hepatitis virus tests and liver function tests (LFTs) will be performed at Visit 1, prior to 
randomization, to exclude those patients with high risk of hepatitis infection or severe liver injury 
from this study (Section 7.2 and Section 9.2.3.5). 
In order to closely follow potential liver abnormalities, assessment of total protein, albumin, total 
bilirubin (in case of values above the normal range, differentiation in conjugated and 
nonconjugated bilirubin), alanine aminotransferase, aspartate aminotransferase, and alkaline 
phosphatase are measured as part of the clinical laboratory testing (Section 9.2.3.5).  
Guidance for the investigation of elevated LFTs is provided in Appendix F. 
10.7 
ADVERSE EVENTS MONITORING 
All events will be managed and reported in compliance with all applicable regulations, and 
included in the final clinical study report. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 102 
11 
STATISTICAL CONSIDERATIONS 
11.1 
DETERMINATION OF SAMPLE SIZE 
The sample size estimation is based on the comparison between dupilumab doses versus placebo 
with regard to the primary endpoint and the key secondary endpoint: percentage reduction of OCS 
dose at Week 24 compared with the baseline dose and proportion of patients achieving a reduction 
of 50% or greater in their OCS dose compared with baseline at Week 24, while maintaining 
asthma control.  For the primary endpoint, assuming a common standard deviation of 50%, with  
90 randomized patients per group, the study will have 94% power to detect a treatment difference 
of 27% (24) at the 2-tailed significance level of Į=0.05.  For the key secondary endpoint, with the 
same sample size of 90 randomized patients per group, the study will have 81% power to detect a 
difference in the proportion of patients achieving 50% or greater in their OCS dose of 33% in the 
placebo group, compared to 54% in the dupilumab group (22), at the 2-tailed significance level of 
Į=0.05. Calculations were made using nQuery Advisor 7.0. 
Patients will be randomized using a 1:1 randomization ratio for dupilumab 300mg q2w and 
placebo. Randomization will be stratified by optimized OCS dose at Week 0 (10 mg/day, 
>10 mg/day) and country. 
Recruitment of patients whose eosinophil level is below 150 cells/μL will stop when 
approximately 46 (25% of the total sample size) of such patients are randomized. Recruitment 
will continue with patients whose eosinophil level is greater than or equal to 150 cells/μL until 
reaching the total sample size of 180.  In addition, the number of patients receiving 5 mg OCS at 
Visit 3 will be limited to approximately 54 patients (approximately 30% of the study population). 
11.2 
DISPOSITION OF PATIENTS 
Screened patients are defined as any patient who signed the informed consent.  
Randomized patients consist of all patients with a treatment kit number allocated and recorded in 
the IVRS database, regardless of whether the treatment kit was used or not. 
Patients treated without being randomized will not be considered as randomized and will not be 
included in any efficacy population. 
11.3 
ANALYSIS POPULATIONS 
11.3.1 Efficacy populations 
The population considered for the efficacy analysis will be the ITT population. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 103 
11.3.1.1 Intent-to-treat population 
The ITT population is defined as all randomized patients analyzed according to the treatment 
group allocated by randomization regardless of whether the treatment kit is used or not.   
11.3.2 Safety population 
The analysis population for the safety endpoints will be the safety population defined as all 
patients exposed to study medication, regardless of the amount of treatment administered. The 
safety analyses will be conducted according to the treatment patients actually received. 
The treatment-emergent period for the safety population is defined as the time between the first 
administration of study medication to the end of the Post-treatment period (12 weeks after the end 
of study treatment) or until the patient rolls over into a long-term study. 
In addition:  
x
Randomized patients for whom it is unclear whether they took the study medication will 
be included in the safety population as randomized. 
x
For patients receiving more than 1 study treatment during the trial, the treatment group 
allocation for as-treated analysis will be the dupilumab group. 
11.3.3 Systemic drug concentration population 
The systemic drug concentration population will consist of all patients in the safety population 
with at least 1 evaluable functional dupilumab concentration result.  Patients will be analyzed 
according to the treatment they actually received. 
11.3.4 Anti-drug antibody population 
The ADA population will consist of all patients in the safety population who had at least 
1 reportable ADA result (either “ADA negative” or “ADA positive”) after the first dose of the 
study treatment. 
11.4 
STATISTICAL METHODS 
11.4.1 Extent of study treatment exposure and compliance 
The extent of study treatment exposure and compliance will be assessed and summarized by 
actual treatment received within the safety population. 
11.4.1.1 Extent of investigational medicinal product exposure 
Duration of IMP exposure is defined as:  last dose date – first dose date + 14 days, regardless of 
unplanned intermittent discontinuations.   
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 104 
11.4.1.2 Compliance  
Compliance with the IMP will be summarized in the following manner. 
A given administration will be considered noncompliant if the patient did not take the planned 
dose of treatment as required by the protocol.  No imputation will be made for patients with 
missing or incomplete data.  
The percentage of compliance for a patient will be defined as the number of administrations the 
patient was compliant divided by the total number of administrations the patient was planned to 
take during the treatment period (ie, from the 1st to the last administration). 
Treatment compliance, above-planned and under-planned dosing percentages will be summarized 
descriptively (N, mean, standard deviation [SD], median, minimum, and maximum).  The 
percentage of patients with a compliance <80% will be summarized.  In addition, the number and 
percentage of patients with at least 1 dose greater than the planned dosing administration will be 
provided, as well as the number and percentage of patients with 0, (0, 20%), and >20% 
under-planned dosing administrations. 
Compliance to OCS and controller medications will be summarized separately and will be 
specified in the SAP. 
11.4.2 Analyses of efficacy endpoints 
11.4.2.1 Analysis of primary efficacy endpoint 
The outcome of the percentage reduction of OCS dose at Week 24 compared with the baseline 
dose, while maintaining asthma control, will be calculated as (optimized OCS dose at  
baseline – final OCS dose at Week 24)/optimized OCS dose at baseline × 100%.   
The percentage reduction will be analyzed using an analysis of covariance (ANCOVA) model.  
The model will include the percentage reduction of OCS dose at Week 24 as the response 
variable, and the treatment groups, optimized OCS dose at baseline, regions (pooled countries), 
and baseline eosinophil level subgroups (<150 cells/μL, 150 cells/μL) as covariates.  A review of 
the residuals will be done to determine whether the normality assumption is met.  If the normality 
assumption is not met, a rank ANCOVA model will be used to corroborate the result. 
The treatment difference will be tested at the 2-sided significance level of Į=0.05.  Descriptive 
statistics for the primary efficacy endpoint will be provided, including the number of patients, 
means, standard errors, and least squares (LS) means by the treatment groups, as well as the 
difference in LS means and the corresponding 95% confidence interval (CI).  
Patients who permanently discontinue the study medication will be asked and encouraged to 
return to the clinic for all remaining study visits and the Investigator will continue to prescribe 
OCS at the dose specified for OCS titration (as described in Section 8.2.2.2).  The off-treatment 
OCS dose at Week 24 will be used in the primary analysis.  For patients with an ongoing severe 
asthma exacerbation and who has not completed treatment of the exacerbation at Week 24, the 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 105 
patient should be placed on the OCS dose 1 step higher than that which he/she was on when the 
exacerbation occurred. 
A sensitivity analysis for the primary efficacy endpoint will be specified in the SAP. 
11.4.2.1.1 Subgroup analysis 
To assess the consistency in treatment effects across the subgroup levels, subgroup analyses will 
be conducted for the primary efficacy endpoint with respect to baseline optimized OCS dose 
strata, age group, gender, region, race, baseline FEV1, predicted FEV1 %, ACQ-5, weight, BMI, 
smoking history, atopic medical history, age of onset of asthma, number of prior asthma 
exacerbations, baseline eosinophil level (<150 cells/μL or 150 cells/μL), and select baseline 
biomarker levels.  The details will be provided in the SAP. 
11.4.2.2 Analyses of secondary efficacy endpoints 
11.4.2.2.1 Analysis of the key secondary efficacy endpoint 
The proportion of patients achieving a reduction of 50% or greater in their OCS dose at Week 24 
compared with baseline will be analyzed using a logistic regression model.  The model will use 
the binary status of whether or not a patient achieved the 50% OCS dose reduction criterion as the 
response variable, and treatment groups, optimized OCS dose at baseline, regions (pooled 
countries), and baseline eosinophil level subgroups (<150 cells/μL or 150 cells/μL) as covariates.  
For patients who permanently discontinue the treatment, their final dose used for the primary 
efficacy endpoint will be used to determine whether or not they achieve the OCS dose reduction 
criterion. 
11.4.2.2.2 Analysis of the absolute reduction of OCS dose  
The absolute reduction of OCS dose at Week 24 will be analyzed using an ANCOVA model in 
the same fashion as for the primary endpoint, percent reduction of OCS dose at Week 24. 
11.4.2.2.3 Analysis of proportion of patients achieving a certain reduction of OCS dose 
The proportion of patients achieving a certain reduction of OCS dose will be analyzed in the same 
manner as the key secondary endpoint.  The model will use the binary status of whether or not a 
patient achieves the prespecified OCS dose reduction criterion as the response variable, and the 
treatment groups, optimized OCS dose at baseline, regions (pooled countries), and baseline 
eosinophil level subgroups (<150 cells/μL or 150 cells/μL) as covariates.  For patients who 
permanently discontinue the treatment, their final dose used for the primary efficacy endpoint will 
be used to determine whether or not they achieve the OCS dose reduction criterion.  
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 106 
11.4.2.3 Analyses of other efficacy endpoints 
11.4.2.3.1 Analysis of annualized event rate 
The annualized event rates (eg, severe asthma exacerbation, exacerbations requiring 
hospitalization or ER visit) will be analyzed using a negative binomial regression model.  The 
model will include the total number of the events occurring during the 24-week Treatment Period 
as the response variable, and the treatment groups, baseline optimized OCS dose strata, regions 
(pooled countries), number of the events within 1 year prior to the study, and baseline eosinophil 
level subgroups (<150 cells/μL, 150 cells/μL) as covariates.  Log-transformed treatment duration 
will be the offset variable.  For patients who permanently discontinue the treatment, the events 
which occurred up to Week 24 will be included and the last contact date at Week 24 will be used 
to calculate offset variable.  For patients who are lost to follow up prior to Week 24, events that 
occurred up to the last contact date will be analyzed, and the last contact date will be used to 
calculate the offset variable. 
11.4.2.3.2 Analysis of time to event variables 
Time to event parameters (eg, first severe asthma exacerbation, first exacerbation requiring 
hospitalization or ED visit) will be analyzed using a Cox regression model with the time to event 
as the response variable, and the treatment groups, baseline optimized OCS dose strata, regions 
(pooled countries), number of the events within 1 year prior to the study, and baseline eosinophil 
level subgroups (<150 cells/μL, 150 cells/μL) as covariates.  The Kaplan-Meier (KM) method 
will be used to derive the proportion of patients with an event at Weeks 12 and 24 specific to each 
treatment group.  For patients who are lost to follow up or who discontinue the study prior to 
Week 24, events that occurred up to the last contact date will be analyzed. 
11.4.2.3.3 Analysis of change/ percentage change from baseline for other continuous variables 
The change/percentage change from baseline for other continuous variables (eg, FEV1, PEF, FVC, 
FEF25-75%, ACQ, asthma symptom scores) will be analyzed using a mixed effect model with 
repeated measures (MMRM) approach.  For a continuous variable, the corresponding MMRM 
model will include the change/percent change from baseline as response variables, and factors 
(fixed effects) for the treatment groups, baseline optimized OCS dose strata, regions (pooled 
countries), baseline eosinophil level subgroups (<150 cells/PL, 150 cells/PL) visits, 
treatment-by-visit interaction, the corresponding baseline value of the endpoint, and 
baseline-by-visit interaction.  Additionally, age, gender, and height will be included as covariates 
in the models for spirometry variables but not for other variables.  An unstructured correlation 
matrix will be used to model the within-patient errors.  Parameters will be estimated using 
restricted maximum likelihood method with the Newton-Raphson algorithm.  Statistical 
inferences on treatment comparisons for an endpoint will be derived from the corresponding 
mixed-effect model.   
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 107 
11.4.2.4 Multiplicity considerations 
The primary endpoint will be tested at a 2-sided 5% significance level.  If the primary endpoint 
meets the significance level, the following secondary endpoints will be tested at a 2-sided 5% 
significance level in the hierarchical order defined below: 
x
Proportion of patients achieving a reduction of 50% or greater in their OCS dose compared 
with baseline at Week 24 while maintaining asthma control; 
x
Proportion of patients achieving a reduction of OCS dose to <5 mg/day at Week 24 while 
maintaining asthma control  
x
Proportion of patients achieving their maximum possible reduction of OCS dose per 
protocol at Week 24 while maintaining asthma control; 
x
Proportion of patients no longer requiring OCS at Week 24 while maintaining asthma 
control. 
11.4.3 Analyses of safety data 
The summary of safety results will be presented by treatment group.   
All safety analyses will be performed on the safety population using the following common rules: 
x
The baseline value is defined generally as the last available value before the first dose of 
study drug. 
x
The following definitions will be applied to laboratory parameters, vital signs and ECG. 
-
The potentially clinically significant abnormality (PCSA) values are defined as 
abnormal values considered medically important by the Sponsor according to 
predefined criteria/thresholds based on a review of the literature and defined by the 
Sponsor for clinical laboratory tests, vital signs, and ECG.  
-
The criteria for PCSA will determine which patients had at least 1 PCSA during the 
treatment-emergent period, taking into account all evaluations performed during the 
on-treatment period, including unscheduled or repeated evaluations.  The number of all 
such patients will be the numerator for the on-treatment PCSA percentage.   
11.4.3.1 Adverse events 
Adverse event incidence tables will present by system organ class (SOC) (sorted by 
internationally agreed order), high-level group term (HLGT), high level term (HLT), and 
preferred term (PT) sorted in alphabetical order for each treatment group, the number (n) and 
percentage (%) of patients experiencing an AE.  Multiple occurrences of the same event in the 
same patient will be counted only once in the tables within a treatment phase.  The denominator 
for computation of percentages is the safety population within each treatment group. 
The proportion of patients with at least 1 TEAE, serious TEAE, and TEAE leading to 
discontinuation of the study will be tabulated by treatment group.  In addition, TEAEs will be 
described according to maximum intensity and relation to the study drug.  Serious AEs and AEs 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 108 
leading to study discontinuation that occur outside the treatment-emergent period will be 
summarized separately. 
11.4.3.1.1 Adverse events of special interest 
The following summaries will be generated: 
x
Incidence of each AESI will be tabulated by treatment group. 
x
An overview summary of the number (%) of patients with 
-
any TEAE 
-
any serious AE (regardless of treatment-emergent status) 
-
any treatment-emergent SAE 
-
any AE leading to death 
-
any TEAE leading to permanent study drug discontinuation 
-
any TEAE by maximum intensity, corrective treatment, and final outcome 
-
cumulative incidence at specified time points (KM estimates at 1, 4, 12, 24, and 
36 weeks) 
Definitions of AESIs and the method to identify AESIs will be specified in the SAP. 
11.4.3.1.2 Deaths 
The following deaths summaries will be generated: 
x
Number (%) of patients who died by study period (TEAE, on-study) and reasons for death 
summarized on the safety population by treatment received 
x
Death in nonrandomized patients or randomized and not treated patients   
x
Treatment-emergent AEs leading to death (death as an outcome on the AE CRF page as 
reported by the Investigator) by primary SOC, HLGT, HLT, and PT showing number (%) 
of patients sorted by the internationally agreed order of SOC and alphabetic order of 
HLGT, HLT, and PT.  
Patient data listings will be provided for all AEs, TEAEs, SAEs, AEs leading to study 
discontinuation, AESIs, and deaths. 
11.4.3.2 Clinical laboratory evaluation, vital signs, and electrocardiogram data 
Results and change from baseline for the parameters will be summarized by treatment group for 
baseline and each post baseline time point, endpoint, minimum and maximum value.  Summary 
statistics will include number of patients, mean, standard deviation, median, first quartile (Q1), 
third quartile (Q3), minimum, and maximum. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 109 
The proportion of patients who had at least 1 incidence of PCSA at any time during the 
treatment-emergent period will be summarized by treatment group.  Shift tables showing changes 
with respect to the baseline status will be provided. 
Listings will be provided with flags indicating clinically out-of range values, as well as PCSA 
values. 
11.4.4 Analyses of systemic drug concentration, anti-drug antibodies, and 
pharmacodynamics variables 
11.4.4.1 Drug concentration analysis 
Concentrations of functional dupilumab in serum will be summarized using arithmetic and 
geometric means, SD, standard error of the mean (SEM), coefficient of variation (CV%), 
minimum, median, and maximum by treatment per visit. 
Concentrations of serum functional dupilumab will be used in the population (Pop) PK analysis.  
Additional details of the Pop PK analysis plan and the results will be provided in separate 
documents. 
11.4.4.2 Anti-drug antibodies analysis 
The incidence of positivity in the ADA assay will be assessed as absolute occurrence (n) and 
percent of patients (%), presented by treatment groups.  Listing of ADA titer levels will be 
provided for patients positive in the ADA assay.  Samples that are positive in the ADA assay will 
be further characterized for the presence of anti-dupilumab neutralizing antibodies. The ADA 
analysis will be detailed in the SAP. 
11.4.4.3 Pharmacodynamic analysis 
The values to be used as baselines will be those collected on Day 1 (predose assessments).  If any 
of the scheduled assessments on Day 1 are technically disqualified (eg, insufficient sample) and 
the parameters are measured at any of the screening visits, then values determined at Screening 
can be used as the baseline. 
For all parameters, raw data, absolute changes from baseline and percent changes from baseline 
will be summarized by treatment group and time point using descriptive statistics. 
Summary plots (mean +/- SEM) on raw data, absolute changes from baseline, and percent changes 
from baseline will be provided by treatment group. 
11.4.5 Analyses of patient-reported outcomes (health-related quality of life/health 
economics variables 
Change from baseline in the following variables: global measure of AQLQ and the 4 domains, the 
quantitative variables of EQ-5D-5L (single index utility), the anxiety and depression scores of 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 110 
HADS will be analyzed using an MMRM approach, described previously for the continuous 
efficacy variables.  Descriptive statistics including number of patients, mean, SEM, and LS means 
will be provided.  In addition, the difference in LS means, the corresponding 95% CIs, and the 
p-values will be provided for comparison between dupilumab and placebo. 
The SNOT-22 (only for those patients with bilateral nasal polyposis) will be analyzed using a 
similar approach. 
11.5 
INTERIM ANALYSIS 
No interim analysis is planned for this study. The primary analysis is planned when the last 
patient completes the week 24 visit or discontinues from the study before the week 24 visit.  The 
primary database lock will be based on the date when the last patient completes the week 24 visit 
or discontinues from the study before the week 24 visit.  Analyses will be based on all data 
collected up to this database lock and will be considered as the final analyses in the CSR (Clinical 
Study Report). Additional data between database lock and last patient completing last visit will be 
summarized in a CSR addendum. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 111 
12 
ETHICAL AND REGULATORY CONSIDERATIONS 
12.1 
ETHICAL AND REGULATORY STANDARDS 
This clinical trial will be conducted by the Sponsor, the Investigator, delegated Investigator staff 
and Subinvestigator, in accordance with the principles laid down by the 18th World Medical 
Assembly (Helsinki, 1964) and all applicable amendments laid down by the World Medical 
Assemblies, and the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) guidelines for good clinical practice 
(GCP), all applicable laws, rules and regulations. 
This clinical trial will be recorded in a free, publicly accessible, internet-based registry, no later 
than 21 days after the first patient enrollment, in compliance with applicable regulatory 
requirements and with Sanofi public disclosure commitments.  
12.2 
INFORMED CONSENT 
The Investigator (according to applicable regulatory requirements), or a person designated by the 
Investigator, and under the Investigator's responsibility, should fully inform the patient of all 
pertinent aspects of the clinical trial including the written information giving approval/favorable 
opinion by the Ethics Committee (IRB or IEC).  All participants should be informed to the fullest 
extent possible about the study, in language and terms they are able to understand. 
Prior to a patient’s participation in the clinical trial, the informed consent form should be signed, 
name filled in and personally dated by the patients (for adult patients) or patient’s parent(s) for 
pediatric patients or by the patient’s legally acceptable representative, and by the person who 
conducted the informed consent discussion.  A copy of the signed and dated written informed 
consent form will be provided to the patient (for adult patients) or patient’s parent(s) for pediatric 
patients.  Local law must be observed in deciding whether 1 or both parents/guardians consent is 
required for pediatric patients.  If only 1 parent or guardian signs the consent form, the 
Investigator must document the reason for only 1 parent or guardian’s signature. 
In addition, participants will assent as detailed below or will follow the Ethics Committee 
(IRB/IEC) approved standard practice for pediatric participants at each participating center (age of 
assent to be determined by the IRB’s/IEC’s or be consistent with the local requirements): 
x
Pediatric participants who can read the assent form will do so before writing their name 
and dating or signing and dating the form. 
x
Pediatric participants who can write but cannot read will have the assent form read to them 
before writing their name on the form. 
x
Pediatric participants who can understand but who can neither write nor read will have the 
assent form read to them in presence of an impartial witness, who will sign and date the 
assent form to confirm that assent was given. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 112 
The informed consent form and the assent form used by the Investigator for obtaining the 
pediatric patient’s Informed Consent must be reviewed and approved by the Sponsor prior to 
submission to the appropriate Ethics Committee (IRB/IEC) for approval/favorable opinion. 
In relation with the population of patients exposed in the trial, ie, pediatric/minor patients, the 
IRB/IEC should ensure proper advice from specialist with pediatrics expertise (competent in the 
area of clinical, ethical and psychosocial problems in the field of pediatrics) according to national 
regulations.  This should be documented. 
Prior to collection of blood for pharmacogenetics, the optional pharmacogenetic informed consent 
form (written) should be signed, name filled in, and personally dated by the patient or by the 
patient’s legally acceptable representative, and by the person who conducted the informed consent 
discussion.  A copy of the signed and dated written optional informed consent form will be 
provided to the patient. 
Prior to collection of blood for archiving of serum, the optional Future Use of Specimens 
informed consent form (written) should be signed, name filled in, and personally dated by the 
patient or by the patient’s legally acceptable representative, and by the person who conducted the 
informed consent discussion.  A copy of the signed and dated written optional informed consent 
form will be provided to the patient. 
The main study informed consent form, the optional Pharmacogenetic informed consent form, and 
the Future Use of Specimens informed consent form to be used by the Investigator for obtaining 
the patient's informed consent must be reviewed and approved by the Sponsor prior to submission 
to the appropriate Ethics Committee (IRB/IEC) for approval/favorable opinion. 
12.3 
INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC) 
As required by local regulation, the Investigator or the Sponsor must submit this clinical trial 
protocol to the appropriate IRB/IEC, and is required to forward to the respective other party a 
copy of the written and dated approval/favorable opinion signed by the Chairman with IRB/IEC 
composition. 
The clinical trial (study number, clinical trial protocol title and version number), the documents 
reviewed (clinical trial protocol, informed consent form, Investigator’s Brochure, Investigator’s 
curriculum vitae, etc) and the date of the review should be clearly stated on the written (IRB/IEC) 
approval/favorable opinion. 
The IMP will not be released at the study site and the Investigator will not start the study before 
the written and dated approval/favorable opinion is received by the Investigator and the Sponsor. 
During the clinical trial, any amendment or modification to the clinical trial protocol should be 
submitted to the IRB/IEC before implementation, unless the change is necessary to eliminate an 
immediate hazard to the patients, in which case the IRB/IEC should be informed as soon as 
possible.  It should also be informed of any event likely to affect the safety of patients or the 
continued conduct of the clinical trial, in particular any change in safety.  All updates to the 
Investigator’s Brochure will be sent to the IRB/IEC. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 113 
A progress report will be sent to the IRB/IEC at least annually and a summary of the clinical 
trial’s outcome at the end of the clinical trial.  
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 114 
13 
STUDY MONITORING 
13.1 
RESPONSIBILITIES OF THE INVESTIGATOR(S) 
The Investigator is required to ensure compliance with all procedures required by the clinical trial 
protocol and with all study procedures provided by the Sponsor (including security rules).  The 
Investigator agrees to provide reliable data and all information requested by the clinical trial 
protocol (with the help of the CRF, Discrepancy Resolution Form [DRF] or other appropriate 
instrument) in an accurate and legible manner according to the instructions provided and to ensure 
direct access to source documents by Sponsor representatives. 
If any circuit includes transfer of data particular attention should be paid to the confidentiality of 
the patient's data to be transferred. 
The Investigator will be responsible for inventory of OCS (including counting of pills at each 
study visit during the Treatment and Post-treatment periods). 
The Investigator may appoint such other individuals as he/she may deem appropriate as 
Subinvestigators to assist in the conduct of the clinical trial in accordance with the clinical trial 
protocol.  All Subinvestigators shall be appointed and listed in a timely manner.  The 
Subinvestigators will be supervised by and work under the responsibility of the Investigator.  The 
Investigator will provide them with a copy of the clinical trial protocol and all necessary 
information. 
13.2 
RESPONSIBILITIES OF THE SPONSOR 
The Sponsor of this clinical trial is responsible to regulatory authorities for taking all reasonable 
steps to ensure the proper conduct of the clinical trial as regards ethics, clinical trial protocol 
compliance, and integrity and validity of the data recorded on the CRFs.  Thus, the main duty of 
the monitoring team is to help the Investigator and the Sponsor maintain a high level of ethical, 
scientific, technical and regulatory quality in all aspects of the clinical trial. 
At regular intervals during the clinical trial, the site will be contacted, through monitoring visits, 
letters or telephone calls, by a representative of the monitoring team to review study progress, 
Investigator and patient compliance with clinical trial protocol requirements and any emergent 
problems.  These monitoring visits will include but not be limited to review of the following 
aspects: patient informed consent, patient recruitment and follow-up, SAE documentation and 
reporting, AESI documentation and reporting, AE documentation, IMP allocation, patient 
compliance with the IMP regimen, IMP accountability, concomitant therapy use and quality of 
data. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 115 
13.3 
SOURCE DOCUMENT REQUIREMENTS 
According to the ICH GCP, the monitoring team must check the CRF entries against the source 
documents, except for the pre-identified source data directly recorded in the CRF.  The informed 
consent form will include a statement by which the patient allows the Sponsor’s duly authorized 
personnel, the Ethics Committee (IRB/IEC), and the regulatory authorities to have direct access to 
original medical records  which support the data on the CRFs (eg, patient's medical file, 
appointment books, original laboratory records, etc).  These personnel, bound by professional 
secrecy, must maintain the confidentiality of all personal identity or personal medical information 
(according to confidentiality and personal data protection rules). 
13.4 
USE AND COMPLETION OF CASE REPORT FORMS AND ADDITIONAL REQUESTS 
It is the responsibility of the Investigator to maintain adequate and accurate CRFs (according to 
the technology used) designed by the Sponsor to record (according to Sponsor instructions) all 
observations and other data pertinent to the clinical investigation in a timely manner. All CRFs 
should be completed in their entirety in a neat, legible manner to ensure accurate interpretation of 
data. 
Should a correction be made, the corrected information will be entered in the e-CRF overwriting 
the initial information.  An audit trail allows identifying the modification.  
Data are available within the system to the Sponsor as soon as they are entered in the e-CRF. 
The computerized handling of the data by the Sponsor may generate additional requests (DRF) to 
which the Investigator is obliged to respond by confirming or modifying the data questioned.  The 
requests with their responses will be managed through the e-CRF. 
13.5 
USE OF COMPUTERIZED SYSTEMS 
The complete list of computerized systems used for the study is provided in a separate document 
which is maintained in the Sponsor and Investigator study files. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 116 
14 
ADDITIONAL REQUIREMENTS 
14.1 
CURRICULUM VITAE 
A current copy of the curriculum vitae describing the experience, qualification and training of 
each Investigator and Subinvestigator will be signed, dated and provided to the Sponsor prior to 
the beginning of the clinical trial. 
14.2 
RECORD RETENTION IN STUDY SITES 
The Investigator must maintain confidential all study documentation, and take measures to 
prevent accidental or premature destruction of these documents. 
The Investigator should retain the study documents at least 15 years after the completion or 
discontinuation of the clinical trial.  
However, applicable regulatory requirements should be taken into account in the event that a 
longer period is required. 
The Investigator must notify the Sponsor prior to destroying any study essential documents 
following the clinical trial completion or discontinuation. 
If the Investigator's personal situation is such that archiving can no longer be ensured by him/her, 
the Investigator shall inform the Sponsor and the relevant records shall be transferred to a 
mutually agreed upon designee.  
14.3 
CONFIDENTIALITY 
All information disclosed or provided by the Sponsor (or any company/institution acting on their 
behalf), or produced during the clinical trial, including, but not limited to, the clinical trial 
protocol, personal data in relation to the patients, the CRFs, the Investigator's Brochure and the 
results obtained during the course of the clinical trial, is confidential, prior to the publication of 
results. The Investigator and any person under his/her authority agree to undertake to keep 
confidential and not to disclose the information to any third party without the prior written 
approval of the Sponsor. 
However, the submission of this clinical trial protocol and other necessary documentation to the 
Ethics committee (IRB/IEC) is expressly permitted, the IRB/IEC members having the same 
obligation of confidentiality. 
The Subinvestigators shall be bound by the same obligation as the Investigator. The Investigator 
shall inform the Subinvestigators of the confidential nature of the clinical trial. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 117 
The Investigator and the Subinvestigators shall use the information solely for the purposes of the 
clinical trial, to the exclusion of any use for their own or for a third party's account. 
14.4 
PROPERTY RIGHTS 
All information, documents and IMP provided by the Sponsor or its designee are and remain the 
sole property of the Sponsor. 
The Investigator shall not and shall cause the delegated Investigator staff /Subinvestigator not to 
mention any information or the Product in any application for a patent or for any other intellectual 
property rights. 
All the results, data, documents and inventions, which arise directly or indirectly from the clinical 
trial in any form, shall be the immediate and exclusive property of the Sponsor. 
The Sponsor may use or exploit all the results at its own discretion, without any limitation to its 
property right (territory, field, continuance). The Sponsor shall be under no obligation to patent, 
develop, market or otherwise use the results of the clinical trial. 
As the case may be, the Investigator and/or the Subinvestigators shall provide all assistance 
required by the Sponsor, at the Sponsor's expense, for obtaining and defending any patent, 
including signature of legal documents. 
14.5 
DATA PROTECTION 
x
The patient's personal data, which are included in the Sponsor database shall be treated in 
compliance with all applicable laws and regulations; 
x
When archiving or processing personal data pertaining to the Investigator and/or to the 
patients, the Sponsor shall take all appropriate measures to safeguard and prevent access to 
this data by any unauthorized third party. 
x
The Sponsor also collects specific data regarding Investigator as well as personal data 
from any person involved in the study which may be included in the Sponsor’s databases, 
shall be treated by both the Sponsor and the Investigator in compliance with all applicable 
laws and regulations. 
Patient race or ethnicity will be collected in this study because these data are required by several 
regulatory authorities (eg, on Afro American population for FDA, on Japanese population for the 
PMDA in Japan, or on Chinese population for the CFDA in China). 
Analyses of patient genetic data will be conducted as described in the protocol as this is needed 
for pharmacogenetics analyses required for the purpose of the study or by regulatory authorities. 
The data collected in this study will only be used for the purpose(s) of the study and to document 
the evaluation of the benefit/ risk ratio, efficacy and safety of the product(s).  They may be further 
processed if they have been anonymized. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 118 
14.6 
INSURANCE COMPENSATION 
The Sponsor certifies that it has taken out a liability insurance policy covering all clinical trials 
under its sponsorship.  This insurance policy is in accordance with local laws and requirements. 
The insurance of the Sponsor does not relieve the Investigator and the collaborators from any 
obligation to maintain their own liability insurance policy. An insurance certificate will be 
provided to the IECs/IRBs or regulatory authorities in countries requiring this document.  
14.7 
SPONSOR AUDITS AND INSPECTIONS BY REGULATORY AGENCIES 
For the purpose of ensuring compliance with the clinical trial protocol, Good Clinical Practice and 
applicable regulatory requirements, the Investigator should permit auditing by or on the behalf of 
the Sponsor and inspection by regulatory authorities. 
The Investigator agrees to allow the auditors/inspectors to have direct access to his/her study 
records for review, being understood that these personnel is bound by professional secrecy, and as 
such will not disclose any personal identity or personal medical information. 
The Investigator will make every effort to help with the performance of the audits and inspections, 
giving access to all necessary facilities, data, and documents. 
As soon as the Investigator is notified of a planned inspection by the authorities, he will inform 
the Sponsor and authorize the Sponsor to participate in this inspection. 
The confidentiality of the data verified and the protection of the patients should be respected 
during these inspections. 
Any result and information arising from the inspections by the regulatory authorities will be 
immediately communicated by the Investigator to the Sponsor. 
The Investigator shall take appropriate measures required by the Sponsor to take corrective 
actions for all problems found during the audit or inspections. 
14.8 
PREMATURE DISCONTINUATION OF THE STUDY OR PREMATURE CLOSE-OUT OF 
A SITE 
14.8.1 By the Sponsor  
The Sponsor has the right to terminate the participation of either an individual site or the study at 
any time, for any reason, including but not limited to the following:  
x
The information on the product leads to doubt as to the benefit/risk ratio 
x
Patient enrollment is unsatisfactory 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 119 
x
The Investigator has received from the Sponsor all IMP, means and information necessary 
to perform the clinical trial and has not included any patient after a reasonable period of 
time mutually agreed upon 
x
Noncompliance of the Investigator or Subinvestigator, delegated staff with any provision 
of the clinical trial protocol, and breach of the applicable laws and regulations or breach of 
the ICH GCP 
x
The total number of patients are included earlier than expected 
In any case the Sponsor will notify the Investigator of its decision by written notice. 
14.8.2 By the Investigator 
The Investigator may terminate his/her participation upon thirty (30) days' prior written notice if 
the study site or the Investigator for any reason becomes unable to perform or complete the 
clinical trial.  
In the event of premature discontinuation of the study or premature close-out of a site, for any 
reason whatsoever, the appropriate IRB/IEC and regulatory authorities should be informed 
according to applicable regulatory requirements. 
14.9 
CLINICAL TRIAL RESULTS 
The Sponsor will be responsible for preparing a clinical study report and to provide a summary of 
study results to the Investigator. 
14.10 PUBLICATIONS AND COMMUNICATIONS 
The Investigator undertakes not to make any publication or release pertaining to the study and/or 
results of the study prior to the Sponsor’s written consent, being understood that the Sponsor will 
not unreasonably withhold its approval. 
As the study is being conducted at multiple sites, the Sponsor agrees that, consistent with 
scientific standards, a primary presentation or publication of the study results based on global 
study outcomes shall be sought.  However, if no multicenter publication is submitted, underway 
or planned within 12 months of the completion of this study at all sites, the Investigator shall have 
the right to publish or present independently the results of this study in agreement with other 
Investigators and stakeholders.  The Investigator shall provide the Sponsor with a copy of any 
such presentation or publication for review and comment at least 30 days in advance of any 
presentation or submission for publication.  In addition, if requested by the Sponsor, any 
presentation or submission for publication shall be delayed for a limited time, not to exceed 
90 days, to allow for filing of a patent application or such other justified measures as the Sponsor 
deems appropriate to establish and preserve its proprietary rights. 
The Investigator shall not use the name(s) of the Sponsor and/or its employees in advertising or 
promotional material or publication without the prior written consent of the Sponsor.  The 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 120 
Sponsor shall not use the name(s) of the Investigator and/or the collaborators in advertising or 
promotional material or publication without having received his/her and/or their prior written 
consent(s). 
The Sponsor has the right at any time to publish the results of the study. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 121 
15 
CLINICAL TRIAL PROTOCOL AMENDMENTS 
All appendices attached hereto and referred to herein are made part of this clinical trial protocol. 
The Investigator should not implement any deviation from, or changes of the clinical trial protocol 
without agreement by the Sponsor and prior review and documented approval/favorable opinion 
from the IRB/IEC of an amendment, except where necessary to eliminate an immediate hazard(s) 
to clinical trial patients, or when the change(s) involves only logistical or administrative aspects of 
the trial. Any change agreed upon will be recorded in writing, the written amendment will be 
signed by the Investigator and by the Sponsor and the signed amendment will be filed with this 
clinical trial protocol. 
Any amendment to the clinical trial protocol requires written approval/favorable opinion by the 
IRB/IEC prior to its implementation, unless there are overriding safety reasons. 
In some instances, an amendment may require a change to the informed consent form. The 
Investigator must receive an IRB/IEC approval/favorable opinion concerning the revised informed 
consent form prior to implementation of the change and patient signature should be re-collected if 
necessary. 
 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 122 
16 
REFERENCES 
1. 
Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties an interpretation of 
three shortened versions of the asthma control questionnaire.  Respir Med. 2005;99:553-8. 
2. 
Juniper EH, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change 
in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81-7. 
3. 
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coateset A,et al. 
Standardization of spirometry. Series ‘‘ATS/ERS TASK FORCE: Standardization of Lung 
Function Testing" Edited by Brusasco V, Crapo R, and Viegi G. Eur Resir J. 2005;26:319-38. 
4. 
Godard P, Chanez P, Siraudin L, Nicoloyannis L, Duru G. Costs of asthma are correlated 
with severity: A 1 year prospaective study. Eur Respir J. 2002;19:61-7. 
5. 
Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Pshycometric validity of the 22-item 
Sinonasal Outcome Test. Clin Otolar. 2009;34:447-54. 
6. 
Hofmann SG, Sawyer AT, Witt AA, Oh D. The effect of mindfulness-based therapy on 
anxiety and depression: A meta-analytic review. J Consult Clin Psychol. 2010;78:169–83. 
7. 
Levine SJ, Wenzel SE, Narrative review: the role of Th2 immune pathway modulation in 
the treatment of severe asthma and its phenotypes. Ann Intern Med 2010;152:232-7. 
8. 
Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. 
Standardization of the measurement of lung volumes.  Series “ATS/ERS TASK FORCE: 
Standardization of Lung Function Testing” Edited by Brusasco V, Crapo R, and Viegi G. Eur 
Respir J. 2005;26:511-52 
9. 
EUroQol Group. EuroQol-a new facility for the measurement of health-related quality of 
life. Health Policy 1990;16:199-208. 
10. 
Sullivan P, Lawrence WF, Ghushchyan A. A national catalog of preference-based scores 
for chronic conditions in the United States. Med Care 2005;43:736–49. 
11. 
Morjoria JB, Polosa R. Recommendation for management of severe refractory asthma. J 
Asthma Allerg 2010;3:43-56. 
12. 
Clienti S, Morjaria JB, Basile E, Polosa R. Monoclonal antibodies for the treatment of 
severe asthma. Curr Allergy Asthma Rep. 2011;11:253-260. 
13. 
Hashimoto S, Bel EH. Current treatment of severe asthma. Cin Exp Allergy 2012;42:693-
705. 
14. 
Juniper EH, Guyatt GH, Willan A. Griffith LE. Determing a minimal important change in 
a disease-specific quality of life questionnaire.  J Clin Epidemiol. 1994;47:81-7. 
(electronic 


Amended Clinical Trial Protocol 02  
25-Jan-2017 
EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
Page 123 
15. 
Czech W, Krutmann J, Schöpf E, Kapp A. Serum eosinophil cationic protein (ECP) is a 
sensitive measure for disease activity in atopic dermatitis. Br. J. Dermatol. April 
1992;126(4):351–5. 
16. 
Gain F, Senna G, Piglia P, Grosso B, Mezzelani P, Pozzi E. Cytokines and Asthma.  
Recenti ProgMed. 1998 Oct;89(10):520-8. 
17. 
Bottaro A, Lansford R, Xu L, Zhang J, Rothman P, Alt FW; S region transcription per se 
promotes basal IgE class switch recombination but additional factors regulate the  efficiency of 
the process.  EMBO J. 1994 Feb 1;13(3): 665-74. 
18. 
Wenzel, S, Ford, L, Pearlman, D, Spector, S, Sher, L, Skobieranda, F, et al.  Dupilumab in 
Persistent Asthma with Elevated Eosinophil Levels. N Engl J Med. 2013; 368:2455-2466 
19. 
Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, et al. Dose-related 
patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119-24. 
20. 
Ververeli K, Chipps B. Oral corticosteroid-sparing effects of inhaled corticosteroids in the 
treatment of persistent and acute asthma. Ann Allergy Asthma Immunol. 2004;92:512-22. 
21. 
Levine SJ, Wenzel SE. Narrative review: The role of Th2 immune pathway modulation in 
the treatment of severe asthma and its phenotypes. Ann Intern Med. 2010;152:232-7. 
22. 
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral 
glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Eng J Med 
2014;371:1189-97. 
23. 
Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in 
persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-66. 
24. 
Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave 
FE, O'Byrne PM, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. 
N Engl J Med. 2009;360:985-93. 
(electronic 

SAP_001.pdf: 
NCT number: NCT02528214


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 2 
TABLE OF CONTENTS 
STATISTICAL ANALYSIS PLAN....................................................................................................................1 
TABLE OF CONTENTS..................................................................................................................................2 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ..........................................................................5 
1 
OVERVIEW AND INVESTIGATIONAL PLAN.................................................................................7 
1.1 
STUDY DESIGN AND RANDOMIZATION ......................................................................................7 
1.2 
OBJECTIVES...................................................................................................................................7 
1.2.1 
Primary objectives............................................................................................................................7 
1.2.2 
Secondary objectives .......................................................................................................................7 
1.2.3 
Exploratory objectives ......................................................................................................................8 
1.3 
DETERMINATION OF SAMPLE SIZE.............................................................................................8 
1.4 
STUDY PLAN...................................................................................................................................8 
1.4.1 
Graphical study design...................................................................................................................14 
1.5 
MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL................................15 
1.6 
STATISTICAL MODIFICATIONS MADE IN THE STATISTICAL ANALYSIS PLAN......................17 
2 
STATISTICAL AND ANALYTICAL PROCEDURES .....................................................................18 
2.1 
ANALYSIS ENDPOINTS................................................................................................................18 
2.1.1 
Demographic and baseline characteristics ....................................................................................18 
2.1.2 
Prior or concomitant medications...................................................................................................20 
2.1.3 
Efficacy endpoints ..........................................................................................................................21 
2.1.3.1 
Primary efficacy endpoint(s)...........................................................................................................21 
2.1.3.2 
Additional efficacy endpoint(s) .......................................................................................................22 
2.1.4 
Safety endpoints.............................................................................................................................29 
2.1.4.1 
Adverse events variables ...............................................................................................................30 
2.1.4.2 
Deaths............................................................................................................................................33 
2.1.4.3 
Laboratory safety variables ............................................................................................................33 
2.1.4.4 
Vital signs variables........................................................................................................................34 
2.1.4.5 
Electrocardiogram variables...........................................................................................................35 
2.1.4.6 
Physical examination......................................................................................................................35 
2.1.5 
Pharmacokinetic variables .............................................................................................................35 
2.1.6 
Anti-drug antibody variables...........................................................................................................35 
2.1.7 
Pharmacodynamics/genomics endpoints ......................................................................................36 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 3 
2.1.8 
Health economic endpoints............................................................................................................37 
2.2 
DISPOSITION OF PATIENTS .......................................................................................................37 
2.2.1 
Randomization and drug dispensing irregularities .........................................................................38 
2.3 
ANALYSIS POPULATIONS ...........................................................................................................39 
2.3.1 
Efficacy populations .......................................................................................................................39 
2.3.1.1 
Intent–to-treat population ...............................................................................................................39 
2.3.2 
Safety population............................................................................................................................40 
2.3.3 
Pharmacokinetics population .........................................................................................................40 
2.3.4 
Anti-drug antibody population.........................................................................................................40 
2.4 
STATISTICAL METHODS .............................................................................................................40 
2.4.1 
Demographics and baseline characteristics ..................................................................................40 
2.4.2 
Prior or concomitant medications...................................................................................................41 
2.4.3 
Extent of investigational medicinal product exposure and compliance..........................................43 
2.4.3.1 
Extent of investigational medicinal product exposure ....................................................................43 
2.4.3.2 
Compliance to the investigational medicinal product .....................................................................44 
2.4.4 
Analyses of efficacy endpoints.......................................................................................................45 
2.4.4.1 
Analysis of primary efficacy endpoint(s).........................................................................................45 
2.4.4.2 
Analyses of secondary efficacy endpoints .....................................................................................51 
2.4.4.3 
Multiplicity issues............................................................................................................................53 
2.4.4.4 
Additional efficacy analyses ...........................................................................................................53 
2.4.5 
Analyses of safety data ..................................................................................................................55 
2.4.5.1 
Analyses of adverse events ...........................................................................................................56 
2.4.5.2 
Deaths............................................................................................................................................59 
2.4.5.3 
Analyses of laboratory variables ....................................................................................................60 
2.4.5.4 
Analyses of vital sign variables ......................................................................................................61 
2.4.5.5 
Analyses of electrocardiogram variables .......................................................................................62 
2.4.6 
Analyses of pharmacokinetic and pharmacodynamics variables...................................................62 
2.4.6.1 
Pharmacokinetic analysis...............................................................................................................62 
2.4.6.2 
Pharmacodynamic/genomic analyses............................................................................................64 
2.4.7 
Analyses of quality of life/health economics variables ...................................................................65 
2.5 
DATA HANDLING CONVENTIONS...............................................................................................65 
2.5.1 
General conventions ......................................................................................................................65 
2.5.2 
Data handling conventions for efficacy variables ...........................................................................66 
2.5.3 
Missing data ...................................................................................................................................67 
2.5.4 
Windows for time points.................................................................................................................69 
2.5.5 
Unscheduled visits .........................................................................................................................72 
2.5.6 
Pooling of centers for statistical analyses ......................................................................................72 
2.5.7 
Statistical technical issues .............................................................................................................73 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 4 
3 
INTERIM ANALYSIS .....................................................................................................................74 
4 
DATABASE LOCK ........................................................................................................................75 
5 
SOFTWARE DOCUMENTATION..................................................................................................76 
6 
REFERENCES...............................................................................................................................77 
7 
LIST OF APPENDICES .................................................................................................................78 
APPENDIX A. 
COMMONLY USED ASTHMA CONTROLLER THERAPIES.............................................79 
APPENDIX B. 
ASTHMA CONTROL QUESTIONNAIRE, 5-QUESTION VERSION ..................................81 
APPENDIX C. 
ASTHMA CONTROL QUESTIONNAIRE, 7-QUESTION VERSION..................................83 
APPENDIX D. 
ASTHMA QUALITY OF LIFE QUESTIONNAIRE...............................................................86 
APPENDIX E. 
22-ITEM SINO NASAL OUTCOME TEST..........................................................................92 
APPENDIX F. 
HOSPITAL ANXIETY AND DEPRESSION SCALE............................................................94 
APPENDIX G. 
EUROQUAL QUESTIONNAIRE.........................................................................................96 
APPENDIX H. 
DEFINITION OF ANAPHYLAXIS .......................................................................................99 
APPENDIX I. 
LIST OF OPPORTUNISTIC INFECTIONS ........................................................................100 
APPENDIX J. 
POTENTIALLY CLINICALLY SIGNIFICANT ABNORMALITY CRITERIA FOR 
INCLUDED LABORATORY PARAMETERS: COMBINED ADULT ( 18) AND 
ADOLESCENT ( 12 TO < 18) CRITERIA ABSTRACTED FROM BTD-009536 V3.0 WITH 
APPROVED MODIFICATIONS....................................................................................................101 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 5 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
 
ACQ-5: 
Asthma Control Questionnaire 5-question verssion 
ACQ-7: 
Asthma Control Questionnaire 7-question version 
ADA: 
anti-drug antibody, anti-drug antibodies 
AE: 
adverse event 
ALT: 
alanine aminotransferase 
ANA: 
anti-nuclear antibody 
ANCOVA: 
analysis of covariance 
AQLQ: 
Asthma Quality of Life Questionnaire 
AST: 
aspartate aminotransferase 
ATC: 
Anatomic Therapeutic Chemical 
ATS: 
American Thoracic Society 
BD: 
bronchodilator 
CI: 
confidence interval 
ECG: 
electrocardiogram 
eCRF: 
electronic case report form 
EOS: 
eosinophil 
EQ-5D-5L: 
EuroQoL Working Group Health Status Measure 5 Dimensions, 5 Levels 
ER: 
emergency room 
ERS: 
European Respiratory Society 
FEF25-75%: 
forced expiratory flow from 25% to 75% of the vital capacity 
FEV1: 
forced expiratory volume in 1 second 
FVC: 
forced vital capacity 
HADS: 
Hospital Anxiety and Depression Scale 
HbA1c: 
hemoglobin A1c 
HBcAb: 
hepatitis B core antibody 
HBsAb: 
hepatitis B surface antibody 
HBsAg: 
hepatitis B surface antigen 
HCAb: 
hepatitis C antibody 
HLGT: 
high-level group term 
HLT: 
high-level term 
IgA: 
immunoglobulin A 
IgG: 
immunoglobulin G 
IgM: 
immunoglobulin M 
ILC2: 
innate lymphoid type 2 
ITT: 
intent-to-treatment 
K-M: 
Kaplan Meier 
LLOQ: 
lower limit of quantification 
LLT: 
lower-level term 
LS: 
least squares 
MCID: 
minimal clinically important difference 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 6 
MDI: 
metered dose inhaler 
MedDRA: 
Medical Dictionary for Regulatory Activities 
MH: 
Mantel-Haenszel 
MMRM: 
mixed effect model with repeated measures 
NIMP: 
noninvestigational medicinal product 
OCS: 
oral corticosteroids 
OLE: 
open-label extension 
PCR: 
polymerase chain reaction 
PD: 
pharmacodynamic 
PROs: 
patient-reported outcomes 
PT: 
preferred term 
SC: 
subcutaneously  
SD: 
standard deviation 
SMQ: 
Standardised MedDRA Query 
SNOT-22: 
22-item Sino Nasal Outcome Test 
SOC: 
system organ class 
TEAE: 
treatment-emergent adverse event 
ULN: 
upper limit of normal 
VAS: 
visual analogue scale 
WBC: 
white blood cell 
WHO-DD: 
World Health Organization-Drug Dictionary 
 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 7 
1 
OVERVIEW AND INVESTIGATIONAL PLAN   
1.1 
STUDY DESIGN AND RANDOMIZATION 
This is a multinational, multicenter, randomized, double-blind, placebo-controlled study assessing 
the effect (efficacy and safety) of dupilumab administered subcutaneously (SC) for a maximum of 
24 weeks in patients with severe steroid-dependent asthma. 
The clinical trial will be divided into the following periods: 
x 
Screening and oral corticosteroids (OCS) Optimization period (from 3 to up to 8 weeks [up 
to 10 weeks for patients experiencing an asthma exacerbation that requires a change in 
OCS dose to allow for 2 weeks of stabilization prior to randomization]): to determine a 
patient’s eligibility status and to ensure that patients enter the treatment period on the 
lowest dose of OCS that will manage their symptoms 
x 
Treatment period (24 weeks): includes a 4-week induction phase, a 16-week OCS 
reduction phase, and a 4-week maintenance phase  
x 
Post-treatment/Follow up period (12 weeks): to monitor a patient’s status after 
completing/withdrawing from study drug treatment for patients not participating in the 
long-term extension study. 
Patients who meet the entry criteria will be randomized via Interactive Response Technology 
(IRT) in a 1:1 ratio to receive a 600 mg loading dose followed by 300 mg once every 2 weeks 
(q2w) of dupilumab or matching placebo, respectively. Randomization will be stratified by 
optimized OCS dose at Week 0 (10 mg/day, >10 mg/day) and country. 
1.2 
OBJECTIVES 
1.2.1 Primary objectives 
The primary objective of this study is to evaluate the efficacy of dupilumab, compared with 
placebo, for reducing the use of maintenance OCS in patients with severe steroid-dependent 
asthma. 
1.2.2 Secondary objectives 
Secondary objectives of the study include: 
x 
To evaluate the safety and tolerability of dupilumab 
x 
To evaluate the effect of dupilumab in improving patient-reported outcomes (PROs)  
x 
To evaluate dupilumab systemic exposure and the incidence of treatment-emergent 
anti-drug antibodies (ADA) 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 8 
1.2.3 Exploratory objectives 
The following objectives will be exploratory: 
x 
To evaluate baseline and on-treatment levels of biomarkers in association with treatment 
response and for their potential to predict treatment responses 
x 
To evaluate patient genetic profiles and their potential to predict treatment responses 
x 
To evaluate the effect of dupilumab on airway markers of inflammation (at select study 
sites within Canada) 
1.3 
DETERMINATION OF SAMPLE SIZE 
The sample size estimation is based on the comparison between dupilumab doses versus placebo 
with regard to the primary endpoint, percentage reduction of OCS dose at Week 24 compared with 
the baseline dose, and a key secondary endpoint, proportion of patients achieving a reduction of 
50% or greater in their OCS dose compared with baseline at Week 24, while maintaining asthma 
control.  For the primary endpoint, assuming a common standard deviation of 50%, with 90 
randomized patients per group, the study will have 94% power to detect a treatment difference of 
27% (1) at the 2-tailed significance level of Į=0.05. For the key secondary endpoint, with the same 
sample size of 90 randomized patients per group, the study will have 81% power to detect a 
difference, at the 2-tailed significance level of Į=0.05, in the proportion of patients achieving 
reduction of 50% or greater in their OCS dose, assuming that the proportions are 33% in the 
placebo group, compared to 54% in the dupilumab group (2). 
Calculations were made using nQuery Advisor 7.0. 
Recruitment of patients whose eosinophil level is below 150 cells/μL will stop when 
approximately 46 (25% of the total sample size) of such patients are randomized. Recruitment will 
continue with patients whose eosinophil (EOS) level is greater than or equal to 150 cells/μL until 
reaching the total sample size of 180.  In addition, the number of patients receiving 5 mg OCS at 
Visit 3 will be limited to approximately 54 patients (approximately 30% of the study population). 
1.4 
STUDY PLAN 
The total duration of the study (per patient) is expected to be up to 44 weeks (or up to 46 weeks in 
patients who experience an asthma exacerbation during the OCS Optimization phase that requires 
a change in OCS dose to allow for 2 weeks of stabilization prior to randomization) and consists 
of: 
x 
Up to 10 weeks for the Screening period/OCS Optimization phase 
x 
24 weeks for the Treatment period 
x 
12 weeks for the Post-treatment/Follow-up period (for patients not participating in the 
open-label extension [LTS12551] study) 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 9 
Screening and OCS Optimization Period 
Patients who meet eligibility criteria at the Screening visit will enter the OCS Optimization Phase.  
Prednisone or prednisolone will be the only OCS used.  At the Screening visit (V1), patients 
currently using other forms of maintenance OCS will have their corticosteroids switched to either 
of these corticosteroids at a dose clinically equivalent to their current stable OCS maintenance 
dose.  The definition of stable OCS maintenance dose in EFC13691 is no change of OCS dose 
within 4 weeks of Screening Visit 1. 
The lowest effective or optimized OCS dose will be defined during this phase as the lowest dose a 
patient can tolerate without experiencing any of the following OCS optimization phase 
interruption criteria: 
x 
Increase in Asthma Control Questionnaire-5 question version (ACQ-5) of  0.5 from the 
last ACQ-5 score recorded in the e-diary 
x 
Severe asthma exacerbation 
x 
Clinically significant event, based on investigator judgment that requires treatment by OCS 
dose adjustment 
A severe asthma exacerbation event during the study is defined as a deterioration of asthma 
requiring: 
x 
Use of systemic corticosteroids for 3 days (at least double the dose currently used) and/or  
x 
Hospitalization or emergency room (ER) visit because of asthma requiring intervention 
with a systemic corticosteroid treatment (at least double the dose currently used)  
In general, the investigator can refer to the ACQ-5 score at Screening Visit 1 to guide the OCS 
dose adjustments made during the optimization phase of the study; however, the decision to titrate 
can be based on the investigator’s clinical judgment.  Once determined, the optimized dose must 
remain stable for 2 consecutive weeks along with baseline medications without meeting any of the 
OCS optimization phase interruption criteria in order to be eligible for randomization. 
Investigators should adjust the OCS dose according to a pre-specified titration schedule Table 1 
based on the OCS optimization phase interruption criteria, and in accordance with their clinical 
judgment.  During the OCS optimization phase, the patient’s asthma control will be assessed 
weekly by reviewing these criteria via scheduled phone calls after Visit 2.  If the patient’s asthma 
status remains controlled and none of the above criteria are met, the investigator should down-
titrate the patient’s OCS dose.  The downward titration will continue until a point when at least 1 
of the OCS optimization phase interruption criteria is met.  If the down-titration is stopped, the 
investigator should up-titrate the OCS dose by 1 step per Table 1, unless the patient’s medical 
condition requires treatment with a higher dose of OCS.    
No change in OCS dose will be made at Visit 1.  One week after the Screening visit (Visit 1), 
patients will return to the clinic for Visit 2.  At Visit 2, and weekly throughout the Optimization 
phase, patient stability will be assessed by the above outlined criteria.   
  
(electronic 






Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 12 
x 
Change in ACQ-5 score  +0.5 from the prior month OCS dose assessment 
x 
Clinically significant asthma exacerbation 
x 
Clinically significant event, based on investigator judgment that requires treatment by OCS 
dose adjustment 
The Investigator should decide, depending on the reason for not reducing the OCS dose per 
schedule, whether to maintain or increase his/her current OCS dose by 1 step. 
Maintenance Phase (4 weeks) 
Patients will be maintained for the last 4 weeks of the Randomized Treatment period on the same 
OCS dose established at Week 20.  However, when any of the above criteria for not reducing OCS 
dose is met, the Investigator should decide whether to maintain or increase the current OCS dose 
accordingly. 
Oral Corticosteroid Dose after an Asthma Exacerbation 
If a severe asthma exacerbation occurs during the Reduction or Maintenance Phases of the 
Randomized Treatment period, the exacerbation should be treated with the use of oral or 
parenteral steroids at a dose at least equivalent to double the dose of current maintenance dose of 
OCS.  Following resolution, the subject should be placed on the OCS dose 1 step higher than that 
which he/she was on when the exacerbation occurred for at least 4 weeks and continue with dose 
reductions (only during the Reduction phase) as per the predefined schedule at the following visit.  
If a patient experiences 2 exacerbations, no further OCS dose reductions will be allowed. 
Handling of patients after permanent treatment discontinuation 
Patients will be followed-up according to the study procedures as specified in this protocol up to 
the scheduled date of study completion, or up to recovery or stabilization of any AE to be 
followed-up as specified in this protocol, whichever comes last. Study investigators should 
continue OCS dose adjustment after treatment discontinuation, as guided by their medical 
judgment, including up-titration and down-titration in accordance with Table 2 (Titration schedule 
for oral corticosteroids during the OCS Reduction Phase of the Randomized Period). 
Post-treatment/Follow-up Period 
After completing the treatment period, patients who do not rollover into a long-term study will be 
evaluated for 12 weeks in the post-treatment period.  During this follow-up period, patients will 
continue treatment with their stable dose of controller medication (includes all medications used 
to control asthma symptoms, with the exception of the investigational medicinal product [IMP]) 
that can be modified based on their level of asthma control, as determined by the Investigator. 
During the post-treatment period, patients will continue to collect e-diary information that can be 
used to determine asthma control.  
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 13 
Eligible patients completing the treatment period may have the opportunity to roll over into a 
long-term study with dupilumab.  Patients subsequently enrolled in this long-term study will not 
participate in the Post-treatment period of this trial. 
Patients who permanently discontinue the study medication will be asked and encouraged to return 
to the clinic for all remaining study visits.  In addition, patients who discontinue early from 
treatment or patients who choose not to roll over into a long-term study may be asked to return to 
the clinic to have additional ADA samples collected for analysis based on the overall assessment 
of antibody titers and clinical presentation. 
(electronic 




Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 15 
1.5 
MODIFICATIONS TO THE STATISTICAL SECTION OF THE PROTOCOL  
This section summarizes major changes to the protocol statistical section with emphasis on 
changes after study start (after the first patient was enrolled).   
The protocol history table below gives the timing, rationale, and key details of major changes to 
the protocol statistical section. “Principal features of the analysis” encompass the confirmatory 
aspects of the trial, including the primary and key secondary endpoints/analyses, and the analysis 
populations associated with these analyses. 
Table 3 - Protocol amendment statistical changes 
Amendment  
Number 
Date 
Approved 
Rationale 
Description of statistical changes 
1 
20-Jul-2016 
Based on the clinical relevance and 
statistical power considerations of 
the secondary endpoints 
The endpoint ‘Proportion of patients 
achieving a reduction of OCS dose to <5 
mg/day at Week 24 while maintaining 
asthma control’ was moved from the 5th 
place to the 3rd place in the multiplicity 
control procedure defined in Section 2.4.4.3. 
 
2 
25-Jan-2017 
Increase the power of detecting a 
significant difference in the key 
secondary endpoint of patients 
achieving a 50% reduction in oral 
corticosteroid (OCS) dosing  
Sample size was increased from 150 to 180. 
Specifically, 
 
The following text: 
The sample size estimation is based on the 
comparison between dupilumab doses 
versus placebo with regard to the primary 
endpoint: percentage reduction of OCS dose 
at Week 24 compared with the baseline 
dose, while maintaining asthma control.  
Assuming a common standard deviation of 
50%, with 75 randomized patients per group, 
the study will have 90% power to detect a 
treatment difference of 27% at the 2-tailed 
significance level of Į=0.05.  
Was replaced with: 
The sample size estimation is based on the 
comparison between dupilumab doses 
versus placebo with regard to the primary 
endpoint and the key secondary endpoint: 
percentage reduction of OCS dose at Week 
24 compared with the baseline dose and 
proportion of patients achieving a reduction 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 16 
Amendment  
Number 
Date 
Approved 
Rationale 
Description of statistical changes 
of 50% or greater in their OCS dose 
compared with baseline at Week 24, while 
maintaining asthma control.  For the primary 
endpoint, Aassuming a common standard 
deviation of 50%, with 7590 randomized 
patients per group, the study will have 
9094% power to detect a treatment 
difference of 27%  at the 2-tailed significance 
level of Į=0.05. For the key secondary 
endpoint, with the same sample size of 90 
randomized patients per group, the study will 
have 81% power to detect a difference in the 
proportion of patients achieving 50% or 
greater in their OCS dose of 33% in the 
placebo group, compared to 54% in the 
dupilumab group, at the 2-tailed significance 
level of Į=0.05. 
The following text: 
Recruitment of patients whose eosinophil 
level is below 150 cells/μL will stop when 
approximately 38 (25% of the total sample 
size) of such patients are randomized. 
Recruitment will continue with patients 
whose eosinophil (EOS) level is greater than 
or equal to 150 cells/μL until reaching the 
total sample size of 150.  In addition, the 
number of patients receiving 5 mg OCS at 
Visit 3 will be limited to approximately 46 
patients (approximately 30% of the study 
population). 
 
Was replaced with: 
Recruitment of patients whose eosinophil 
level is below 150 cells/μL will stop when 
approximately 3846 (25% of the total sample 
size) of such patients are randomized. 
Recruitment will continue with patients 
whose eosinophil (EOS) level is greater than 
or equal to 150 cells/μL until reaching the 
total sample size of 150180.  In addition, the 
number of patients receiving 5 mg OCS at 
Visit 3 will be limited to approximately 4654 
patients (approximately 30% of the study 
population). 
 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 17 
1.6 
STATISTICAL MODIFICATIONS MADE IN THE STATISTICAL ANALYSIS PLAN 
This section summarize major changes in statistical analysis features made in approved SAP 
versions from statistical considerations in protocol or previous SAP versions, with emphasis on 
changes after study start (after the first patient was enrolled). These changes are not based on any 
unblinded study data.  
The statistical analysis plan history table below gives the timing, rationale, and key details for 
major changes to the statistical analysis features in the statistical analysis plan. 
 
Table 4 - Statistical analysis plan statistical changes 
SAP 
version  
number 
Date 
approved 
Rationale 
Description of statistical changes 
 
 
 
 
1 
This version 
The medical significance of the 
endpoint 
The endpoint ‘The proportion of patients 
achieving a reduction of OCS dose to <5 
mg/day at Week 24 while maintaining asthma 
control’ becomes a key secondary efficacy 
endpoint. 
 
 
 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 18 
2 
STATISTICAL AND ANALYTICAL PROCEDURES 
2.1 
ANALYSIS ENDPOINTS 
2.1.1 Demographic and baseline characteristics 
The baseline value of the efficacy parameters is defined as the last available value up to 
randomization date but prior to the first dose of IMP unless otherwise specified. The baseline 
value of safety parameters is defined as the last available value prior to the first dose of the 
investigational medicinal product (IMP). The baseline value of the other parameters is defined as 
the last available value prior to the first dose of IMP if the patient is treated, or the last available 
value up to randomization date if the patient is not exposed to IMP. 
All baseline safety, efficacy, and pharmacodynamic (PD) parameters (apart from those listed 
below) are presented along with the summary statistics in the safety and efficacy sections 
(Sections 2.4.5, 2.4.4 and 2.4.6.2). 
Demographic characteristics 
Demographic variables are:  
x 
Gender (Male, Female),  
x 
Race (Caucasian/white, Black, Asian/Oriental, American Indian or Alaska Native, Native 
Hawaiian or other Pacific Island, other),  
x 
Age in years (quantitative and qualitative variable : <18, 18-64, 65 years), 
x 
Ethnicity (Hispanic, non-Hispanic),  
x 
Region (East Europe: Hungary, Poland, Romania, Russia, and Ukraine; Latin America: 
Argentina, Brazil, Chile, Colombia, and Mexico; Western Countries: Belgium, Canada, 
Israel, Italy, Netherlands, Spain, and USA), 
x 
Weight in kg (quantitative and qualitative variable : <50, 50-<100 and 100 kg), 
x 
BMI in kg/m2 (quantitative and qualitative variable: <25, 25 - <30, and 30 kg/m2). 
Medical or surgical history 
Medical (or surgical) history includes all the relevant medical (or surgical) history during the 
lifetime of the patient.  
This information will be coded using the version of Medical Dictionary for Regulatory Activities 
(MedDRA) currently in effect at Sanofi at the time of database lock. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 19 
Comorbidity history will be summarized separately and includes: 
x Any comorbidity history (if occurred, if ongoing condition) 
x Atopic dermatitis history (if occurred, if ongoing condition) 
x Allergic conjunctivitis history (if occurred, if ongoing condition) 
x Allergic rhinitis history (if occurred, if ongoing condition) 
x Allergic conjunctivitis and rhinitis history (if occurred, if ongoing condition) 
x Chronic rhinosinusitis history (if occurred, if ongoing condition) 
x Nasal polyposis history (if occurred, if ongoing condition) 
x Eosinophillic esophagitis history (if occurred, if ongoing condition) 
x Food allergy history (if occurred, if ongoing condition) 
x Hives history (if occurred, if ongoing condition) 
A patient is considered to have atopic medical condition if he/she has any of the following: atopic 
dermatitis, allergic conjunctivitis or rhinitis, eosinophilic esophagitis, food allergy, hives; or has 
baseline total IgE  100 IU/mL and at least one aeroantigen specific IgE  0.35 IU/mL at baseline. 
Disease characteristics at baseline   
The following baseline disease characteristics will be summarized by treatment group separately: 
x 
Age of asthma onset (quantitative variable and qualitative variable: <18, 18-40, >40 years ) 
x 
Time since first diagnosis of asthma (years)  
x 
Time since last severe asthma exacerbation (months) 
x 
Number of severe asthma exacerbations experienced within1 year before Visit 1 
(quantitative variable and qualitative variable: 0, 1, 2, 3, 4) 
x 
Number of severe asthma exacerbations experienced requiring hospitalization or urgent 
medical care within1 year before Visit 1 (quantitative variable and qualitative variable: 0, 
1, 2, 3, 4) 
x 
With ongoing atopic medical condition (qualitative variable: yes) 
x 
Smoking history (Never, Former), time since cessation of smoking (months) and smoking 
quantity in pack-years for former smokers 
x 
Baseline blood eosinophil level (quantitative variable and qualitative variable: <0.15, 
0.15 - <0.3, 0.3 Giga/L) 
x 
Daily OCS dose at Visit 1(quantitative variable and qualitative variable: 5mg/day, >5-
10mg/day, >10-15 mg/day, >15-25 mg/day, >25 mg/day) 
x 
Optimized daily OCS dose at baseline (quantitative variable and qualitative variable: 
5mg/day, >5-10mg/day, >10-15 mg/day, >15-25 mg/day, >25 mg/day) 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 20 
x 
Number of puffs of salbutamol/albuterol and levosalbutamol/levabuterol per day 
x 
Spirometry data including pre-bronchodilator (BD) FEV1 (L), percent predicted FEV1, 
post-bronchodilator FEV1 (L),  FEV1 reversibility (L), and percent FEV1 reversibility (%). 
x 
AM and PM PEF (L/min) 
x 
AM and PM symptom scores 
x 
Number of nocturnal awakenings/day 
x 
ACQ-5 score (quantitative variable and qualitative variable:  2, >2) 
x 
Asthma Control Questionnaire 7-question version (ACQ-7) score 
x 
Asthma Quality Of Life Questionnaire (AQLQ) global score 
x 
With hypersensitivity to aspirin or other NSAID (qualitative variable: yes, ongoing 
condition) 
Any technical details related to computation, dates, and imputation for missing dates are described 
in Section 2.5.  
2.1.2 Prior or concomitant medications  
All medications taken within 30 days before screening and until the end of the study, including 
oral corticosteroids and asthma controller medications are to be reported in the case report form 
pages. 
All medications will be coded using the World Health Organization-Drug Dictionary (WHO-DD) 
using the version currently in effect at Sanofi at the time of database lock. 
x 
Prior medications are those the patient used prior to first IMP intake.  Prior medications 
can be discontinued before first administration or can be ongoing during treatment phase.   
Concomitant medications are any treatments received by the patient concomitantly to the IMP, 
from the first administration of IMP to the last administration of IMP + 98 days (2 weeks after last 
administration of IMP plus 12 weeks of residual treatment epoch) or till rollover to the LTS12551 
study.  A given medication can be classified both as a prior medication and as a concomitant 
medication. Concomitant medications do not include medications started during the posttreatment 
epoch (as defined in the observation period in Section 2.1.4).  
x 
Posttreatment medications are those the patient took in the period running from the last 
administration of IMP + 99 days up to the end of the study. 
Oral corticosteroids 
To be enrolled in the study, a patient should be on well-documented, regular prescribed treatment 
of maintenance systemic corticosteroids in the 6 months prior to Visit 1 and using a stable OCS 
(ie, no change of OCS dose) dose for 4 weeks prior to Visit 1. At Visit 1, patients currently using 
other forms of maintenance OCS will have their corticosteroids switched to 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 21 
prednisone/prednisolone at a dose clinically equivalent to their current stable OCS maintenance 
dose. During the course of the study, including the post-treatment period, patients will receive 
variable doses of OCS.   
Inhaled corticosteroid with a second or third controller 
Prior to and during the Screening period, patients must be on a stable dose of high dose ICS 
(>500 Pg total daily dose of fluticasone propionate or equivalent) in combination with a second 
controller medication (LABA, LTRA , theophylline, etc) for at least 3 months with a stable dose 
of ICS for 1 month prior to Visit 1.  In addition, patients requiring a third controller for their 
asthma are considered eligible for this study, and it should also be used for at least 3 months with 
a stable dose 1 month prior to Visit 1. 
During the Randomized Treatment period and Post-treatment period (for those patients not 
enrolling in the LTS12551), patients will continue taking their controller medication(s). 
The recognized controllers in this study will include the following 5 classes: ICS, LABA, LAMA, 
anti-leukotrienes and methylxanthine. For examples of commonly used asthma controller 
therapies, refer to Appendix A for a list of controller medications approved for this study. 
Reliever Medication 
Patients may administer albuterol/salbutamol or levalbuterol/levosalbutamol metered dose inhaler 
(MDI) as reliever medication as needed during the study.  Nebulizer solutions may be used as an 
alternative delivery method. Nebulizer doses recorded in mg can be converted to puff unit using 
the following conversion factors: 
x 
Salbutamol/albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs; 
x 
Levosalbutamol/levalbuterol nebulizer solution (1.25 mg) corresponds to 4 puffs. 
Any technical details related to computation, dates, imputation for missing dates are described in 
Section 2.5. 
2.1.3 Efficacy endpoints 
2.1.3.1 Primary efficacy endpoint(s) 
The primary efficacy endpoint for this study is the percentage reduction of OCS dose at Week 24 
compared with the baseline dose, while maintaining asthma control.  The percent reduction in 
OCS dose will be calculated as: (optimized OCS dose at baseline – final OCS dose at Week 
24)/optimized OCS dose at baseline × 100.  A patient will be considered as having maintained 
asthma control between Week 20 and Week 24 if he/she does not have a clinically significant 
event, based on investigator judgment that requires treatment by OCS dose adjustment during this 
period.  For those patients who experience an exacerbation, the final OCS dose will be considered 
to be 1 step higher than the dose they were receiving at the time of the exacerbation.  Both the 
optimized dose at baseline and the final OCS dose at Week 24 will be recorded on the electronic 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 22 
case report form (eCRF). Patients who permanently discontinue the study medication will be 
asked and encouraged to return to the clinic for all remaining study visits and the Investigator will 
continue to prescribe OCS at the dose specified for OCS titration. The off-treatment OCS dose at 
Week 24 will be used in the primary analysis.  
2.1.3.1.1 Oral corticosteroid dose adjustments 
The dose adjustment of OCS through the OCS Reduction phase of the study will be based on the 
following: 
x 
Asthma symptom data collected through the eDiary (ACQ-5 score) 
x 
Clinically significant asthma exacerbation(s) 
x 
Mean morning PEF <70% of baseline stability limit as assessed in the week prior to the 
clinical visit 
x 
FEV1 20% reduction from baseline stability limit 
x 
Rescue medication use requiring 4 or more puffs/day above the mean baseline value for 
any 2 consecutive days in the prior week, or 12 puffs on any 1 day in the week prior to 
the clinical visit 
x 
Clinically significant event, based on Investigator judgment that requires treatment by 
OCS dose adjustment 
The patient will complete the ACQ-5 on a weekly basis and record the score in the eDiary 
(starting with Visit 1 onwards).  The Investigator will review the eDiary data on a weekly basis 
during the OCS Optimization phase and monthly during the Randomized Treatment period. Daily 
OCS dose will be recorded using the eDiary. 
2.1.3.2 Additional efficacy endpoint(s) 
2.1.3.2.1 Secondary efficacy endpoints related to adjustments in oral corticosteroid dosing 
2.1.3.2.1.1 Key secondary endpoints 
x 
The key secondary endpoints of this study are:  
x 
The proportion of patients achieving a reduction of 50% or greater in their OCS dose 
compared with baseline at Week 24 while maintaining asthma control, and 
x 
The proportion of patients achieving a reduction of OCS dose to <5 mg/day at Week 24 
while maintaining asthma control. 
2.1.3.2.1.2 Other secondary efficacy endpoints 
x 
Absolute reduction of OCS dose at Week 24 compared with the baseline dose while 
maintaining asthma control 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 23 
x 
Proportion of patients achieving their maximum possible reduction of OCS dose per 
protocol at Week 24 while maintaining asthma control 
x 
Proportion of patients no longer requiring OCS at Week 24 while maintaining asthma 
control 
2.1.3.2.2 Other efficacy measures 
The following additional disease-specific efficacy endpoints will be evaluated: 
x 
Annualized rate of severe asthma exacerbation events during the treatment period 
x 
Time to first severe asthma exacerbation event 
x 
Change from baseline in pre-bronchodilator FEV1 at Weeks 2, 4, 8, 12, 16, 20, and 24 
x 
Percent change from baseline in pre-bronchodilator FEV1 at Weeks 2, 4, 8, 12, 16, 20, and 
24 
x 
Change from baseline in other lung function measurements (percent predicted FEV1, 
morning/evening PEF, forced vital capacity [FVC], forced expiratory flow from 25% to 
75% of the vital capacity [FEF25-75%]), at Weeks 2, 4, 8, 12, 16, 20, and 24 
x 
Percent and absolute change from baseline in post-bronchodilator FEV1 at Weeks 12 and 
24 
x 
Change from baseline in ACQ-5 score at Weeks 2, 4, 8, 12, 16, 20, and 24 
x 
Annualized rate of severe asthma exacerbations requiring hospitalization or ER visit 
during the treatment period 
x 
Time to first severe asthma exacerbation requiring hospitalization or ER visit 
x 
Change from baseline at Weeks 12 and 24 in: 
- 
AQLQ 
- 
22-item Sino Nasal Outcome Test (SNOT-22) in patients with bilateral nasal 
polyposis/chronic rhinosinusitis 
- 
Hospital Anxiety and Depression Scale (HADS) 
- 
EQ-5D-5L 
x 
Change from baseline at Weeks 2, 4, 8 12, 16, 20, and 24 in: 
- 
Morning/evening asthma symptom score and nocturnal awakenings (eDiary) 
- 
Use of rescue medication 
- 
Health Care Resource Utilization 
x 
Change from baseline in airway hyperresponsiveness at Week 24 (for select study sites in 
Canada) 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 24 
2.1.3.2.2.1 Disease-specific efficacy measures 
2.1.3.2.2.1.1 Severe asthma exacerbation events 
A severe asthma exacerbation event during the study is defined as a deterioration of asthma 
requiring: 
x 
Use of systemic corticosteroids for 3 days (at least double the dose currently used); and/or 
x 
Hospitalization because of asthma symptoms or emergency room visit because of asthma 
requiring intervention with additional systemic corticosteroid treatment 
Two events will be considered as different if the interval between their start dates is equal or 
greater than 28 days. 
The period of time for which severe asthma exacerbation information will be included in the 
endpoint analysis will be from randomization until Visit 11 at Week 24.    
For safety reasons, alerts will be programmed into the eDiary that will notify both the patient and 
the site to monitor the clinical situation closely in case the patient’s asthma worsens.  However, an 
alert in itself will not be classified as a clinically significant asthma exacerbation.  
The reasons (eg, infections including viral and bacterial, allergen exposure, exercise, or others) of 
the severe asthma exacerbation events will be collected on the eCRF. 
2.1.3.2.2.1.2 Time to first severe asthma exacerbation event 
If a patient has an event during the 24-week treatment period, regardless the patient is on the study 
treatment or discontinues the study treatment but remains in the study, the time to first severe 
asthma exacerbation event is defined as (onset date of the first severe asthma exacerbation event – 
randomization date +1). If a patient has no severe asthma exacerbation event during the study up 
to Visit 11 at Week 24, then the patient will be considered as free of event till the date of Visit 11 
or the last contact date, whichever happens earlier.  
2.1.3.2.2.1.3 Spirometry 
The following parameters will be measured using spirometry:  FEV1 (pre- and post-
bronchodilator), percent predicted FEV1, FVC, and FEF25-75%. 
A spirometer that meets the 2005 American Thoracic Society (ATS)/European Respiratory 
Society (ERS) recommendations will be used.  Spirometry should be performed in accordance 
with the ATS/ERS guidelines (3).  For pre-bronchodilator measured parameters, including FEV1, 
PEF, FVC, and FEV25-75%, spirometry will be performed after withholding the last dose of 
salbutamol/albuterol or levosalbutamol/levalbuterol for at least 6 hours and withholding the last 
dose of LABA for at least 12 hours and withholding the last dose of LAMA for at least 24 hours. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 25 
For post-bronchodilator FEV1, the measure should follow the steps described for reversibility 
validation. 
At all visits, spirometry should be performed in the morning if possible, but if the test can only be 
done at a different time of the day, the testing should be done at approximately the same time of 
the day at each visit throughout the study.  The same spirometer and standard spirometric 
techniques, including calibration, will be used to perform spirometry at all visits and, whenever 
possible, the same person should perform the measurements.   
Pulmonary function tests will be measured in the sitting position; however, if necessary to 
undertake the testing with the subject standing or in another position, this should be noted on the 
spirometry report.  For any subject, the position should be consistent throughout the study. 
Three measurements fulfilling the ATS acceptability and repeatability criteria should be obtained 
at every visit, if possible.  The acceptability criteria must be applied before the repeatability 
criteria.  Unacceptable maneuvers must be discarded before applying the repeatability criteria.  If a 
patient fails to provide repeatable and/or acceptable maneuvers, an explanation should be 
documented.   
The largest FEV1 and largest FVC should be recorded after the data are examined from all of the 
acceptable curves, even if they do not come from the same curve.  The FEF25-75% should be 
obtained from the single curve that meets the acceptability criteria and gives the largest sum of 
FVC plus FEV1 (best performance). 
Reversibility/post-bronchodilator FEV1 
A reversibility test will be administered (if not done and documented within 12 months of Visit 1) 
following pulmonary function testing after asthma medications have been withheld for the 
appropriate intervals.  Subjects will receive 2 to up to 4 puffs of albuterol/salbutamol.  
Alternatively, and only if it is consistent with usual office practice (to be documented), 
reversibility may be performed using inhalation of nebulized albuterol/salbutamol.  Spirometry 
may be repeated several times within 30 minutes after administration of bronchodilator. If the 
subject does not meet the reversibility at Visit 1, 2 additional assessments can be performed at any 
time (ie, unscheduled visits) prior to randomization (Visit 3). FEV1 reversibility is calculated as 
post-BD FEV1 - pre-BD FEV1.  Percent FEV1 reversibility is calculated as 
(post-BD FEV1 - pre-BD FEV1) / pre-BD FEV1* 100. 
2.1.3.2.2.1.4 Electronic diary/peak expiratory flow meter 
On a daily basis throughout the study, the patient uses an electronic diary/PEF meter to: 
x 
Measure morning and evening PEF 
x 
Respond to the morning and evening asthma symptom scale questions 
x 
Record daily prednisone/prednisolone usage 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 26 
x 
Indicate the number of puffs/day of salbutamol/albuterol or levosalbutamol/levalbuterol 
for symptom relief 
x 
Record the use of daily controller medications  
x 
Record the number of nocturnal awakenings due to asthma symptoms 
x 
Record oral steroids use for asthma exacerbation event 
At Screening (Visit 1), patients will be issued an eDiary/PEF.  Patients will be instructed on the 
use of the device, and written instructions on the use of the electronic PEF meter will be provided 
to the patients.  In addition, the Investigator will instruct the patients on how to record the 
following variables in the electronic PEF meter: 
x 
Morning PEF performed within 15 minutes after arising (between 5:30 AM and 10 AM) 
prior to taking any albuterol or levalbuterol 
x 
Evening PEF performed in the evening (between 5:30 PM and 10 PM) prior to taking any 
albuterol or levalbuterol 
x 
Patients should try to withhold albuterol/salbutamol or levalbuterol/levosalbutamol for at 
least 6 hours prior to measuring their PEF 
x 
Three PEF efforts will be performed by the patient; all 3 values will be recorded by the 
electronic PEF meter, and the highest value will be used for evaluation 
Baseline morning PEF will be the mean AM measurement recorded for the 7 days prior to the 
randomization, and baseline evening PEF will be the mean PM measurement recorded for the 7 
days prior to the randomization.  Period stability limit is defined as the respective mean morning 
or evening PEF obtained over the last 7 days prior to Day1.  There should be at least 4 days’ 
measurement for setting up the stability limit, and the first dosing visit should be rescheduled until 
data for 4 days are available. In case less than 4 days’ measurement is available during the 7 days 
prior to randomization, the baseline AM(PM) PEF is the mean of the 4 AM(PM) PEF prior to and 
closest to randomization during the whole screening period. 
2.1.3.2.2.1.5 Asthma Control Questionnaire 
The ACQ was designed to measure both the adequacy of asthma control and change in asthma 
control which occurs either spontaneously or as a result of treatment.  During the OCS 
Optimization period, the ACQ-5 will be completed weekly in the patient’s eDiary.  During the 
treatment period, the ACQ-7 will be performed at clinic visits and the ACQ-5 will be completed 
on a weekly basis for those weeks that the patient does not have a scheduled clinic visit. 
Asthma Control Questionnaire-5 question version 
The ACQ-5 is a 5-item questionnaire, which has been developed as a measure of subjects’ asthma 
control that can be quickly and easily completed in clinical practice (4).  The questions are 
designed to be self-completed by the subject.  The 5 questions enquire about the frequency and/or 
severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, 
shortness of breath, and wheezing).  The response options for all these questions consist of a 0 (no 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 27 
impairment/limitation) to 6 (total impairment/ limitation) scale (Appendix B).  The ACQ-5 score 
is a mean of the values recorded for the individual questions. On the 7-point scale of the ACQ-5, a 
change or difference in score of 0.5 at patient level is the smallest change that can be considered 
clinically important, corresponding to the Minimal Clinically Important Difference (MCID) 
defined by the developer. 
Throughout the study subjects should complete the ACQ-5 on a weekly basis using their eDiary.  
The results from the ACQ-5 will be used as a part of the assessment to determine subject 
eligibility for OCS dose adjustment.  If the ACQ-5 is completed through the eDiary while the 
subject is at a scheduled in-clinic visit, it is recommended that the ACQ-5 be administered at the 
same time during the visit.   
Based on the eDiary device design, each question needs to be completed otherwise a patient 
cannot proceed to submit his/her response to the entire ACQ-5 questionnaire. Therefore, no partial 
missing data is expected. 
Asthma Control Quesionnaire-7 question version 
The ACQ-7 consists of 7 questions.  The first 5 questions assess the most common asthma 
symptoms: 1. frequency in past week awoken by asthma during the night, 2. severity of asthma 
symptoms in the morning, 3. limitation of daily activities due to asthma, 4. shortness of breath due 
to asthma and 5. wheeze, plus 6. short-acting bronchodilator use and 7. FEV1 (pre-bronchodilator 
use, % and % predicted use).  Patients are asked to recall how their asthma has been during the 
previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 
6= maximum impairment; Appendix C). 
Clinic staff scores the FEV1% predicted on a 7-point scale.  
A global score is calculated: the questions are equally weighted and the ACQ-7 score is the mean 
of the 7 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled).  
Higher score indicates lower asthma control.      
The answer to the first 5 questions will be used to calculate an ACQ-5 score for the analysis of the 
ACQ-5 endpoint. 
2.1.3.2.2.2 Patient Reported Outcomes (Health-related Quality of Life/health economic 
variables/other endpoints) 
Patients should complete PROs before undergoing spirometry testing.  
For all the questionnaires, similar to the ACQ-5, each question of any questionnaire needs to be 
completed otherwise a patient cannot proceed to submit his/her response to the entire 
questionnaire on the ediary device. Therefore, no partial missing data is expected. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 28 
2.1.3.2.2.2.1 Asthma Quality of Life Questionnaire 
The AQLQ was designed as a self-administered PRO to measure the functional impairments that 
are most troublesome to patients as a result of their asthma (see Appendix D).  The instrument is 
comprised of 32 items, each rated on a 7-point Likert scale (from 1 to 7).  The AQLQ has 4 
domains.  The domains and the number of items in each domain are as follows: 
x 
Symptoms (12 items) 
x 
Activity limitation (11 items) 
x 
Emotional function (5 items) 
x 
Environmental Stimuli (4 items) 
A global score is calculated as the mean of all the 32 items ranging from 1 to 7 and a score by 
domain is the mean of items in each domain.  Higher scores indicate better quality of life. 
2.1.3.2.2.2.2  SNOT-22 
The SNOT-22 is a validated questionnaire to assess the impact of chronic rhinosinusitis on health 
related quality of life (see Appendix E).  The SNOT-22 has 22 items, 5 domains and a global 
score.  The 5 domains include: 
x 
Nasal (range 0-30)  
x 
Ear (range 0-15)  
x 
Sleep (0-20)  
x 
General and practical (0-30)  
x 
Emotional (0-15)  
The range of the global score is 0-110.  Lower scores indicate less impact.  The recall period of the 
assessment is within the past 2 weeks. 
2.1.3.2.2.2.3 Hospital Anxiety and Depression Scale 
The HADS is a general scale used to detect states of anxiety and depression and has been 
validated in patients with asthma (see Appendix F).  The instrument is comprised of 14 items: 
7 items each related to anxiety and depression.  Each item on the questionnaire is scored from 0-3; 
with a score for either anxiety or depression ranging between 0 and 21. 
2.1.3.2.2.2.4 EQ-5D-5L 
The EQ-5D-5L is a standardized health-related quality of life questionnaire developed by the 
EuroQol Group in order to provide a simple, generic measure of health for clinical and economic 
appraisal (5).  The EQ-5D is designed for self-completion by patients. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 29 
The EQ-5D essentially consists of 2 pages – the EQ-5D descriptive system and the EQ visual 
analogue scale (VAS; see Appendix G).  The EQ-5D descriptive system comprises 5 dimensions: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.  Each dimension has 
5 levels: no problems, slight problems, moderate problems, severe problems, and extreme 
problems.  The EQ VAS records the respondent’s self-rated health on a vertical visual analogue 
scale.  The EQ VAS ‘thermometer’ has endpoints of 100 (best imaginable health state) at the top 
and 0 (worst imaginable health state) at the bottom. 
2.1.3.2.2.2.5 Asthma symptom score 
Patients will record overall symptom scores in an eDiary twice a day prior to measuring their PEF.  
Symptoms experienced during the night will be recorded upon arising (AM symptom score).  The 
patient’s overall asthma symptoms experienced during the waking hours will be recorded in the 
evening (PM symptom score).  Baseline symptom scores will be the mean AM and mean PM 
scores recorded for the 7 days prior to randomization.  Scores can range between 0-4 with 0 
indicating more mild symptoms and 4 indicating more severe symptoms.  There is no global score, 
just an AM score and a PM score. 
2.1.3.2.2.3 Airway hyperresponsiveness (optional; only for patients enrolled in select sites in 
Canada) 
Airway hyperresponsiveness will be assessed through a bronchial provocation test using 
methacholine (to be done only if the patient’s FEV1 is 70% predicted normal).  A 20% decrease 
in the FEV1 will be considered as a positive test and the PC20 of agonist to cause this decrease is 
calculated by interpolation from the dose-response curve.  
2.1.4 Safety endpoints 
The safety analysis will be based on the reported adverse events (AE) and other safety 
information, such as clinical laboratory data, vital signs, physical examination, electrocardiogram 
(ECG), etc.  
Observation period  
The observation period will be divided into 4 epochs: 
x 
The screening epoch is defined as the time from the signed informed consent date up to 
the first administration of the IMP. 
x 
The treatment epoch is defined as the time from the first administration of the IMP to the 
last administration of the IMP + 14 days or until the patient enters the extension study. 
x 
The residual treatment epoch is defined as the time from the last administration of the 
IMP + 15 days to the last administration of the IMP + 98 days or until the patient enters the 
extension study. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 30 
The treatment-emergent adverse event (TEAE) period will include both treatment and residual 
treatment epochs. 
x 
The posttreatment epoch is defined as the period of time starting the day after the end of 
the treatment-emergent adverse event period up to the end of the study (defined as last 
protocol-planned visit or lost to follow-up or the resolution/stabilization of all serious 
adverse events and adverse events with prespecified monitoring). 
The on-study observation period is defined as the time from start of treatment until the end of the 
study.  
2.1.4.1 Adverse events variables 
Adverse event observation period  
x 
Pretreatment adverse events are adverse events that developed or worsened or became 
serious from the signed informed consent date up to first administration of IMP. 
x 
Treatment-emergent adverse events are adverse events that developed or worsened or 
became serious during the treatment-emergent adverse event epoch. 
x 
Posttreatment adverse events are adverse events that developed or worsened or became 
serious during the posttreatment epoch. 
All adverse events (including serious adverse events and adverse events with prespecified 
monitoring) will be coded to a lower-level term (LLT), preferred term (PT), high-level term 
(HLT), high-level group term (HLGT), and associated primary system organ class (SOC) using the 
version of MedDRA currently in effect at Sanofi at the time of database lock. 
Adverse events for each patient will be monitored and documented from the time the subject gives 
informed consent at Visit 1 until the End-of-Study visit (Visit 14) or till the rollover to the 
extension study, except for: 
x 
Serious AEs 
x 
Adverse events that are ongoing at database lock 
For ongoing AEs at database lock, observations may continue beyond the last planned visit per 
protocol, and additional investigations may be requested by the monitoring team up to as noticed 
by the Sponsor. Patients who experience an ongoing SAE or an AESI, at the prespecified study 
end-date, should be followed until resolution, stabilization, or death and related data will be 
collected. Any SAE brought to the attention of the Investigator at any time after the end of the 
study and considered by him/her to be caused by the IMP with a reasonable possibility, should be 
reported to the monitoring team. 
Adverse events of special interests include the following terms: 
x 
Anaphylactic or systemic allergic reactions, that are related to IMP and that require 
treatment (refer to Appendix H for the definition of anaphylaxis). 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 31 
x 
Severe injection site reactions that last longer than 24 hours. 
x 
Any infection meeting at least 1 of the following criteria: 
- 
Any serious infection (SAE) 
- 
Requires parenteral (intravenous, intramuscular, subcutaneous) antimicrobial therapy  
- 
Requires oral antimicrobial therapy for longer than 2 weeks 
- 
Is a parasitic infection 
- 
Is an opportunistic infection (Appendix I) 
Note:  Antimicrobial therapy refers to antibiotic, antiviral, and antifungal agents. 
x 
Significant elevation of alanine aminotransferase (ALT) 
- 
ALT >5 × upper limit of normal (ULN) in patients with baseline ALT 2 × ULN; or 
- 
ALT >8 × ULN if baseline ALT >2 × ULN 
x 
Pregnancy of a female subject entered in a study as well as pregnancy occurring in a 
female partner of a male subject entered in a study with IMP/noninvestigational medicinal 
product (NIMP) 
- 
Pregnancy occurring in a female patient entered in the clinical trial or in a female 
partner of a male patient entered in the clinical trial.  It will be qualified as an SAE 
only if it fulfills 1 of the seriousness criteria. 
- 
In the event of pregnancy in a female participant, IMP should be discontinued.  
- 
Follow-up of the pregnancy in a female participant or in a female partner of a male 
participant is mandatory until the outcome has been determined. 
x 
Symptomatic overdose (serious or non-serious) with IMP/NIMP 
- 
An overdose (accidental or intentional) with the IMP is an event suspected by the 
Investigator or spontaneously notified by the patient and defined as at least twice the 
intended dose during an interval of less than 11 days.  The circumstances (ie, 
accidental or intentional) should be clearly specified in the verbatim and symptoms, if 
any, entered on separate AE forms. 
- 
An overdose (accidental or intentional) with any NIMP is an event suspected by the 
Investigator or spontaneously notified by the patient and defined as at least twice of the 
intended dose within the intended therapeutic interval. The circumstances (ie, 
accidental or intentional) should be clearly specified in the verbatim and symptoms, if 
any, entered on separate AE forms. 
Of note, asymptomatic overdose has to be reported as a standard AE. 
AESIs and other selected AE groupings will be searched based on the criteria in Table 5. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 32 
Table 5 - Criteria for adverse events of special interest and other selected AE groupings 
AE Grouping 
Criteria 
AESI 
 
Anaphylactic reaction 
Anaphylactic reaction algorithmic approach (Introductory Guide for 
Standardised MedDRA Queries (SMQs) Version 18.1): includes 
anaphylactic reaction narrow SMQ (20000021) terms; for selection 
based on occurrence of multiple events, the events must have occurred 
within 24 hours of each other 
Hypersensitivity (medically 
reviewed) 
SMQ hypersensitivity (20000214) narrow search and [AE corrective 
treatment/therapy=’Y’ or Action taken with IMP=’Drug withdrawn’ or 
Action taken with IMP=’Drug interrupted’] followed by blinded medical 
review (documented process) for selection of relevant systemic 
hypersensitivity events  
Serious injection site 
reactions or severe 
injection site reactions that 
last longer than 24 hours  
HLT = ‘Injection site reaction’ and either with serious status, or with 
severe status and (AE end date/time - AE start date/time)  24 hours or 
ongoing 
Severe or serious infection Primary SOC = ‘Infections and infestations’ and with severe or 
serious status 
Parasitic infection 
Infection Type ‘Parasitic’ checked on eCRF Infection Defined as AESI 
Complementary Form 
Opportunistic infection 
Infection Type ‘Opportunistic’ checked on eCRF Infection Defined as 
AESI Complementary Form 
Drug-related hepatic 
disorder 
Drug-related hepatic disorders-Comprehensive search narrow SMQ 
(20000006) 
Pregnancy 
Primary SOC = ‘Pregnancy, puerperium and perinatal conditions’ or PT 
in (Aborted pregnancy, False negative pregnancy test, Pregnancy test 
positive, Pregnancy test urine positive, Ectopic pregnancy termination) 
Symptomatic overdose with 
IMP 
Is the event a Symptomatic Overdose with IMP? is answered Yes on 
AE eCRF. 
Symptomatic overdose with 
NIMP 
Is the event a Symptomatic Overdose with NIMP? is answered Yes on 
AE eCRF 
Other selected AE 
grouping 
 
Injection site reaction  
HLT = ‘Injection site reaction’  
Malignancy 
Sub-SMQ (20000091)– Malignant or unspecified tumors 
Suicidal behavior 
PT in (Completed suicide, Suicidal ideation, Depression suicidal, 
Suicidal behavior, Suicide attempt) 
Partner pregnancy 
PT in (Pregnancy of partner, Miscarriage of partner) 
Conjunctivitis (narrow) 
PT in (Conjunctivitis, Conjunctivitis allergic, Conjunctivitis bacterial, 
Conjunctivitis viral, Atopic keratoconjunctivitis) 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 33 
AE Grouping 
Criteria 
Conjunctivitis (broad) 
PT in (Conjunctivitis, Conjunctivitis allergic, Conjunctivitis bacterial, 
Conjunctivitis viral, Atopic keratoconjunctivitis, Blepharitis, Dry eye, Eye 
irritation, Eye pruritus, Lacrimation increased, Eye discharge, Foreign 
body sensation in eyes, Photophobia, Xerophthalmia, Ocular 
hyperaemia, Conjunctival hyperaemia) 
Hypereosinophilia 
HLT = ‘Eosinophilic disorders’ or PT = ‘Eosinophil count increased’ 
2.1.4.2 Deaths 
The deaths observation period are per the observation periods defined above.  
x 
Death on-study:  deaths occurring during the on-study observation period 
x 
Death on-treatment:  deaths occurring during the treatment-emergent adverse event period  
x 
Death post-study:  deaths occurring after the end of the study  
2.1.4.3 Laboratory safety variables 
Clinical laboratory data consists of blood analysis, including hematology, clinical chemistry, 
serum immunoglobulins, and urinalysis.  Clinical laboratory values after conversion will be 
analyzed into standard international units and international units will be used in all listings and 
tables. 
Blood samples for clinical laboratories will be taken at Visits 1 (Week -8 to -3), 3 (Week 0), 
5 (Week 4), 7 (Week 8), 8 (Week 12), 9 (Week 16), 10 (Week 20), 11 (Week 24), 14 (Week 36), 
and early termination unless otherwise specified.  The laboratory parameters will be classified as 
follows:  
x 
Hematology  
- 
Red blood cells and platelets and coagulation:  hemoglobin, hematocrit, platelet 
count, total red blood cell count 
- 
White blood cells:  total white blood cell (WBC) count, neutrophils, lymphocytes, 
monocytes, basophils, eosinophils 
x 
Clinical chemistry  
- 
Metabolism:  glucose, hemoglobin A1c (HbA1c), total cholesterol, total protein, 
albumin, creatine phosphokinase 
- 
Electrolytes:  sodium, potassium, chloride, bicarbonate  
- 
Renal function:  creatinine, blood urea nitrogen, uric acid 
- 
Liver function:  ALT, aspartate aminotransferase (AST), alkaline phosphatase, lactate 
dehydrogenase, total bilirubin (in case of values above the normal range, 
differentiation in conjugated and non-conjugated bilirubin) 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 34 
- 
Pregnancy test:  A serum pregnancy test (ȕ-human chorionic gonadotrophin) will be 
performed at Screening (Visit 1, Week -8 to -3) in women of childbearing potential 
- 
Hepatitis screen (at Visits 1 [Week -8 to -3] and 10 [Week 20]):  hepatitis B surface 
antigen (HBsAg), hepatitis B Surface antibody (HBsAb),  Immunoglobulin M (IgM) 
and Immunoglobulin G (IgG)/total-hepatitis B core antibody (HBcAb), hepatitis C 
antibody (HCAb). Patients who are IgG/total-HBcAb positive and HBsAg negative at 
Visit 1 must undergo HBV DNA testing prior to randomization to determine 
eligibility.  In case of results showing HCVAb positive, HCV RNA testing must be 
negative prior to randomization.  
- 
HIV screening (at Visits 1 [Week -8 to -3] and 10 [Week 20]):  anti-HIV-1 and HIV-2 
antibodies 
- 
Anti-nuclear antibody (ANA) (at Visits 1 [Week -8 to -3] and 10 [Week 20]).  Note: 
anti-double-stranded DNA antibody will be tested if ANA is positive (1:160 titer). 
Serum immunoglobulins 
- 
Quantitative immunoassays for total IgG, IgG subclasses 1-4, IgM, and 
Immunoglobulin A (IgA) at Visits 1 (Week -8 to -3), 3 (Week 0), 8 (Week 12), 
11 (Week 24), and 14 (Week 36). 
Urine samples will be collected as follows:  
- 
Urine dipstick analysis (at Visits 1 [Week -8 to -3], 3 [Week 0], 8 [Week 12], 
11 [Week 24], and 14 [Week 36]): specific gravity, pH, glucose, ketones, blood, 
protein, nitrate, leukocyte esterase, urobilinogen and bilirubin (by dipstick).  If any 
parameter on the dipstick is abnormal, a urine sample should be sent to the central 
laboratory for testing. If positive for proteins, microscopic analysis is performed by 
central laboratory. 
- 
A urine dipstick pregnancy test will be performed at Visit 3 (Week 0) prior to 
randomization and Visits 5 (Week 4), 7 (Week 8), 8 (Week 12), 9 (Week 16), 
10 (Week 20), 11 (Week 24), and 14 (Week 36) prior to investigational product 
administration 
Technical formulas are described in Section 2.5.1. 
2.1.4.4 Vital signs variables 
Vital signs including blood pressure (mmHg), heart rate (beats per minute), respiratory rate 
(breaths per minute), body temperature (degrees Celsius) and body weight will be measured at 
every visit.  Height (cm) will be measured at the Screening visit (Visit 1) only.  
Vital signs will be measured in the sitting position using the same arm at each visit, and will be 
measured prior to receiving investigational product at the clinic visits.  
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 35 
2.1.4.5 Electrocardiogram variables 
One recording of a standard 12-lead ECG will be performed centrally at Visits 1 (Week -8 to -3), 
3 (Week 0), 8 (Week 12), 11 (Week 24), and 14 (Week 36).  At the post-randomization visits in 
which an ECG is scheduled, the ECG will be performed prior to investigational product 
administration.   
All measurements will be made from a single lead: lead II, lead I (if lead II is not possible), or lead 
V5 (if leads II and I are not possible).  A minimum of 3 complexes in an appropriate lead (lead II) 
will be averaged to determine the PR-interval, QT/QTc-interval, QRS-complex and heart rate will 
be measured for each ECG. 
The ECGs will be manually read at a central lab.   
2.1.4.6 Physical examination 
Physical examinations will be performed at Visits 1 (Week -8 to -3) and 11 (Week 24). They will 
include an assessment of general appearance, skin, eyes, ear/nose/throat, heart, chest, abdomen, 
reflexes, lymph nodes, spine, and extremities.  All deviations from normal will be recorded, 
including those attributable to the patient’s disease. 
2.1.5 Pharmacokinetic variables 
Blood samples of serum functional dupilumab will be collected at Visit 3 (Week 0) as sample 
before the first dose, at Visits 5 (Week 4), 7 (Week 8), 8 (Week 12), 11 (Week 24) as trough 
samples prior to IMP dosing at each visit, and at Visit 14 (Week 36) during the follow up period.  
2.1.6 Anti-drug antibody variables 
Determination of anti-drug antibody (ADA) status will be performed at Visits 3 (Week 0), 
8 (Week 12), 11 (Week 24), and 14 (Week 36). The ADA status can be negative or a titer value if 
it is positive. Samples that are positive in the ADA assay will be further characterized for the 
presence of anti-dupilumab neutralizing antibodies. Patients who discontinue early from treatment 
or patients who choose not to participate in the LTS12551 study visit may be asked to return to the 
clinic to have additional ADA samples collected for analysis based on the overall clinical 
presentation at that time.  
ADA incidence will be classified as the following: 
Pre-existing immunoreactivity is defined as: 
x 
An ADA-positive response in the assay at baseline with all post treatment ADA results 
negative, OR 
x 
An ADA-positive response in the assay at baseline with all post treatment ADA responses 
less than 4-fold over baseline titer levels. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 36 
Treatment-emergent anti-drug antibodies is defined as: 
x 
An ADA-positive response in the assay post first dose, when baseline results are negative 
or missing. 
Treatment-boosted anti-drug antibodies is defined as: 
x 
An ADA-positive response in the assay post first dose that is greater than or equal to 4-fold 
over baseline titer levels, when baseline results are positive. 
Treatment-emergent (TE) ADA responses are further classified as transient, persistent or 
indeterminate 
x 
Persistent response is defined as a treatment-emergent response with 2 or more 
consecutive ADA-positive sampling time points separated by more than a 12-week period 
(84 days), with no ADA negative samples in between. 
x 
Indeterminate response is defined as a treatment-emergent response with only the last 
collected sample positive in the ADA assay. 
x 
Transient response is defined as a treatment-emergent response that is not considered 
persistent OR indeterminate. 
Titer values (titer value category) 
x 
Low (titer <1000) 
x 
Moderate (1000  titer 10000) 
x 
High (titer >10000) 
2.1.7 Pharmacodynamics/genomics endpoints 
PD endpoints include:   
x 
Whole blood biomarkers: Blood eosinophil count will be measured as part of the 
standard clinical lab test at Visits 1 (Week -8 to -3), 3 (Week 0), 5 (Week 4), 7 (Week 8), 
8 (Week 12), 9 (Week 16), 10 (Week 20), 11 (Week 24), 14 (Week 36) 
x 
Plasma biomarkers: Eotaxin-3 measured at Visits 3 (Week 0), 5 (Week 4), 8 (Week 12), 
10 (Week 20), 11 (Week 24) 
x 
Serum biomarkers: Antigen-specific IgE, Total IgE, TARC, and periostin at Visits 
3 (Week 0), 5 (Week 4), 8 (Week 12), 10 (Week 20), 11 (Week 24) 
x 
Fractional exhaled nitric oxide: will be measured at every visit 
x 
ILC2 and CD34 cells and cytokines in sputum and blood (optional; only for patients 
enrolled in select sites in Canada): Innate lymphoid type 2 (ILC2) cells and CD34+ cells 
will be measured in the blood and induced sputum.  Cytokines will be assayed in the 
sputum and blood. At Visits 3 (Week 0) and 11 (Week 24), both sputum and blood will be 
collected.  At Visit 14, only a sputum sample will be collected (for patients who have not 
entered into the long-term study).   
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 37 
Pharmacogenetic testing is optional and voluntary. For those patients who sign the optional 
pharmacogenetic informed consent form, blood samples for exploratory genetic analysis of DNA 
or RNA will be collected at Visit 3 (Week 0).  The DNA or RNA samples may be used to 
determine a possible relationship between genes and response to treatment with dupilumab, 
possible adverse reactions to dupilumab, and to study the genetics of asthma.  The DNA may be 
subjected to a genome-wide association study by whole genome array (common single nucleotide 
polymorphisms) analysis and/or to whole exome sequencing or whole genome analysis in order to 
thoroughly explore genetic associations with disease progression or treatment response.  The RNA 
may be subjected to discrete panels of polymerase chain reaction (PCR) analyses, microarray 
analyses, or RNA sequencing analyses. 
2.1.8 Health economic endpoints 
A questionnaire of health care resource utilization (reliever medication, specialist visit, 
hospitalization, emergency or urgent medical care facility visit, outcome, sick leaves, school days’ 
loss, etc) will be administered at each visit. 
2.2 
DISPOSITION OF PATIENTS 
This section describes patient disposition for both patient study status and the patient analysis 
populations. 
Screened patients are defined as any patient who signed the informed consent. 
Randomized patients consist of all patients with a signed informed consent form who have had a 
treatment kit number allocated and recorded in the IRT database, regardless of whether the 
treatment kit was used. 
For patient study status, the total number of patients in each of the following categories will be 
presented in the clinical study report using a summary table: 
x 
Screened patients 
x 
Screen failure patients and reasons for screen failure 
x 
Nonrandomized but treated patients 
x 
Randomized patients 
x 
Randomized but not treated patients 
x 
Randomized and treated patients 
x 
Patients who did not complete the study treatment period as per protocol 
x 
Patients who discontinued study treatment by main reason for permanent treatment 
discontinuation 
x 
Patients who withdraw from study prior to Week 24 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 38 
x 
Patients who withdraw from study prior to Week 24 by main reason for study 
discontinuation 
x 
Patients who continued into LTS12551 study 
x 
Status at last study contact 
For all categories of patients (except for the screened and nonrandomized categories) percentages 
will be calculated using the number of randomized patients as the denominator.  Reasons for 
treatment discontinuation will be supplied in tables giving numbers and percentages by treatment 
group.  This summary will be provided by treatment group and may also be further subgrouped by 
region/stratum as applicable. 
All critical or major deviations potentially impacting efficacy analyses, randomization, and 
drug-dispensing irregularities, and other major or critical deviations will be summarized in tables 
giving numbers and percentages of deviations by treatment group. 
Additionally, the analysis populations for safety, pharmacokinetics/pharmacodynamics, and ADA 
will be summarized in a table by number of patients in the safety population as the denominator.  
2.2.1 Randomization and drug dispensing irregularities 
Randomization and drug-dispensing irregularities occur whenever: 
1. A randomization is not in accordance with the protocol-defined randomization method, 
such as a) an ineligible patient is randomized, b) a patient is randomized based on an 
incorrect stratum, or c) a patient is randomized twice.  
 
OR 
2. A patient is dispensed an IMP kit not allocated by the protocol-defined randomization, 
such as a) a patient at any time in the study is dispensed a different treatment kit than as 
randomized (which may or may not contain the correct-as-randomized IMP), or b) a 
nonrandomized patient is treated with IMP reserved for randomized patients. 
Randomization and drug-dispensing irregularities will be monitored throughout the study and 
reviewed on an ongoing basis.  
All randomization and drug-dispensing irregularities will be documented in the IRT database.  If 
the number of irregularities is large enough to make a tabular summary useful, the irregularities 
will be categorized and summarized among randomized patients (number and percentages).  
Nonrandomized, treated patients will be described separately.  
Randomization and drug-dispensing irregularities to be prospectively identified include but are not 
limited to:  
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 39 
 
Randomization and drug allocation irregularities 
Kit dispensation without IRT transaction 
Erroneous kit dispensation 
Kit not available 
Randomization by error 
Patient randomized twice 
Stratification error 
Patient switched to another site 
Therapy administration without IRT transaction 
Erroneous therapy administration 
Therapy not available 
2.3 
ANALYSIS POPULATIONS 
Patients treated without being randomized will not be considered randomized and will not be 
included in any efficacy population.   
The randomized population includes any patient who has been allocated to a randomized 
treatment regardless of whether the treatment kit was used. 
For any patient randomized more than once, only the data associated with the first randomization 
will be used in any analysis population.  The safety experience associated with any later 
randomization will be assessed separately. 
2.3.1 Efficacy populations 
The primary efficacy analysis population will be the ITT population.  
Per the OCS titration Table 2 for the treatment period, patients starting with 35mg/day at baseline 
cannot achieve complete (100%) reduction at Week 24. Therefore, for the analysis of the 
secondary endpoint, proportion of patients no longer requiring OCS at Week 24 while maintaining 
asthma control, the analysis population will be all the patients in the ITT population whose 
optimized OCS dose at baseline is less than or equal to 30mg/day.  
2.3.1.1 Intent–to-treat population 
The intent-to-treat (ITT) population is the randomized population analyzed according to the 
treatment group allocated by randomization regardless of whether the treatment kit is used or not.  
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 40 
2.3.2 Safety population 
The safety population is defined as all patients who actually received at least 1 dose or part of a 
dose of the IMP, analyzed according to the treatment actually received. The safety analyses will be 
conducted according to the treatment patients actually received. In addition:  
x 
Randomized patients for whom it is unclear whether they took the IMP will be included in 
the safety population as randomized 
x 
For patients receiving both dupilumab and placebo during the trial, the treatment group 
allocation for as-treated analysis will be the dupilumab group. 
x 
PD biomarkers will be analyzed in the safety population. 
2.3.3 Pharmacokinetics population 
The PK population will consist of all patients in the safety population with at least 1 evaluable 
functional dupilumab concentration result.  Patients will be analyzed according to the treatment 
they actually received. 
2.3.4 Anti-drug antibody population 
The ADA population will consist of all patients in the safety population who had at least one 
reportable ADA results (either ‘ADA negative’ or ‘ADA positive’) after first dose of the study 
treatment. 
2.4 
STATISTICAL METHODS 
2.4.1 Demographics and baseline characteristics 
Parameters described in Section 2.1.1 will be summarized by treatment group and overall 
treatment groups using descriptive statistics.  
Continuous data will be summarized using the number of available data, mean, standard 
deviation (SD), median, minimum, and maximum for each treatment group.  Categorical and 
ordinal data will be summarized using the number and percentage of patients in each treatment 
group.  
Parameters will be summarized on the ITT population analyzed in the treatment group to which 
they were randomized.  Analyses for the safety population will be included in the appendices if the 
size of the safety population is different (>10%) from the size of that in the ITT population for any 
treatment group. 
Medical history will be summarized by SOC and PT by treatment group and overall treatment 
groups. They will be first sorted by SOC using the internationally agreed order and then by the 
decreasing frequency of PT within each SOC in the overall treatment groups. Comorbidity 
medical history will be summarized separately. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 41 
No hypothesis testing on demographic and baseline characteristic data will be performed.  
2.4.2 Prior or concomitant medications 
The prior and concomitant medications will be presented for the randomized population.  
Medications will be summarized by treatment group according to the WHO-DD dictionary, 
considering the first digit of the Anatomical Therapeutic Chemical (ATC) class (anatomic 
category) and the first 3 digits of the ATC class (therapeutic category).  All ATC codes 
corresponding to a medication will be summarized, and patients will be counted once in each ATC 
category (anatomic or therapeutic) linked to the medication. Therefore patients may be counted 
several times for the same medication.  
The table for prior medications will be sorted by decreasing frequency of ATC followed by all 
other therapeutic classes based on the overall incidence across treatment groups.  In case of equal 
frequency regarding ATCs (anatomic or therapeutic categories), alphabetical order will be used. 
The tables for concomitant medications will be sorted by decreasing frequency of ATC followed 
by all other therapeutic classes based on the incidence in the dupilumab group. In case of equal 
frequency regarding ATCs (anatomic or therapeutic categories), alphabetical order will be used.  
Concomitant medications will be summarized for the treatment epoch and treatment emergent 
period separately.  
Inhaled corticosteroid in combination with other controllers will be summarized separately. 
Oral corticosteroids 
Compliance to OCS 
Compliance to the prescribed OCS dose will be calculated from Visit 3 (Week 0) until Visit 11 
(Week 24) for patients who stay in the study until that time, or until the later between end of 
treatment and the last scheduled visit that occurred where the OCS dose adjustment is still 
recorded for patients who withdraw from the study before Visit 11. For each day, a patient is 
considered as compliant to the prescribed OCS if the patient takes the dose as prescribed. Days 
with missing OCS dose use record will be considered as non-compliant. Days when the ediary 
record of prescribed OCS dose was later corrected by the investigator (which will result in an 
inconsistency between the answer to the compliance question in ediary and compliance derived 
from comparing the actual dose to the prescribed dose) will be excluded from the compliance 
calculation. 
Percentage of OCS compliance for a patient will be defined as the number of days that the 
patient was compliant divided by the total number of days during the period defined above. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 42 
Above-prescribed OCS dosing percentage for a patient will be defined as the number of days 
that the patient took a higher OCS dose than prescribed divided by the total number of days during 
the period defined above.  
Under-prescribed OCS dosing percentage for a patient will be defined as the number of days 
that the patient took a lower dose than prescribed divided by the total number of days during the 
period defined above.  
Missing actual OCS dose data percentage for a patient will be defined as the number of days 
that the patient has a missing actual dose record in ediary divided by the total number of days 
during the period defined above.  
OCS compliance, above-prescribed and under-prescribed dosing, and missing actual OCS dose 
data percentages will be summarized descriptively as quantitative variables (number, mean, SD, 
median, minimum, and maximum).  The percentage of patients whose compliance is <80% will be 
summarized.  In addition, numbers and percentages of patients with 0, (0, 20%], and >20% above-
prescribed OCS dose as well of patients with 0, (0, 20%], and >20% under-prescribed OCS dose 
will be summarized separately. 
Inhaled corticosteroid with a second or third controller 
Prior asthma controller medications will be summarized by treatment group sorted by decreasing 
frequency of standardized medication name based on the overall incidence across treatment 
groups. 
Concomitant asthma controller medications at randomization will be summarized by treatment 
group sorted by decreasing frequency of standardized medication name based on the incidence in 
the dupilumab group. 
If a patient takes more than one medication containing ICS, the ICS dose of different products will 
be standardized according to equivalent dose specified in Table 6. After conversion, the total daily 
dose for inhaled corticosteroid will be calculated. 
Table 6 - Equivalent dose for inhaled corticosteroids for adults and adolescents ( 12 years) 
Inhaled corticosteroid  
Equivalent dose (mcg) to 500 mcg Fluticasone 
propionate (DPI or HFA) 
FLUTICASONE FUROATE 
100 
BECLOMETASONE DIPROPIONATE (CFC) 
1000 
BECLOMETASONE DIPROPIONATE (HFA) 
400 
BUDESONIDE (DPI) 
800 
CICLESONIDE (HFA) 
320 
MOMETASONE FUROATE 
440 
TRIAMCINOLONE ACETONIDE 
2000 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 43 
Inhaled corticosteroid  
Equivalent dose (mcg) to 500 mcg Fluticasone 
propionate (DPI or HFA) 
HFA=hydrofluoroalkane, DPI= Dry Powder Inhaler 
Example: A patient received 400 mcg budesonide (DPI) and 440 mcg mometasone furoate. They are equivalent to 250 mcg and 500 mcg 
fluticasone propionate correspondingly. The combined total daily dose is equivalent to 750 mcg fluticasone propionate and classified as high 
dose. 
Compliance to controller medications 
Compliance to the controller medication(s) with ICS component and overall compliance to all 
prescribed controller medications will be calculated for each patient during treatment epoch 
defined under Section 2.1.4. For each day, a patient is considered as compliant to the prescribed 
controller medication with ICS component if the actual dose of each controller medication with 
ICS component is same as or greater than the prescribed dose. Similarly, a patient is considered as 
compliant to all controller medication if the actual dose of each controller medication is same as 
or greater than the prescribed dose.  
 
Compliance for controller medication(s) with ICS component is defined as the number of days 
when the patient is compliant to the prescribed controller medication(s) with ICS component 
divided by the number of days of the patient in the treatment epoch. Overall controller 
medication(s) compliance is defined as the number of days when the patient is compliant to all 
prescribed controller medication divided by the number of days of the patient stays in the 
treatment epoch. Patients are considered non-compliance for the days of missing controller 
medication intake data.  
2.4.3 Extent of investigational medicinal product exposure and compliance  
The extent of IMP exposure and compliance will be assessed and summarized by actual treatment 
within the safety population (Section 2.3.2). 
2.4.3.1 Extent of investigational medicinal product exposure 
The extent of IMP exposure will be assessed by the duration of IMP exposure. 
Duration of IMP exposure is defined as last dose date – first dose date + 14 day, regardless of 
unplanned intermittent discontinuations (see Section 2.5.3 for calculation in case of missing or 
incomplete data).  Duration of IMP exposure will be summarized descriptively as a quantitative 
variable (number, mean, SD, median, minimum, and maximum).  In addition, duration of 
treatment exposure will also be summarized categorically by numbers and percentages for each of 
the following categories and cumulatively according to these categories:  
x 
>0 and 2 weeks 
x 
>2 and 4 weeks 
x 
>4 and 6 weeks 
x 
>6 and 8 weeks 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 44 
x 
>8 and 12 weeks 
x 
>12 and 16 weeks 
x 
>16 and 20 weeks 
x 
>20 and 24 weeks 
x 
>24 Weeks 
x 
Additionally, the cumulative duration of treatment exposure will be provided, defined as 
the sum of the duration of treatment exposure for all patients, and will be expressed in 
patient years. 
2.4.3.2 Compliance to the investigational medicinal product  
A given administration will be considered noncompliant if the patient did not take the planned 
dose of treatment as required by the protocol.  No imputation will be made for patients with 
missing or incomplete data.  
Percentage of compliance for a patient will be defined as the number of administrations that the 
patient was compliant divided by the total number of administrations that the patient was planned 
to take during the treatment epoch defined in Section 2.1.4. 
Above-planned dosing percentage for a patient will be defined as the number of administrations 
that the patient took a higher dose than planned divided by the total number of administrations that 
the patient was planned to take during the treatment epoch.  
Under-planned dosing percentage for a patient will be defined as the number of administrations 
that the patient took a lower dose than planned divided by the total number of administrations that 
the patient was planned to take during the treatment epoch.  
Treatment compliance, above-planned, and under-planned dosing percentages will be summarized 
descriptively as quantitative variables (number, mean, SD, median, minimum, and maximum).  
The percentage of patients whose compliance is <80% will be summarized.  In addition, numbers 
and percentages of patients with at least 1 above-planned dose administration will also be 
provided, as well as numbers and percentages of patients with 0, (0, 20%], and >20% under-
planned dose administrations. 
Cases of overdose (at least twice the intended dose during an interval of less than 11 days) will 
constitute serious adverse events and will be listed as such.  More generally, dosing irregularities 
will be listed in Section 2.2.1. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 45 
2.4.4 Analyses of efficacy endpoints 
2.4.4.1 Analysis of primary efficacy endpoint(s) 
2.4.4.1.1 Main statistical model and adjustment of covariates 
The primary estimand is the intent-to-treat estimand, the treatment difference between dupilumab 
and control in the mean percentage reduction of OCS dose at Week 24 while maintaining asthma 
control of all patients in the ITT population no matter whether the patients discontinue treatment 
before Week 24 or not. To estimate the estimand, data of patients who permanently discontinue 
treatment will be incorporated in the primary analysis, and missing data due to patients dropping 
out from study will be handled by approaches specified in the missing data handling section 
below. 
The primary efficacy endpoint will be analyzed using an analysis of covariance (ANCOVA) 
model.  The model will include the percentage reduction of OCS dose at Week 24 as the response 
variable, and the treatment groups, optimized OCS dose at baseline, regions (pooled countries), 
and baseline eosinophil level subgroups (<0.15 Giga/L, 0.15 Giga/L) as covariates. The 
treatment difference will be tested at the 2-sided significance level of Į=0.05.  Descriptive 
statistics for the primary efficacy endpoint will be provided, including the number of patients, 
means, standard errors, and least squares (LS) means by the treatment groups, as well as the 
difference in LS means and the corresponding 95% confidence interval (CI). Provided below is 
sample SAS code for running the model: 
 
   proc glm data= ocsdata; 
        class eosbgp2n cntygr1 trt01pn;  
        model ocspcw24 = ocsbl eosbgp2n cntygr1 trt01pn; 
        lsmeans trt01pn / stderr pdiff cl; 
        estimate 'Diff Dupilumab vs Placebo' trt01pn -1 1; 
        ods output LSMeans=lsmeans Estimates=lsmeandiff 
                    LSMeanDiffCL=lsmeandiffcl; 
   run; 
If there are any missing data in the primary efficacy endpoint, the number of subjects, means, and 
standard errors by treatment group will be calculated from patients with observed data, while the 
LS means, difference in LS means and the corresponding CI will be calculated based on each 
particular missing data handling approach as described below.  
A review of the residuals will be done to determine whether the normality assumption is met.  If 
the normality assumption is not met, a rank ANCOVA model will be used to corroborate the result 
of the significance test. Details will be given below. 
2.4.4.1.2 Missing data handling 
Patients who permanently discontinue the study medication will be asked and encouraged to return 
to the clinic for all remaining study visits and the Study investigators should continue OCS dose 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 46 
adjustment after treatment discontinuation, as guided by their medical judgment, including up-
titration and down-titration in accordance with Table 2.  The off-treatment OCS dose will be used 
in the primary analysis. During the study, only monotone missing pattern is expected. The number 
of patients with missing data will be summarized for each treatment group by reason of treatment 
discontinuation and the last time without missing data. The percent reduction for these patients 
will be summarized using descriptive statistics by treatment group and visit.     
For statistical inference based on the main model, the following approaches will be used to handle 
the missing data: 
Primary approach – pattern mixture model by multiple imputation 
This approach will impute missing percent reduction of OCS dose at Visits 5 (Week 4), 7 (Week 
8), 8 (Week 12), 9 (Week 16), 10 (Week 20) and 11 (Week 24), using multiple regression models.  
Imputation will be conducted sequentially by visit, since the imputation for each visit will 
incorporate information at prior visits. Specifically, the model for each visit will focus on the 
percent reduction of OCS dose at the visit as the response variable and include the following 
predictors: the covariates incorporated in the primary statistical model, including baseline 
eosinophil level subgroup, region (pooled countries), the treatment group, optimized OCS dose at 
baseline, and the percent reduction of OCS dose from baseline at all the prior visits. Of note, since 
per protocol a new dose, and therefore the corresponding percent reduction from baseline, if not 
missing should be one of three possible values corresponding to decreasing, maintaining, or 
increasing from the previous dose based on the titration Table 2, the imputed value for each 
missing percent reduction will be the one among the three possible values that is closest to the 
initially imputed predicted percent reduction from the imputation model.  Forty imputations will 
be performed. For each imputation, the complete percent reduction of OCS dose at Week 24 will 
be analyzed using the main statistical model described above. LS means by the treatment groups 
and difference in the LS means will be obtained. Rubin’s rule will be used to combine results from 
all the imputations into a single inference for each of the parameters. P-value and CI will be 
obtained for the treatment difference. The details of obtaining the observed OCS doses for each 
visit are described in the data handling convention section.   
This approach will be implemented using procs MI and MIANALYZE with the following steps.  
1. For the first visit among Visits 5, 7, 8, 9, 10 and 11 that has missing data on prescribed 
daily maintenance OCS dose, generate 40 imputed dataset, where the missing percent 
reduction of OCS dose at the visit is imputed from the model described above. Sample 
SAS code is provided below: 
 
proc mi data=ocsdata nimpute=40 seed=&seed out=data_imp;   
    class eosbgp2n cntygr1 trt01pn; 
var eosbgp2n cntygr1 trt01pn ocsbl &ocspc_prior                      
&ocspc_curr; 
monotone reg(&ocspc_curr); 
run; 
 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 47 
where  &ocspc_curr is the percent reduction of OCS dose at the current visit/time, and 
&ocspc_prior includes the percent reduction of OCS at all the prior visits considered in 
the imputation. If the current visit is Visit 5 (Week 4), no prior percent reduction will be 
included. For each missing percent reduction data, the three possible values can be 
identified from titration Table 2 based on the dose at baseline and the dose immediately 
before the current visit. The imputed percent reduction will be the one closest to the 
predicted from the model. Of note dose increase beyond baseline level is possible and will 
follow the first row of the titration table.  For each of the subsequent visits until Visit 11 
(Week 24), similar imputation model will be built with the following sample SAS code: 
 
proc mi data=data_imp nimpute=1 seed=&seed out=data_imp;   
    by _imputation_; 
class eosbgp2n cntygr1 trt01pn; 
var eosbgp2n cntygr1 trt01pn ocsbl &ocspc_prior                      
&ocspc curr; 
monotone reg(&ocspc_curr); 
run; 
 
One seed will be used to generate random seeds for the MI at each visit.  
2. Each of the 40 imputed datasets will be analyzed using the main statistical model. Sample 
code: 
 
   proc glm data= data_imp; 
        by _imputation_; 
        class eosbgp2n cntygr1 trt01pn;  
        model ocspcw24 = ocsbl eosbgp2n cntygr1 trt01pn; 
        lsmeans trt01pn / stderr; 
        estimate 'Diff Dupilumab vs Placebo' trt01pn -1 1; 
        ods output LSMeans=implsmeans Estimates=implsmeandiff; 
   run; 
3. Applying Rubin’s rule to combine analysis results (point estimates and variance) from 40 
imputations using proc MIANALYZE for the LS means and difference in LS means 
between dupilumab and placebo. Sample code: 
proc sort data=implsMeans; by trt01pn _imputation_;run; 
 
   
proc mianalyze data= implsmeans; 
     by trt01pn; 
     modeleffects lsmean; 
     stderr stderr; 
     ods output ParameterEstimates=lsmeans; 
     run; 
 
    
proc mianalyze data=implsmeandiff; 
       
modeleffects estimate; 
       
stderr stderr; 
       
ods output ParameterEstimates=lsmeandiff; 
     run;   
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 48 
Sensitivity analysis 
Pattern mixture model by control-based multiple imputation  
The same MI method as the primary approach will be used except that only data of patients in the 
control group will be used to fit the MI models and the treatment variable will not be incorporated 
as one of the covariates in the MI models. In Step 1 above, at each visit, missing data of patients in 
both dupilumab and control groups will be imputed using the models fitted with control patients. 
This approach assumes that at each visit the missing OCS percent reduction in both treatment 
groups has the same distribution as those observed in the control group conditional on the 
covariates in the MI models. 
Worse of the last two observations carry forward 
For the missing OCS dose at Week 24, the worse (higher) dose between the doses at the last two 
scheduled visits with available maintenance OCS doses during the treatment period will be used to 
impute the OCS dose at Week 24 to calculate the primary efficacy endpoint.  If a patient drops out 
of study before Visit 5, the baseline dose (0% reduction) will be used. The main statistical model 
will be applied to the complete dataset after the imputation.  
Tipping point analysis 
Tipping point analysis will be conducted to evaluate the robustness of the primary analysis result. 
This will be conducted by sequentially increasing the imputed percent OCS reduction at Week 24 
in the control group and decreasing the imputed values in the treatment group from the primary 
missing data handling approach. Specifically, for patients in the dupilumab group missing the 
endpoint, one sequentially subtracts 10% from each imputed value. For patients in the placebo 
group missing the endpoint, one sequentially adds 10% to each imputed value, until all the 
patients in all imputations reach their maximum possible percent reduction of OCS dose per 
protocol. The mean increase in the percent reduction of OCS dose from the original imputed 
values will be calculated to reflect the actual amount of shift in the placebo group. For each 
combination of increase in the placebo group and decrease in the dupilumab group, the new 
dataset will be analyzed and results will be combined using the same methods in Steps 2 and 3 of 
the primary missing data handling approach. The LS mean difference in percent reduction of OCS 
dose between the two treatment groups and the corresponding p-values will be reported. 
2.4.4.1.3 Other supportive analysis 
Rank ANCOVA 
If the normality assumption is not met, rank ANCOVA with the extended Mantel-Haenszel (MH) 
statistics will be used for nonparametric comparisons between treatment groups. The same 
covariates in the main ANCOVA model, namely, optimized OCS dose at baseline, regions 
(pooled countries), and baseline eosinophil level subgroups (<0.15 Giga/L, 0.15 Giga/L) will be 
adjusted for in this method. P-value will be obtained from the MH mean score statistic that is 
asymptotically chi-square distributed with 1 degree of freedom under the null hypothesis that there 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 49 
is no location shift in the distribution of the rank percent reduction in OCS between dupilumab 
and placebo groups.  Specifically, the approach will be implemented with the following steps. 
 
1. Compute standardized ranks of the percent reduction in OCS at Week 24 and the 
baseline optimized OCS dose in each combination of region and baseline eosinophil 
level subgroup. Standardized ranks are used to adjust for the fact that the number of 
patients differs among the subgroups. Sample SAS code: 
 
proc rank data=ocsdata nplus1 ties=mean out=rankdata     
(rename=(base=base_rank ocspcw24=ocspcw24_rank)); 
by cntygr1 eosbgp2n; 
var ocsbl ocspcw24; 
run; 
 
The NPLUS1 option of the RANK procedure requests fractional ranks using the 
denominator as the subgroup specific sample size plus 1. The TIES=MEAN option 
requests that tied values receive the mean of the corresponding ranks (midranks).  
 
2. Fit separate multiple regression models for the subgroups. In each model, the 
standardized ranks of the percent reduction in OCS at Week 24 and the baseline 
optimized OCS dose are used as the dependent and independent variables, respectively.  
Residuals from the regression models for each patient are obtained. Sample SAS code: 
 
proc glm data=rankdata; 
by cntygr1 eosbgp2n; 
model ocspcw24_rank=base_rank; 
output out=residual r=resid; 
run; 
 
3. The extended Mantel-Haenszel mean score statistic is used to compare the mean values 
of the residuals between dupilumab and placebo in all subgroups of patients. Sample 
SAS code: 
 
proc freq data=residual; 
tables cntygr1*eosbgp2n*trt01pn*resid/noprint cmh2; 
run; 
 
If there are any missing data in the primary efficacy endpoint, the statistical test will be performed 
based on imputed datasets generated from the primary missing data handling approach. The 
approach proposed in (6) will be used for combining the MH statistics from each imputation to 
obtain the p-value of testing treatment difference. Specifically, the combined test statistic is 
    
R
R
m
m
C
D

u



 
1
)1
/(
)1
(
,  
  
where C  is the average of  MH statistics from all imputations, m is the number of imputations, 
and R   is (
1
1

 m
) times the sample variance of the square root of the MH statistics from all 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 50 
imputations.  The reference distribution is an F distribution with 1 and 
2
1)
1
)(
1
(



R
m
 as 
numerator and denominator degrees of freedom.   
On treatment analysis  
This analysis will only be performed when there are any patients who permanently discontinue 
treatment and still stay in the study for the remaining visits. The main statistical model will be 
used. Data collected after treatment discontinuation will be excluded from analysis. Then the 
primary missing data handling approach, PMM by MI, will be applied to impute missing data and 
estimate the LS means by the treatment groups and difference in the LS means. 
2.4.4.1.4 Subgroup analysis 
To assess the consistency in treatment effects across different subgroup levels, subgroup analyses 
will be conducted for the primary efficacy endpoint with respect to  
x 
Baseline optimized OCS dose strata (10mg/day, >10mg/day), 
x 
Age group (<40, 40 years), 
x 
Gender (Male, Female), 
x 
Region (East Europe: Hungary, Poland, Romania, Russia, and Ukraine; Latin America: 
Argentina, Brazil, Colombia, Chile, and Mexico; Western Countries: Belgium, Canada, 
Israel, Italy, Netherlands, Spain, and USA), 
x 
Race (Caucasian/White, the others), 
x 
Baseline pre-BD FEV1 ( 1.75L, > 1.75L),  
x 
baseline predicted FEV1 % (<60%, 60%),  
x 
ACQ-5 ( 2, >2),  
x 
Weight (< 70,  70 - < 90,  90 kg ), 
x 
BMI (<25, 25 - <30,  30 kg/m2), 
x 
Smoking history (Former, Never),  
x 
Ongoing atopic medical history (Yes, No),  
x 
Age of onset of asthma (<18, 18-40, >40 years ),  
x 
Number of severe asthma exacerbation within1 year before Visit 1 (1,>1) 
x 
Baseline eosinophil level subgrouping 1 (<0.15 Giga/L or 0.15 Giga/L) 
x 
Baseline eosinophil level subgrouping 2 (<0.3 Giga/L or 0.3 Giga/L) 
An ANCOVA model incorporating subgroup-by-treatment interaction will be built for each 
subgroup factor. The model will include all the covariates in the main statistical model plus the 
subgroup variable (if not one of the covariates adjusted in the main model) and the subgroup-by-
treatment interaction. A p-value for the test of interaction will be provided. If the subgroup factor 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 51 
has more than two levels, then an F-test will be performed to evaluate the overall significance of 
all interaction tests.  
Forest plots of treatment difference between dupilumab and placebo in percent reduction of OCS 
dose at Week 24 and corresponding CIs for subgroups will be provided. 
If there are any missing data in the primary efficacy endpoint, subgroup analysis will be performed 
based on imputed datasets generated from the primary missing data handling approach.  Rubin’s 
rule will be used to combine estimated interaction effect from all the imputations. 
2.4.4.2 Analyses of secondary efficacy endpoints 
2.4.4.2.1 Analysis of the key secondary efficacy endpoints 
The proportion of patients achieving a reduction of 50% or greater in their OCS dose at Week 24 
compared with baseline and the proportion of patients achieving a reduction of OCS dose to 
<5 mg/day at Week 24 will be analyzed using a logistic regression model.  The model will use the 
binary status of whether or not a patient achieved the corresponding OCS reduction criterion as 
the response variable, and treatment groups, optimized OCS dose at baseline, regions (pooled 
countries), and baseline eosinophil level subgroups (<0.15 Giga/L or 0.15 Giga/L) as covariates. 
The number and proportion of patients achieving the OCS dose reduction  criterion of the efficacy 
endpoint will be summarized by treatment group. The adjusted probabilities of achieving the 
reduction in the two treatment groups and the estimated odds ratio between dupilumab and 
placebo groups, its 95% CI and associated p-value will be provided. 
 
proc genmod data=ocsdata descending; 
    class trt01pn eosbgp2n cntygr1; 
    model resp = basedose eosbgp2n cntygr1 trt01pn 
    / dist=bin link=logit type3; 
estimate 'Odds ratio Dupilumab vs Placebo' trt01pn -1 1 /exp; 
run; 
2.4.4.2.1.1 Missing data handling 
If there are any missing data in the percent reduction in OCS at Week 24, the following missing 
data handling approaches will be used. 
Primary approach – pattern mixture model by multiple imputation 
The imputed datasets from the primary missing data handling approach for the primary efficacy 
endpoint will be used, and the binary response status of each patient with missing endpoint will be 
determined from the imputed percent reduction at Week 24. The logistic regression model 
described above will be applied to analyze each imputation dataset, and Rubin’s rule will be 
applied to combine results. Of note, Rubin’s rule will be applied on log odds ratio (the regression 
coefficient of the treatment variable) whose posterior distribution given data can be better 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 52 
approximated by normal distribution. The estimated odds ratio and 95% CI of the odds ratio will 
be obtained by taking anti-log transformation on the corresponding statistics for the log odds ratio.  
Sensitivity analysis 
Pattern mixture model by control-based multiple imputation  
The imputed datasets using the pattern mixture model by control-based multiple imputation for 
the primary efficacy endpoint will be used, and the binary response status of each patient with 
missing endpoint will be determined from the imputed percent reduction at Week 24. The analysis 
method is the same as the primary missing data handling approach for the key secondary 
endpoints.  
Patients dropped out from study considered as non-responders  
The patients who drop out from study will be considered as non-responders. The main logistic 
regression model will be applied to the complete dataset.  
2.4.4.2.1.2 Other supportive analysis 
On treatment analysis  
This analysis will only be performed when there are any patients who permanently discontinue 
treatment and still stay in the study for the remaining visits. The imputed data from the on-
treatment analysis for the primary efficacy endpoint will be used.  The analysis method is the same 
as the primary missing data handling approach for the key secondary endpoints. 
2.4.4.2.2 Analysis of the absolute reduction of OCS dose  
The absolute reduction of OCS dose at Week 24 will be analyzed using an ANCOVA model in the 
same manner as for the primary endpoint. The same covariates will be incorporated. If there are 
any missing data in the endpoint, the imputed datasets generated from the primary missing data 
handling approach for the primary efficacy endpoint will be used, and the second and third step of 
the primary missing data handling approach will be applied to analyze data of absolute reduction 
of OCS dose and combine results from each imputation.   
2.4.4.2.3 Analysis of proportion of subjects achieving a certain reduction of OCS dose 
The proportion of patients achieving a certain reduction of OCS dose will be analyzed in the same 
manner as the key secondary endpoints.  The model will use the binary status of whether or not a 
patient achieves the prespecified OCS dose reduction criterion as the response variable, and the 
treatment groups, optimized OCS dose at baseline, regions (pooled countries), and baseline 
eosinophil level subgroups (<0.15 Giga/L or 0.15 Giga/L) as covariates. The estimated odds ratio 
between dupilumab and placebo groups, its 95% CI and associated p-value will be provided. Of 
note, patients in the efficacy population with a baseline optimized OCS dose at 35mg/day will be 
excluded from the analysis of the proportion of patients achieving a reduction of OCS dose to 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 53 
0 mg/day at Week 24, because per protocol, 0mg/day is not achievable for these patients. If there 
is any missing data at Week 24, the primary missing data handling approach for the key secondary 
endpoints will be applied. 
2.4.4.3 Multiplicity issues 
The primary endpoint will be tested at a 2-sided 5% significance level.  If the primary endpoint 
meets the significance level, the following secondary endpoints will be tested at a 2-sided 
5% significance level in the hierarchical order defined below: 
x 
Proportion of patients achieving a reduction of 50% or greater in their OCS dose compared 
with baseline at Week 24 while maintaining asthma control; 
x 
Proportion of patients achieving a reduction of OCS dose to <5 mg/day at Week 24 while 
maintaining asthma control;  
x 
Proportion of patients achieving their maximum possible reduction of OCS dose per 
protocol at Week 24 while maintaining asthma control; 
x 
Proportion of patients no longer requiring OCS at Week 24 while maintaining asthma 
control. 
No multiple testing adjustment will be performed for the other efficacy endpoints.  
2.4.4.4 Additional efficacy analyses 
2.4.4.4.1 Analysis of annualized event rate 
The annualized event rates during the 24-week Treatment Period, including the rate of severe 
asthma exacerbation and rate of exacerbations requiring hospitalization or ER visit will be 
analyzed using negative binomial regression models.  The model corresponding to each type of 
event will include the total number of the events occurring during the 24 weeks as the response 
variable, and the treatment groups, baseline optimized OCS dose strata, regions (pooled 
countries), number of the events within 1 year prior to the study, and baseline eosinophil level 
subgroups (<0.15 Giga/L, 0.15 Giga/L) as covariates.  Log-transformed treatment duration will 
be the offset variable.  Annual rates on the two treatment arms, the ratio of the rates, 95% 
confidence intervals for the ratio and a p-value for testing treatment difference in the event rate 
will be provided. Sample SAS code: 
 
proc glimmix data=event; 
class ocsblg2n eosbgp2n trt01pn cntygr1; 
model numevents= ocsblg2n eosbgp2n cntygr1 asmanum trt01pn      
                  /offset=logdur dist=negbin link=log solution; 
estimate 'rate ratio Dupilumab vs Placebo' trt01pn -1 1/alpha=0.05 
exp; 
lsmeans trt01pn/alpha=0.05 cl ilink cov;                                 
run; 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 54 
For patients who permanently discontinue the treatment but stay in the study, the events which 
occurred up to Visit 11 (Week 24) will be included.  For all patients stay in the study till Visit 11, 
the treatment duration is from randomization to Visit 11.  For patients who withdraw from study 
prior to Visit 11, events that occurred up to the last contact date will be analyzed, and the last 
contact date will be used to calculate the offset variable.  
Analysis of the asthma exacerbations requiring hospitalization or ED visits will only be performed 
if sufficient numbers of patients have multiple exacerbations requiring hospitalization or ED visit 
for the model to converge satisfactorily. 
2.4.4.4.2 Analysis of time to event variables 
Time to event parameters, including time to first severe asthma exacerbation and time to first 
exacerbation requiring hospitalization or ED visit will be analyzed using a Cox regression model 
with the time to event as the response variable, and the treatment groups, baseline optimized OCS 
dose strata, regions (pooled countries), number of the events within 1 year prior to the study, and 
baseline eosinophil level subgroups (<0.15 Giga/L, 0.15 Giga/L) as covariates. Hazard ratio 
between treatment and placebo will be estimated with 95% CI. The Kaplan-Meier (K-M) method 
will be used to estimate the probability of patients with at least one event up to Weeks 12 and 24 
specific to each treatment group. Sample SAS code for the Cox regression: 
 
proc phreg data=ttevent; 
class ocsblg2n eosbgp2n trt01pn cntygr1 /param=glm; 
model aval*CNSR(1) = ocsblg2n eosbgp2n cntygr1 asmanum trt01pn; 
contrast 'Hazard ratio Dupilumab vs Placebo' 
trt01pn –1 1/estimate=exp; 
run; 
 
The calculation of time has been specified in Section 2.1.3.2.2.1.2. For patients who discontinue 
the study prior to Week 24, events that occurred up to the last contact date will be considered. If 
there is no event observed, the last contact date will be used to calculate a free of event duration. 
2.4.4.4.3 Analysis of change/ percentage change from baseline for other continuous variables 
The change and/or percentage change from baseline for other continuous variables, including pre-
BD FEV1,  post-BD FEV1,  FEV1 reversibility, percent predicted FEV1, PEF, FVC, FEF25-75%, 
ACQ-5, asthma symptom scores, nocturnal awakenings, number of  puffs/day of 
salbutamol/albuterol or levosalbutamol/levalbuterol for symptom relief, AQLQ, EQ-5D-5L, and 
HADS, will be analyzed using a mixed effect model with repeated measures (MMRM) approach.  
For a continuous variable, the corresponding MMRM model will include the change/percent 
change from baseline as response variables, and factors (fixed effects) for the treatment groups, 
baseline optimized OCS dose strata, regions (pooled countries), baseline eosinophil level 
subgroups (<0.15 Giga/L, 0.15 Giga/L,) visits, treatment-by-visit interaction, the corresponding 
baseline value of the endpoint, and baseline-by-visit interaction.  Additionally, age, gender, and 
height at baseline will be included as covariates in the models for spirometry variables but not for 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 55 
other variables.  An unstructured correlation matrix will be used to model the within-patient 
errors.  Parameters will be estimated using restricted maximum likelihood method with the 
Newton-Raphson algorithm. For each endpoint, all visits up to Visit 11 where there is a scheduled 
measurement will be included in analysis. For ACQ-5, only those questionnaires assigned to each 
visit will be included. For the daily measurements, the periodical average specified in 
Section 2.5.2 will be performed.  
For each endpoint, descriptive statistics including number of patients, mean, standard error and LS 
mean for each treatment group will be obtained for the visits specified in Section 2.1.3.2.2. 
Difference in LS mean, its 95% CI and a nominal p-value with Kenward-Roger adjustment will be 
provided for comparison between dupilumab and placebo groups. For patients who dropout from 
study prior to Visit 11 (Week 24), missing data will not be imputed. Provided below is sample 
SAS code for analyzing change from baseline in pre-BD FEV1 and estimating treatment difference 
at Week 24. 
 
proc mixed data=adsd.adre method=reml; 
where paramcd='FEV1' and avisitn ge 4 and avisitn le 11 and 
anl01fl='Y' and dtype ne 'LOCF' and ittfl='Y'; 
 
class subjid sex ocsblg2n eosbgp2n trt01pn avisitn cntygr1; 
model chg = trt01pn sex age height ocsblg2n eosbgp2n cntygr1 
avisitn trt01p*avisitn base base*avisitn/ddfm=kr residual; 
 
repeated avisitn/type=un subject=subjid; 
 
lsmeans trt01pn*avisitn /cl; 
     estimate 'Diff Dupilumab vs Placebo at Week 24'  
      
trt01pn -1 1 trt01pn*avisitn  0 0 0 0 0 0 0 -1   
                        
              0 0 0 0 0 0 0  1/ cl;   
run; 
For the ACQ-5 score, a supportive analysis of the proportion of patients reaching MCID will be 
performed using logistic regression models at each of the time points analyzed for the endpoint. At 
each time point, the patients with change from baseline in ACQ-5  -0.5 at the time point will be 
considered as responders, while the patients with change from baseline in ACQ-5 >-0.5 or with 
missing value at the time point will be considered as non-responders. The model will include 
treatment groups, baseline optimized OCS dose strata, regions (pooled countries), baseline 
eosinophil level subgroups (<0.15 Giga/L or 0.15 Giga/L), and baseline ACQ-5 score as 
covariates. The estimated odds ratio between dupilumab and placebo groups, its 95% CI and 
associated p-value will be provided. 
Change from baseline in airway hyperresponsiveness at Week 24 will be summarized with 
descriptive statistics including number of patients, mean, and standard error by treatment groups. 
If the number of subjects with available data is small, then a listing of the endpoint data instead of 
the summary statistics will be provided. 
2.4.5 Analyses of safety data 
The summary of safety results will be presented by treatment group.  
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 56 
General common rules 
All safety analyses will be performed on the safety population as defined in Section 2.3.2, unless 
otherwise specified, using the following common rules: 
x 
The baseline value is defined as last available value prior to the first dose of IMP. 
x 
The potentially clinically significant abnormality (PCSA) values are defined as abnormal 
values considered medically important by the Sponsor according to predefined 
criteria/thresholds based on literature review and defined by the Sponsor for clinical 
laboratory tests, vital signs, and ECG (PCSA version dated May 2014 [Appendix J] ).  
x 
PCSA criteria will determine which patients had at least 1 PCSA during the treatment-
emergent adverse event period, taking into account all evaluations performed during the 
treatment-emergent adverse event period, including nonscheduled or repeated evaluations.  
The number of all such patients will be the numerator for the on-treatment PCSA 
percentage. 
x 
The treatment-emergent PCSA denominator by group for a given parameter will be based 
on the number of patients assessed for that given parameter in the treatment-emergent 
adverse event period by treatment group on the safety population. 
x 
For quantitative safety parameters based on central laboratory/reading measurements, 
descriptive statistics will be used to summarize results and change from baseline values by 
visit and treatment group.  Summaries will include the endpoint value and/or the worst on-
treatment value.  The endpoint value is commonly defined as the value collected at the end 
of treatment.  If this value is missing, this endpoint value will be the closest value prior to 
the end of treatment epoch. The worst value is defined as the nadir and /or the peak 
postbaseline (up to the end of treatment epoch or EOT) according to the direction 
(minimum or maximum) of the abnormality as defined in the PCSA list. 
x 
The analysis of the safety variables will be essentially descriptive and no systematic testing 
is planned.   
All safety values including unscheduled measurements will be assigned to a safety analysis visit 
window defined in Section 2.5.4. 
2.4.5.1 Analyses of adverse events 
Generalities 
The primary focus of adverse event reporting will be on treatment-emergent adverse events.  
Pretreatment adverse events will be described separately.  
If an adverse event date/time of onset (occurrence, worsening, or becoming serious) is incomplete, 
an imputation algorithm will be used to classify the adverse event as pretreatment or treatment-
emergent.  The algorithm for imputing date/time of onset will be conservative and will classify an 
adverse event as treatment emergent unless there is definitive information to determine it is 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 57 
pretreatment.  Details on classification of adverse events with missing or partial onset dates are 
provided in Section 2.5.3. 
Adverse event incidence tables will present by SOC, HLGT, HLT, and PT, sorted in alphabetical 
order for each treatment group, the number (n) and percentage (%) of patients experiencing an 
adverse event.  Multiple occurrences of the same event in the same patient will be counted only 
once in the tables within a treatment phase.  The denominator for computation of percentages is 
the safety population within each treatment group. 
For tables presented by SOC and PT, SOCs will be sorted by the internationally agreed SOC order 
and PTs within SOCs will be sorted by decreasing incidence in the dupilumab arm.  
Analysis of all treatment-emergent adverse events 
The following treatment-emergent adverse event summaries will be generated for the safety 
population. 
x 
Overview of treatment-emergent adverse events, summarizing number (%) of patients with 
any 
- 
Treatment-emergent adverse event 
- 
Serious treatment-emergent adverse event 
- 
Treatment-emergent adverse event leading to death 
- 
Treatment-emergent adverse event leading to permanent treatment discontinuation 
x 
All treatment-emergent adverse events by primary SOC, showing number (%) of patients 
with at least 1 treatment-emergent adverse event, sorted by internationally agreed order of 
primary system organ class  
x 
All treatment-emergent adverse event by primary SOC, HLGT, HLT, and PT, showing 
number (%) of patients with at least 1 treatment-emergent adverse event sorted by the SOC 
internationally agreed order.  The other levels (HLGT, HLT, PT) will be presented in 
alphabetical order 
x 
Number (%) of patients experiencing TEAE(s) presented by PT, sorted by decreasing 
incidence of PT  
x 
All treatment-emergent adverse events by primary SOC and PT, showing the number (%) 
of patients with at least 1 treatment-emergent adverse event, sorted by the internationally 
agreed SOC order and by decreasing incidence of PTs within each SOC.   
x 
All treatment-emergent adverse events regardless of relationship and related to IMP by 
primary SOC, HLGT, HLT and PT, showing the number (%) of patients with at least 1 
treatment-emergent adverse event, sorted by the internationally agreed SOC order.  The 
other levels (HLGT, HLT, PT) will be presented in alphabetical order 
x 
All treatment-emergent adverse events by maximal severity, presented by primary SOC 
and PT, showing the number (%) of patients with at least 1 treatment-emergent adverse 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 58 
event by severity (ie, mild, moderate, or severe), sorted by the internationally agreed SOC 
order and by decreasing incidence of PTs within each SOC 
x 
Number (%) of patients experiencing treatment-emergent adverse event(s) presented by 
primary and secondary SOC, HLGT, HLT, and PT sorted by the internationally agreed 
SOC order.  The other levels (HLGT, HLT, PT) will be presented in alphabetical order 
x 
Listing of all treatment-emergent adverse events 
Analysis of all treatment emergent serious adverse event(s) 
x 
All treatment-emergent serious adverse events by primary SOC, HLGT, HLT, and PT, 
showing the number (%) of patients with at least 1 serious treatment-emergent adverse 
event, sorted by the internationally agreed SOC order.  The other levels (HLGT, HLT, PT) 
will be presented in alphabetical order 
x 
All treatment-emergent serious adverse events regardless of relationship and related to 
IMP, by primary SOC, HLGT, HLT, and PT, showing the number (%) of patients with at 
least 1 treatment-emergent serious adverse event, sorted by the internationally agreed SOC 
order.  The other levels (HLGT, HLT, PT) will be presented in alphabetical order 
x 
All treatment-emergent serious adverse events by primary SOC and PT, showing the 
number (%) of patients with at least 1 treatment-emergent serious adverse event, sorted by 
the internationally agreed SOC order and by decreasing incidence of PTs within each SOC 
x 
Listing of all treatment-emergent serious adverse events  
Analysis of all treatment-emergent adverse event(s) leading to permanent treatment 
discontinuation or drug interruption 
x 
All treatment-emergent adverse events leading to permanent treatment discontinuation or 
drug interruption, by primary SOC, HLGT, HLT, and PT, showing the number (%) of 
patients sorted by the internationally agreed SOC order.  The other levels (HLGT, HLT, 
PT) will be presented in alphabetical order 
x 
All treatment-emergent adverse events leading to permanent treatment discontinuation or 
drug interruption, by primary SOC and PT, showing the number (%) of patients sorted by 
the internationally agreed SOC order and by decreasing incidence of PTs within each SOC   
Analysis of all treatment-emergent adverse event(s) of special interests and other selected AE 
groupings 
x 
All treatment-emergent adverse events, by selected standardized MedDRA query (SMQ) 
and PT or by laboratory values (as in ALT elevation), showing the number (%) of patients 
with at least 1 PT, sorted by decreasing incidence of PTs within each SMQ 
x 
For each prespecified AESI and selected events,  
- 
Number (%) of patients with any of the specific TEAE 
- 
Number (%) of patients with any of the specific serious AE (regardless of treatment 
emergent status) 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 59 
- 
Number (%) of patients with any of the specific treatment emergent serious AE 
- 
Number (%) of patients with any of the specific AE leading to death 
- 
Number (%) of patients with any of the specific TEAE leading to permanent study 
drug discontinuation 
- 
Number (%) of patients with any of the specific TEAE by maximum intensity, 
corrective treatment, and final outcome 
- 
Number of the specific TEAE adjusted by exposure duration 
- 
All of the specific TEAE, by PT, showing the number (%) of patients, sorted by 
decreasing incidence of PT 
- 
K-M estimates of cumulative incidence of the specific TEAE at Weeks 12 and 24 and 
K-M plot may be provided to depict the course of onset over time if the number of 
events is large enough 
x Number (%) of patients with injection site reactions by the related injection 
x Number (%) of patients with different number of injection site reactions 
Analysis of pretreatment adverse events  
x 
All pretreatment adverse events by primary SOC and PT, showing the number (%) of 
patients with at least 1 pretreatment adverse event, sorted by the internationally agreed 
SOC order and decreasing incidence of PTs within each SOC 
x 
All pretreatment serious adverse events by primary SOC and PT, showing the number (%) 
of patients with at least 1 pretreatment serious adverse event, sorted by the internationally 
agreed SOC order and decreasing incidence of PTs within each SOC 
x 
All pretreatment adverse events leading to permanent treatment discontinuation by primary 
SOC and PT, showing the number (%) of patients, sorted by the internationally agreed 
SOC order and decreasing incidence of PTs within each SOC 
x 
All pretreatment adverse events leading to death  by primary SOC and PT, showing the 
number (%) of patients, sorted by the internationally agreed SOC order and decreasing 
incidence of PTs within each SOC 
The above pretreatment AEs will be presented as listings if there are only a few of them. 
2.4.5.2 Deaths 
The following summaries of deaths will be generated for the safety population. 
x 
Number (%) of patients who died by study period (on-study, on-treatment, post-study) 
Treatment-emergent adverse events leading to death (death as an outcome on the adverse 
event case report form page as reported by the Investigator) by primary SOC , HLGT, 
HLT, and PT showing number (%) of patients sorted by internationally agreed SOC order, 
with HLGT, HLT, and PT presented in alphabetical order within each SOC .  
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 60 
x 
All pretreatment adverse events leading to death by primary SOC and PT, showing the 
number (%) of patients, sorted by the internationally agreed SOC order and decreasing 
incidence of PTs within each SOC 
x 
Deaths in nonrandomized patients or in randomized but not treated patients will be 
summarized separately. 
2.4.5.3 Analyses of laboratory variables  
The summary statistics (including number, mean, median, Q1, Q3, standard deviation, minimum 
and maximum) of all laboratory variables (central laboratory values and changes from baseline) 
will be calculated for each visit or study assessment (baseline, each post baseline time point, last 
on-treatment and/or worst on-treatment value) by treatment group.  For each continuous laboratory 
variables listed in Section 2.1.4.3, mean changes from baseline with the corresponding standard 
error will be plotted over time (at same time points) in each treatment group. This section will be 
organized by biological function as specified in Section 2.1.4.3 . 
The incidence of PCSAs (list provided in Appendix J) at any time during the treatment-emergent 
adverse event period will be summarized by biological function and treatment group whatever the 
baseline level and/or according to the following baseline status categories:  
x 
Normal/missing 
x 
Abnormal according to PCSA criterion or criteria 
For parameters for which no PCSA criteria are defined, similar table(s) using the normal range 
will be provided. 
For PCSA analyses, the laboratory measurements obtained at either scheduled or unscheduled 
visits should be used; and, both the centralized and local test results should be used, as long as 
their available dates/time is different from each other’s. Centralized data will be used 
preferentially to the local measures in the PCSA analyses when measurements are performed on 
the same date and at the same time for a given laboratory test. 
Drug-induced liver injury 
If there is imbalance in the incidence of liver-related adverse events across the treatment groups, 
the following analysis of liver-related adverse events will be performed. 
The liver function tests, namely AST, ALT, alkaline phosphatase, and total bilirubin, are used to 
assess possible drug-induced liver toxicity.  The proportion of patients with PCSA values at any 
postbaseline visit by baseline status will be displayed by treatment group for each parameter.  The 
proportion of patients with PCSA values at any postbaseline visit will also be displayed by 
duration of exposure for each treatment group.  
Time to onset of the initial ALT and AST elevation (>3 x ULN) and total bilirubin elevation 
(>2 x ULN) (time to first observation of ALT > 3 x ULN or total bilirubin > 2 x ULN, whichever 
comes first) will be analyzed using Kaplan-Meier estimates, presented by treatment group.  
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 61 
Consideration should be given to the impact of the spacing of scheduled tests.  A graph of 
distribution of peak values of ALT versus peak values of total bilirubin will also be presented.  
Note that the ALT and total bilirubin values are presented on a logarithmic scale. The graph will 
be divided into 4 quadrants with a vertical line corresponding to 3 x ULN for ALT and a 
horizontal line corresponding to 2 x ULN for total bilirubin. 
Listing of possible Hy’s law cases identified by treatment group (eg, patients with any elevated 
ALT>3 x ULN, and associated with an increase in bilirubin 2 x ULN) with ALT, AST, alkaline 
phosphatase, total bilirubin, and the following complementary parameters:  conjugated bilirubin, 
creatine phosphokinase, serum creatinine, HCV RNA.  
Summarize the normalization by parameter (to 1 x ULN or return to baseline) of elevated liver 
function tests by categories of elevation (3 x, 5 x, 10 x, 20 x ULN for ALT and AST, 1.5 x ULN 
for alkaline phosphatase, and 1.5 x and 2 x ULN for total bilirubin), with the following categories 
of normalization:  never normalized, normalized despite treatment continuation of IMP, or 
normalized after IMP discontinuation.  Note that a patient will be counted only under the 
maximum elevation category. 
Change in Blood Eosinophil 
Mean changes from baseline in eosinophil with the corresponding standard error will be plotted 
over time in each treatment group for patients with baseline blood eosinophil < 0.5 Giga/L and 
patients with baseline blood eosinophil 0.5 Giga/L. Number (%) of patients with post-baseline 
peak blood eosinophil  1 Giga/L, 3 Giga/L and 5 Giga/L will also be summarized in each 
treatment group and by baseline blood eosinophil status (All, <0.5 Giga/L,0.5 Giga/L). 
2.4.5.4 Analyses of vital sign variables 
The summary statistics (including number, mean, median, Q1, Q3, standard deviation, minimum 
and maximum) of all vital signs variables (values and changes from baseline) will be calculated 
for each visit or study assessment (baseline, each postbaseline time point, last on-treatment and/or 
worst on-treatment value) by treatment group.  For all the parameters, mean changes from 
baseline with the corresponding standard error will be plotted over time (at same time points) in 
each treatment group.  
The incidence of PCSAs at any time during the treatment-emergent adverse event period will be 
summarized by treatment group irrespective of the baseline level and/or according to the following 
baseline status categories:  
x 
Normal/missing 
x 
Abnormal according to PCSA criterion or criteria 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 62 
2.4.5.5 Analyses of electrocardiogram variables 
The summary statistics (including number, mean, median, Q1, Q3, standard deviation, minimum 
and maximum) of all ECG variables (central laboratory values and changes from baseline) will be 
calculated for each visit or study assessment (baseline, each postbaseline time point, last 
on-treatment and/or worst on-treatment value) by treatment group.  For all the parameters, mean 
changes from baseline with the corresponding standard error will be plotted over time (at the same 
time points) in each treatment group.  
The incidence of PCSAs at any time during the treatment-emergent adverse event period will be 
summarized by treatment group irrespective of the baseline level and/or according to the following 
baseline status categories:  
x 
Normal/missing 
x 
Abnormal according to PCSA criterion or criteria 
2.4.6 Analyses of pharmacokinetic and pharmacodynamics variables 
2.4.6.1 Pharmacokinetic analysis 
2.4.6.1.1 Analyses of serum concentrations of dupilumab 
Serum concentrations of dupilumab will be summarized in the PK population using arithmetic and 
geometric means, SD, standard error of the mean, coefficient of variation, minimum, median and 
maximum by visit. If date and/or time of the drug injection and/or sampling is missing then the 
concentration will not be taken into account. For dupilumab-treated patients, where concentration 
values are below the lower limit of quantification (LLOQ), one-half of the LLOQ will be used. 
Values will be expressed in the tables with no more than three significant figures. For patients not 
treated by dupilumab, concentration values below the LLOQ will be taken into account with a 
plasma concentration considered equal to 0. 
2.4.6.1.2 Analyses of ADA variables  
The following summary will be provided based on ADA population: 
x 
Number (%) of patients negative in ADA assay at all time points analyzed 
x 
Number (%) of patients positive in ADA assay at any time points analyzed 
x 
Number (%) of patients with pre-existing immunoreactivity 
x 
Number (%) of patients with treatment-emergent ADA response 
x 
The summary statistics (including number, median, Q1, Q3, minimum and maximum) of 
the peak post-baseline titer for patients with treatment-emergent ADA response 
x 
Number (%) of patient with transient treatment-emergent ADA response  
x 
Number (%) of patients with persistent treatment-emergent ADA response 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 63 
x 
Number (%) of patients with indeterminate treatment-emergent ADA response 
x 
Number (%) of patients with treatment-boosted ADA response 
x 
The summary statistics (including number, median, Q1, Q3, minimum and maximum) of 
the peak post-baseline titer for patients with treatment-boosted ADA response , and 
patients with persistent, indeterminate and transient ADA response 
x 
The summary statistics (including number, mean, SD, median, Q1, Q3, minimum and 
maximum) of the ratio of peak post-baseline titer to baseline titer for patients with 
treatment-boosted ADA response 
x 
Number (%) of patients with ADA status (negative or positive in the ADA assay) at ADA 
time points analyzed 
x 
Number (%) of patients with neutralizing antibody status (negative or positive in the 
neutralizing antibody assay) for the ADA positive patients at ADA time points analyzed 
x 
The summary statistics (median, Q1, Q3, minimum and maximum) of ADA titers at ADA 
time points analyzed   
x 
Listing of ADA peak titer levels and neutralizing antibody status at time points analyzed 
for patients positive in the ADA assay 
x 
Number(%) of patients with neutralizing antibody status  
Kinetics of treatment-emergent ADA positive response 
Number (%) of patients with treatment-emergent ADA positive response at time points analyzed 
will be summarized by each treatment group. 
Plot of percentage of patients with treatment-emergent ADA positive response at time points 
analyzed will be provided by each treatment group. 
Impact of ADA on PK, clinical efficacy, and clinical safety  
Associations between the PK, efficacy and safety endpoints and the following ADA categories 
will be explored: 
x 
Treatment-emergent +treatment-boosted ADA response 
x 
Pre-existing immunoreactivity + negative at all time points 
x 
Treatment-emergent ADA response 
x 
Persistent treatment-emergent ADA response 
x 
Transient treatment-emergent ADA response 
x 
Indeterminate treatment-emergent ADA response 
x 
Treatment-boosted ADA response 
x 
Pre-existing immunoreactivity 
x 
Negative at all time points 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 64 
x 
Neutralizing antibody positive 
x 
Neutralizing antibody negative 
Impact of ADA on PK  
Associations between the ADA categories and serum concentration of dupilumab may be explored 
for the dupilumab dosed group. Plot of serum concentration of functional dupilumab by visit will 
be provided by the ADA categories for the dupilumab dosed group. 
Impact of ADA on clinical efficacy 
Associations between the ADA categories and the primary efficacy endpoint may be explored for 
the dupilumab dosed group by generating descriptive statistics of the endpoint (numbers of 
patients, means, and standard errors) by the ADA categories. 
Impact of ADA on clinical safety 
Associations between the ADA categories and safety may be explored by providing the 
number (n) and percentage (%) of patients with the following events by the ADA categories: 
x 
Injection site reaction HLT 
x 
Hypersensitivity reactions (medically reviewed) 
x 
Anaphylactic reactions  
x 
Overall incidence of severe TEAEs 
x 
Overall incidence of serious TEAEs 
x 
Overall incidence of TEAEs leading to permanent treatment discontinuation 
x 
Additionally, the above events occurred on or after the first identified ADA-positive 
response after the first dose will be summarized for patients with treatment-emergent 
ADA. 
2.4.6.2 Pharmacodynamic/genomic analyses 
PD biomarkers will be analyzed in the safety population. Baseline values will be the last value 
collected prior to the first IMP.  
For all parameters including antigen-specific IgEs with 0.35 kUA/L incidence of greater than 
25% at baseline, levels at each visit, absolute changes from baseline and percent changes from 
baseline will be summarized in descriptive statistics (mean, SD, median, Q1, Q3, min, max)  and 
plotted (mean +/- standard error of the mean) by treatment group and time point. For summarizing 
and plotting antigen-specific IgEs, only those individuals with a baseline value 0.35 kUA/L will 
be included in the calculation of descriptive statistics. 
Values reported as below the LLQ (lower limit of quantitation) will be imputed as a value one half 
of the LLQ. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 65 
Number and percentage of patients with no 0.35 kUA/L antigen-specific IgE, with 0.35 kUA/L 
for only one antigen, and with  0.35 kUA/L for at least two antigens will be summarized by 
treatment group and time point. Same analysis will also be performed using LLQ as the threshold. 
Additionally, descriptive statistics (including number, mean, SD, median, Q1, Q3, min, max) of 
biomarkers at baseline will be summarized for the ITT population. For randomized but not treated 
patients, baseline value will be the last value collected prior to the randomization.   
For the PD endpoints collected only for subjects enrolled in selected sites in Canada, if the number 
of subjects with available data is small, then listings of the levels of the endpoints instead of the 
summary statistics will be provided. 
 
Exploratory analysis of DNA/RNA will be addressed in a separate document. 
2.4.7 Analyses of quality of life/health economics variables 
Change from baseline in ACQ-5, AQLQ, EQ-5D-5L, SNOT-22, and HADS are analyzed as 
efficacy endpoints as described in Section 2.4.4.4.3. 
Analyses of health care resource utilization will be performed under the responsibility of the 
Health Economics and Reimbursement Argumentation department of Sanofi. Methods and results 
will be made available in a separate report. 
2.5 
DATA HANDLING CONVENTIONS 
2.5.1 General conventions 
The following formulas will be used for computation of parameters. 
Demographic formulas 
Age is calculated as: 
Integer part of (informed consent date -birth date)/365.25 
 
Age of asthma onset is calculated as: 
Integer part of (asthma onset date - birth date)/365.25 
x 
Time since first diagnosis of asthma (years) is calculated as: 
x 
(Year of randomization -Year of first diagnosis of asthma) + (month of randomization -
month of first diagnosis of asthma)/12 
x 
Time since cessation of smoking is calculated as: 
x 
(Year of randomization - Year of cessation)×12 + (month of randomization -month of 
cessation) 
x 
Time since last asthma exacerbation (months) is calculated as: 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 66 
(Year of randomization – Year of last asthma exacerbation)×12 + (month of randomization – 
month of last asthma exacerbation) 
 
BMI is calculated as: 
Weight in kg / (height2 in meters) 
 
Smoking quantity (pack-year) is calculated as following: 
Number of pack-year= (packs smoked per day) u   (years as a smoker) 
 
Renal function formulas  
For patients  18 years old, creatinine clearance (CLcr) value will be derived using the equation of 
Cockroft and Gault: 
CLcr (ml/min) = (140 - age) u  weight (kg) u   (1 - 0.15 u  sex (0-M, 1-F))/ (0.814 u  creatinine 
(μmol/l)) 
CLcr will be calculated using the last weight  measurement on or before the creatinine 
measurement was assessed and age at the lab sampling date. Here age is calculated as following: 
Age = integer part of (lab sampling date - birth date)/365.25 
For patients < 18 years old, CLcr value will be derived using the equation of GFR Bedside 
Schwartz  
GFR (mL/min/1.73 m2) = k u  height (cm) / sCr (mg/dL)], 
Where the coefficient k=0.65 for adolescent male patients, or k=0.55 for adolescent female 
patients. 
2.5.2 Data handling conventions for efficacy variables 
 
OCS dose handling conventions  
The percentage reduction of OCS dose at the visits will be calculated as (optimized OCS dose at 
baseline – OCS dose at the visit)/optimized OCS dose at baseline × 100%.  A negative percent 
reduction value is possible if at any visit the prescribed dose is higher than the baseline.  
 
Calculation of salbutamol/albuterol or levosalbutamol/levalbuterol puffs/day 
A diary day is defined as the period beginning with an Evening diary, and ending with the 
following day’s Morning Diary. The number of salbutamol/albuterol or 
levosalbutamol/levalbuterol puffs per day is the sum of number of puffs recorded in one diary day 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 67 
including the evening diary and the following day’s morning diary. If one of the values is missing 
for a diary day, then the data for the diary day is considered missing. 
 
Periodical average of daily efficacy endpoints at designated study days 
For the daily efficacy endpoints, the time period used to calculate the periodical average at each 
designated study time point is summarized in Table 7. Randomization day is used as the reference 
day (Day 1). 
Table 7 - Periodical average of daily efficacy assessment 
Time point 
Morning PEF, 
asthma symptom 
score, number of 
awakenings 
Evening PEF, 
asthma symptom 
score 
Number of puffs/day of 
salbutamol/albuterol or 
levosalbutamol/levalbuterol for 
symptom relief 
Week 2 
Diary day 2-15 
Diary day 1-14 
Diary day 1-14 
Week 4 
Diary day 16-29 
Diary day 15-28 
Diary day 15-28 
Week 6 
Diary day 30-43 
Diary day 29-42 
Diary day 29-42 
Week 8 
Diary day 44-57 
Diary day 43-56 
Diary day 43-56 
Week 12 
Diary day 58-85 
Diary day 57-84 
Diary day 57-84 
Week 16 
Diary day 86-113 
Diary day 85-112 
Diary day 85-112 
Week 20 
Diary day 114-141 
Diary day 113-140 
Diary day 113-140 
Week 24 
Diary day 142-169 
Diary day 141-168 
Diary day 141-168 
Week 28 
Diary day 170-197 
Diary day 169-196 
Diary day 169-196 
Week 32 
Diary day 198-225 
Diary day 197-224 
Diary day 197-224 
Week 36 
Diary day 226-253 
Diary day 225-252 
Diary day 225-252 
Note: A diary day is defined as the period beginning with an Evening diary, and ending with the following day’s Morning Diary. For 
example, diary day 1 includes the evening dairy on day 1 and the morning dairy on day 2. 
2.5.3 Missing data 
For categorical variables, patients with missing data are not included in calculations of 
percentages unless otherwise specified.  When relevant, the number of patients with missing data 
is presented. 
Handling of missing answer to the 7th question in ACQ-7  
If the score is missing from the site report, the FEV1 % predicted value from spirometry test will 
be used to derive the 7th score. Only the spirometry performed on the same day when ACQ-7 is 
evaluated will be used. And if there are multiple FEV1% predicted values available on the same 
day, the lowest one will be used to score the 7th item.  If the score of the 7th question is still 
missing but the questionnaire is complete at the prior visit, the missing score for the 7th question 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 68 
will be imputed as: (score of the 7th question at the prior visit) × (sum of scores of the first six 
questions at the current visit) / (sum of scores of the first six questions at the prior visit). If the 
questionnaire from the prior visit is not complete either or if the ACQ-7 score at the prior visit is 
0, which makes it infeasible to implement the algorithm, the missing score will be imputed as the 
average of the other six questions at the current visit. If scores of the first six questions are 
missing, then the ACQ-7 score for the current visit will be missing.   
Handling of computation of treatment duration if investigational medicinal product end of 
treatment date is missing  
For the calculation of the treatment duration, the date of the last dose of IMP is equal to the date of 
last administration reported on the Investigational Product Administration report form page.  If 
this date is missing, the exposure duration should be left as missing.  
The last dose intake should be clearly identified in the case report form and should not be 
approximated by the last returned package date. 
Handling of medication missing/partial dates 
No imputation of medication start/end dates or times will be performed.  If a medication date or 
time is missing or partially missing and it cannot be determined whether it was taken prior or 
concomitantly, it will be considered as a prior and a concomitant medication. 
Handling of adverse events with missing or partial date/time of onset 
Missing or partial adverse event onset dates and times will be imputed so that if the partial adverse 
event onset date/time information does not indicate that the adverse event started prior to 
treatment or after the treatment-emergent adverse event period, the adverse event will be classified 
as treatment-emergent.  No imputation of adverse event end dates/times will be performed.  These 
data imputations are for categorization purpose only and will not be used in listings.  No 
imputation is planned for date/time of adverse event resolution. 
Handling of adverse events when date and time of first investigational medicinal product 
administration is missing 
When the date and time of the first IMP administration is missing, all adverse events that occurred 
on or after the day of randomization should be considered as treatment-emergent adverse events.  
The exposure duration should be kept as missing. 
The last dose intake should be clearly identified in the case report form and should not be 
approximated by the last returned package date. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 69 
Handling of missing assessment of relationship of adverse events to investigational medicinal 
product  
If the assessment of the relationship to IMP is missing, then the relationship to IMP has to be 
assumed and the adverse event considered as such in the frequency tables of possibly related 
adverse events, but no imputation should be done at the data level. 
Handling of missing severity of adverse events 
If the severity is missing for 1 of the treatment-emergent occurrences of an adverse event, the 
maximal severity on the remaining occurrences will be considered.  If the severity is missing for 
all the occurrences, a “missing” category will be added in the summary table. 
Handling of potentially clinically significant abnormalities  
If a patient has a missing baseline he will be grouped in the category “normal/missing at baseline.” 
For PCSAs with 2 conditions, one based on a change from baseline value or a normal range and 
the other on a threshold value, with the first condition being missing, the PCSA will be based only 
on the second condition. 
For a PCSA defined on a threshold and/or a normal range, this PCSA will be derived using this 
threshold if the normal range is missing; eg, for eosinophils the PCSA is > 0.5 GIGA/L or >ULN 
if ULN 0.5 GIGA/L.  When ULN is missing, the value 0.5 should be used. 
Measurements flagged as invalid by the laboratory will not be summarized or taken into account 
in the computation of PCSA values.   
2.5.4 Windows for time points 
For the safety assessments, the reference date for the derivation of relative days of events or 
findings will be the date of first IMP administration. Selected safety variables will be summarized 
by the analysis window define in Table 8 for the by visit descriptive analysis. All available values 
from central lab will be assigned to the appropriate visit window. In the event of multiple 
measurements of the same test in the same window, the one closest to the targeted visit date will 
be used for the by-visit summary. If they are at the same distance to the target day, the latest one 
will be used. For procedures planned on Visit 3, if it is done on the same date as the first IMP 
injection but the performance time is missing, it will belong to Visit 3 time window. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 70 
 
Table 8 – Time window for safety endpoints 
 
Time windows for 
Visit 
Target 
Day 
Vital 
signs 
Clinical lab 
testing, Urine 
pregnancy 
test 
Serum 
pregnancy 
test 
ECG, Urinalysis, 
Serum 
immunoglobulins 
Hepatitis 
screen, HIV 
screen, 
ANA and 
Anti-ds 
DNA 
antibogy 
Visit 1 (Week -8 to 
-3) 
-56 to -
21 
 
 
1- 
 
1- 
Visit 3 (Week 0) 
1 
1- 
1- 
 
1- 
 
Visit 4 (Week 2) 
15 
1+-21 
 
 
 
 
Visit 5 (Week 4) 
29 
22-35 
1+-42 
 
 
 
Visit 6 (Week 6) 
43 
36-49 
 
 
 
 
Visit 7 (Week 8) 
57 
50-70 
43-70 
 
 
 
Visit 8 (Week 12) 
85 
71-98 
71-98 
 
1+-126 
 
Visit 9 (Week 16) 
113 
99-126 
99-126 
 
 
 
Visit 10 (Week 20) 
141 
127-154 
127-154 
 
 
1+ 
Visit 11 (Week 24) 
169 
155-182 
155-210 
 
127-210 
 
Visit 12 (Week 28) 
197 
183-210 
 
 
 
 
Visit 13 (Week 32) 
225 
211-238 
 
 
 
 
Visit 14 (Week 36) 
253 
>238 
>210 
 
>210 
 
1-: up to 1st dose date/time; 1+: after 1st dose date/time 
 
For the OCS dose used for efficacy assessment, the baseline dose and the final dose at Week 
24/Visit 11 are recorded in the corresponding CRF pages. OCS doses at Visits 5, 7, 8, 9, and 10 
during the treatment period will be obtained from the prescribed dose recorded in ediary based on 
the date of OCS adjustments recorded in the ‘Oral Corticosteroid Dose Adjustment - Treatment 
Phase’ eCRF pages associated with each visit. If it is recorded that there was no dose adjustment 
for a visit, the dose of the previous visit will be considered maintained for the current visit and 
thus carried forward. For patients permanently discontinue treatment before Week 24/Visit 11, any 
dose adjustment recorded at the Early Treatment Discontinuation visit will be assigned to the 
regular visit after the last on treatment visit. In case there were more than one adjustments 
associated with one visit, the last dose will be used for the visit. 
 
For the other efficacy assessments, the reference date for the derivation of relative days of events 
or findings will be the randomization day. If a patient receives IMP prior to the randomization by 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 71 
mistake, the reference date of efficacy assessment will be the date of the first IMP administration 
for that patient.  Table 9 assigns all scheduled measurements of efficacy endpoints for visits to the 
appropriate visit window. The ACQ-5 questionnaires planned for the weeks between visits will 
not be assigned to the visits. In the event of multiple measurements of the same test in the same 
window, the one closest to the targeted visit date will be used for the by-visit summary. If they are 
at the same distance to the target day, the latest one will be used.  
Table 9 – Time window for efficacy variables 
Time windows for  
 
Visit 
Target 
Day 
Spirometry, ACQ-5, 
ACQ-7 
 
Post-bronchodilator FEV1, 
AQLQ(S), EQ-5D-5L, HADS, 
SNOT-22 
Airway 
hyperresponsiveness 
(selected study sites 
within Canada) 
Visit 3 (Week 0) 
1 
-14-1- 
 
1- 
1- 
Visit 4 (Week 2) 
15 
1+-21 
 
 
 
Visit 5 (Week 4) 
29 
22-35 
 
 
 
Visit 6 (Week 6) 
43 
36-49 
 
 
 
Visit 7 (Week 8) 
57 
50-70 
 
 
 
Visit 8 (Week 12) 
85 
71-98 
 
1+-126 
 
Visit 9 (Week 16) 
113 
99-126 
 
 
 
Visit 10 (Week 
20) 
141 
127-154 
 
 
 
Visit 11 (Week 
24) 
169 
155-182 
 
127-210 
1+ 
Visit 12 (Week 
28) 
197 
183-210 
 
 
 
Visit 13 (Week 
32) 
225 
211-238 
 
 
 
Visit 14 (Week 
36) 
253 
>238 
 
>210 
 
1-: up to min(1st dose date/time, end of randomization date); 1+: after min(1st dose date/time, end of randomization date). 
 
For the pharmacokinetics/pharmacodynamics variables summary, the reference date for the 
derivation of relative days of measurements will be the date of first IMP administration if the 
patient is treated with study treatment, or the randomization date if the patient is not treated. 
Pharmacokinetics /pharmacodynamics variables will be summarized by the analysis window 
defined in Table 10 for the by visit descriptive analyses. All available values of measurements will 
be assigned to the appropriate visit window. In the event of multiple measurements of the same 
test in the same window, the one closest to the targeted visit date will be used for the by-visit 
summary. If they are at the same distance to the target day, the latest one will be used. For 
procedures planned on Visit 3, if it is done on the same date as the first IMP injection but the 
performance time is missing, it will belong to Visit 3 time window. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 72 
 
 
Table 10 – Time window for pharmacokinetics/pharmacodynamics variables 
 
 
 
Time windows for 
Visit 
Target 
day 
Blood 
eosinophil 
Exhaled 
NO 
Systemic 
drug 
concentration 
Anti-drug 
antibodies 
Eotaxin-3, 
total IgE, 
TARC 
Antigen-
specific 
IgE, 
periostin 
Sputum 
ILC2 and 
CD34 cells 
and sputum 
and blood 
cytokines  
 
Visit 3 (Week 0) 
1 
<-1- 
-14-1- 
<-1- 
1- 
1- 
1- 
 
Visit 4 (Week 2) 
15 
 
1+-21 
 
 
 
 
 
Visit 5 (Week 4) 
29 
1+-42 
22-35 
1+-42 
 
1+-56 
 
 
Visit 6 (Week 6) 
43 
 
36-49 
 
 
 
 
 
Visit 7 (Week 8) 
57 
43-70 
50-70 
43-70 
 
 
 
 
Visit 8 (Week 12) 
85 
71-98 
71-98 
71-126 
1+-126 
57-112 
 
 
Visit 9 (Week 16) 
113 
99-126 
99-126 
 
 
 
 
 
Visit 10 (Week 20) 
141 
127-154 
127-154 
 
 
113-154 
 
 
Visit 11 (Week 24) 
169 
155-210 
155-182 
127-210 
127-210 
>154 
1+-210 
 
Visit 12 (Week 28) 
197 
 
183-210 
 
 
 
 
 
Visit 13 (Week 32) 
225 
 
211-238 
 
 
 
 
 
Visit 14 (Week 36) 
253 
>210 
>238 
>210 
>210 
 
>210 
 
1-: up to 1st dose date/time; 1+: after 1st dose date/time; 
For not treated but randomized patients: 1-: up to randomization date; 1+: after randomization date 
2.5.5 Unscheduled visits 
Unscheduled visit measurements of laboratory data, vital signs, and ECG will be included in the 
by-visit summaries, and will be used for computation of baseline, worst values, and PCSAs. 
2.5.6 Pooling of centers for statistical analyses 
Due to the large number of centers, the randomization is stratified by country. Due to small 
sample size in some countries, the countries will be pooled into regions as defined below for 
analyses: 
x 
East Europe: Hungary, Poland, Romania, Russia, and Ukraine;  
x 
Latin America: Argentina, Brazil, Chile, Colombia, and Mexico;  
x 
Western Countries: Belgium, Canada, Israel, Italy, Netherlands, Spain, and USA 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 73 
2.5.7 Statistical technical issues 
None. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 74 
3 
INTERIM ANALYSIS 
There is no interim analysis planned for this study. The primary analysis is planned when the last 
patient completes Week 24 visit or discontinue from the study before week 24. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 75 
4 
DATABASE LOCK 
The database is planned to be locked at approximately 30 days after last patient completes Week 
24 visit or discontinue from the study before week 24. Additional data between the database lock 
and the last patient completing last visit will be summarized in CSR addendum.  
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 76 
5 
SOFTWARE DOCUMENTATION 
All summaries and statistical analyses will be generated using SAS version 9.4 or higher. 
(electronic 


Statistical Analysis Plan  
18-May-2017 
SAR231893-EFC13691 - dupilumab 
Version number: 1 
Property of the Sanofi Group - 
 
Page 77 
6 
REFERENCES 
1. 
Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E,  et al.  
Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 
2009;360:985-93. 
2. 
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral 
glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 
2014;371:1189-97. 
3. 
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coateset A, et al. 
Standardization of spirometry. Series ‘‘ATS/ERS TASK FORCE: Standardization of Lung 
Function Testing" Edited by Brusasco V, Crapo R, and Viegi G. Eur Resir J. 2005;26:319-38. 
4. 
Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of 
three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553-8. 
5. 
EUroQol Group. EuroQol-a new facility for the measurement of health-related quality of 
life. Health Policy 1990;16:199-208. 
6. 
Li, KH, Meng, XL, Raghunanthan, TE,  Rubin, DB. Significance levels from repeated p-
values with multiply-imputed data. Statistica Sinica 1991;1:65-92. 
(electronic 